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 The fermentation of dietary fiber by our gut microbiota produces short-chain 
fatty acids (SCFAs), namely acetate, propionate and butyrate. SCFAs activate GPR41 
and GPR43– G protein-coupled receptors implicated in obesity, colitis, asthma and 
arthritis by knockout mice studies. The GPR43 studies suggest that the control of 
GPR43 expression may be pertinent in a range of physiological processes. However, 
the GPR43 promoter remains uncharacterized. Here, we present the first full 
characterization of the GPR43 promoter and 5'-UTR. 5'-RACE of the GPR43 
transcript identified the transcription start site (TSS) and a 124 bp 5'-UTR followed by 
a 1335 bp intron upstream of the ATG start codon. The sequence spanning -4560 to 
+68 bp relative to the GPR43 TSS was found to contain strong promoter activity, 
increasing luciferase reporter expression by 100-fold in U937 monocytes. Stepwise 
deletions further narrowed the putative GPR43 promoter to span -451 to +68 bp. Site-
directed mutagenesis identified XBP1 as a core cis element, the mutation of which 
abrogated transcriptional activity. Mutations of predicted CREB, CHOP, NFAT and 
STAT5 binding sites, partially reduced the promoter activity, indicating these sites to 
be potential enhancer elements. ChIP assays confirmed the binding of XBP1 to the 
endogenous GPR43 promoter. Consistently, GPR43 expression was reduced in U937 
cells upon siRNA-knockdown of XBP1, while A549 cells overexpressing XBP1 
displayed elevated GPR43 mRNA level. Based on its ability to activate XBP1, we 
determined that TNF may potentially induce GPR43 expression in human monocytes, 
which was empirically confirmed. 
 The elevated GPR43 expression during inflammation may facilitate the 
monocyte response to SCFAs. However, the role of GPR43 and its sister SCFA 
receptor, GPR41, in monocytes remains ill-defined. To address this question, wild 
 XI 
type and GPR43 and GPR41 knockout monocytes were cultured ex vivo and treated 
with synthetic GPR43 and GPR41 agonists. These assays confirmed that SCFAs act 
via GPR43 and GPR41 to suppress C5, CCL1, CCL2, GM-CSF, IL-1α, IL-1β, 
ICAM-1 and TNF cytokine expression in human monocytes during inflammation. 
GPR43 mediated this cytokine inhibition through the repression of Akt and ERK2 
signaling. Surprisingly, these GPR43 and GPR41 inhibition pathways were absent in  
mice monocytes, resulting in a distinct cytokine profile where CXCL10, IL-1rα, 
TIMP-1, and CCL2 were repressed, but CXCL1, IL-1α, and IL-1β were elevated 
during acetate SCFA treatment. GPR43 also activated p38 signaling in both human 
and mouse monocytes.  
 Collectively, we revealed that acetate treatment induces distinct inflammatory 
cytokine profiles in human and mouse monocytes due to species-specific GPR43 and 
GPR41 signaling. This suggests that mice may not fully model the role of GPR43 and 
GPR41 in human chronic inflammatory diseases. GPR43 expression is also 
modulated during inflammation, potentially enhancing the anti-inflammatory effect of 
acetate.   
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Chapter 1 | Introduction 
1.1. The importance of the gut microbiota in immune 
homeostasis 
 
 The human gut is host to a vast ecological community of microorganism that 
is estimated to outnumber the cells of the human host by a factor of 10 1. This 
community is collectively referred to as the intestinal microbiota and is approximated 
to contain more than 35 000 bacterial species 2. Of these, the Bacteroidetes and the 
Firmicutes predominate; while Proteobacteria, Verrucomicrobia, Actinobacteria, 
Fusobacteria, and Cyanobacteria are present in minor proportions 3. 
 The relationship we share with our gut microbiota was once thought to be 
merely commensal, but our increasing understanding of the benefits provided by these 
residents has revealed that it is in fact a mutualistic one. The intestinal microbiota has 
been linked to a number of beneficial functions: modulating immune development, 
metabolic function, and preventing diseases such as allergies, colon cancer, and 
inflammatory bowel disease 4,5 [Figure 1.1]. The importance of the gut flora is most 
dramatically illustrated in germ-free mice which are found to be more susceptible to 
infection and have multiple physiological defects in their gut mucosal tissues while 
the reconstitution of intestinal flora into these mice is sufficient to restore the mucosal 
immune system 6. Indeed, such is the importance of the gut microbiota that it has been 




Figure 1.1 | Examples of known beneficial functions of the human gut microbiota. 
Arrows depict causal relationships. Figure reproduced with permission from Prakash et. al. 
2011 8, which is under Open Access licensing. 
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1.2. The benefits of gut microbiota derived short-chain fatty 
acids (SCFAs) 
 
 While the importance of the gut flora in maintaining immune homeostasis is 
recognized, how exactly this is mediated is not fully understood. This homeostatic 
effect is at least partly mediated by the short-chain fatty acids (SCFAs) [Figure 1.2], 
consisting predominantly of acetate, propionate and butyrate 3, which are produced in 
millimolar concentrations (around 60 mM, 20 mM and 20 mM, respectively) in the 
colonic lumen during the anaerobic fermentation of dietary fiber by saccarolytic gut 
bacteria 9,10 [Figure 1.3]. In addition to being an important energy source 11, SFCAs 
have also been shown to affect blood glucose and lipid levels, the colonic 
environment, and immune functions 12–14.  
 
 
Acetic acid Propionic acid Butyric acid
 





























• Eubacterium rectale, Roseburia spp.









Figure 1.3 | The metabolism of short-chain fatty acids by gut microbes. 
Species and phyla information are from cultured microorganisms. Whereas most colonic 
bacteria use the Embden–Meyerfhof pathway for hexose metabolism, bifidobacteria 
(Actinobacteria) use the bifid shunt pathway (not shown here). Figure adapted from Flint et. 
al. 2012 15 with permission from Macmillan Publishers Ltd: Nature Reviews Gastroenterology 
and Hepatology 15, copyright 2012. 
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1.3. SCFAs activate the GPR41 and GPR43 G protein-coupled 
receptors (GPCRs) 
 
 In 2003, a potential pathway for the action of SCFAs was identified with the 
deorphanization of a pair of cell surface G protein-coupled receptor (GPCR) proteins, 
namely GPR41 and GPR43 16–18. Cell lines heterologously expressing these receptors 
were found by ligand screening, to be activated by SCFAs. The functional similarities 
between GPR41 and GPR43 is unsurprising as these receptors appear to be 
evolutionarily related, with around 42% aligned peptide sequence identity for the 
human homolog. The SCFAs: acetate, propionate and butyrate, are the most potent 
agonists for GPR41 and GPR43, with EC50 around 0.5 mM. The millimolar SCFA 
concentrations required to activate GPR43 and GPR41 suggest a low potency, 
especially when compared to other known GPCR ligands such as the chemokine 
receptor, CCR2, which is activated by the CCL2 chemokine with an EC50 of around 1 
nM 19. This low potency may be due to the relatively high concentrations of SCFAs 
found in the gut (20 to 60 mM) 3, which may restrict the systemic activation of 
GPR43 and GPR41. 
 
1.4. Synthetic agonists allow for the specific activation of GPR41 
and GPR43 
 
 In addition to acting through GPR41/43, both butyrate and propionate 
reportedly inhibit histone deacetylases 20 while butyrate also activates GPR109A 21. 
Acetate, on the other hand, has no other known receptor targets but can be taken up by 
cells via passive diffusion and converted to acetyl-CoA in both the cytosol and 
mitochondria by acetyl-CoA synthetase 22, a common metabolic intermediate. More 
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recently, the development of synthetic agonists has enabled the specific activation of 
both GPR41 and GPR43 at allosteric sites 23,24. 
 
1.5. The G protein-coupled receptor (GPCR) family 
 
 As members of the GPCR family, GPR41 and GPR43 contain many of the 
features that are characteristic of this group of receptors. All GPCRs have a seven 
transmembrane helix structure [Figure 1.4] and signal via one or more G proteins 
[Figure 1.5]. The GPCR family collectively form one of the largest and most studied 
gene families 25, with the human genome estimated to contain about 700 GPCRs 26. In 
general, GPCRs recognize extracellular ligands or stimuli such as hormones, proteins, 
lipids, and pheromones; and transduce their signals into the cell 25. Virtually all types 
of tissues and cells express GPCRs, which are involved in most physiological 
processes, ranging from the photoreceptors in the retina responsible for vision, to the 
neurotransmitter receptors in the brain. Approximately 45% of currently available 
drugs target around 30 GPCRs 27, leaving a large number of GPCRs as potential 
targets for new drugs 28. 
 
 
Figure 1.4 | The seven-transmembrane α-helical 
structure of a G protein-coupled receptor. 
Based on PDB 1hzx 29 and the 
Heller/Schaefer/Schulten 30 lipid bilayer coordinates . 







Figure 1.5 | G protein-coupled receptor (GPCR) signaling pathways mediated by G 
proteins. 
G-protein-coupled receptors are a large family of receptors that detect various ligands/stimuli. 
At the resting state, GPCRs are bound to heterotrimeric G proteins composed of α, β and γ 
subunits with GDP bound. Agonist binding triggers receptor conformational change, which 
catalyses the dissociation of GDP from the α subunit followed by GTP-binding to Gα and the 
dissociation of Gα from Gβγ subunits. The α subunits of G proteins are divided into four 
subfamilies: Gαs, Gαi, Gαq and Gα12. A single GPCR can couple to one or more families of 
Gα proteins. Each G protein then activates several downstream effectors 31,32. 5-HT, 5-
hydroxytryptamine; ECM, extracellular matrix; GABA, gamma-aminobutyric acid; GEF, 
guanine nucleotide exchange factor; GRK, G protein receptor kinase; LPA, lysophosphatidic 
acid; PI3K, phophatidylinositol 3-kninase; PKA and PKC, protein kinase A and C; S1P 
sphingosine-1-phosphate. Reprinted by permission from Macmillan Publishers Ltd: Nature 
Reviews Cancer 33, copyright 2007. 
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1.6. GPR41 and GPR43 expression is tissue specific and are 
upregulated in monocytes 
 
 GPR41 expression has been detected in a variety of tissues, namely in adipose 
tissue, pancreas, spleen, lymph nodes, bone marrow, and peripheral blood 
mononuclear cells including monocytes 16,17. Consistent with its role as an SCFA 
receptor, GPR43 expression is found in cells that are exposed to the highest 
concentrations of SCFAs. These include cells of the distal ileum, colon and adipose 
tissue, with the highest expression found in immune cells such as monocytes and 
neutrophils 16–18. In addition, GPR43 expression appears to be modulated during 
inflammation since immune challenge by lipopolysaccharide (LPS) or treatment with 
granulocyte-macrophage colony stimulating factor (GM-CSF) raises GPR43 
transcript levels in human monocytes 34.  
 
1.7. The transcriptional control of GPR41 and GPR43 
 
 A study on the transcriptional regulation of GPR41 have revealed that the 
GPR41 protein is translated from the bicistronic mRNA encoding GPR40 and GPR41, 
where an internal ribosome entry site (IRES) is utilized for the GPR41 coding 
sequence downstream of GPR40 [Figure 1.6] 35. Thus, the tissue expression of GPR41 
is likely to be highly correlated with that of the medium to long chain fatty acid 
receptor, GPR40, as both receptors share the same promoter. Unlike GPR41, little is 








Internal ribosomal entry site 
(IRES) containing region
 
Figure 1.6 | GPR41 uses the GPR40 promoter. 
Shown is a diagrammatic representation of the bicistronic GPR40/41 mRNA being 
transcribed under the control of the GPR40 promoter. An internal ribosomal entry site (IRES) 
is utilized for the translation of the GPR41 peptide. Figure adapted with permission from the 
Journal of Biological Chemistry 35. 
 
 
1.8. Monocytes form the frontline of the immune response 
 
 A cell found with high expression levels of GPR43 is the monocytes 16,17. 
Monocytes form part of the white blood cell or leukocyte population and constitute up 
to 10% of all leukocytes in the human body 36. They form in the bone marrow and 
circulate through the peripheral blood, acting as part of the innate immune system by 
mediating the immediate immune response to pathogen invasion [Figure 1.7]. 
Monocytes replenishing resident macrophages under normal states, and in response to 
inflammation signals, can move quickly (approximately 8 to 12 hours) to sites of 
infection in the tissues to elicit an immune response. A small subset of monocytes will 
differentiate into macrophages and dendritic cells. 
 10 
 
Figure 1.7 | The known functions of monocytes. 
Reprinted by permission from Macmillan Publishers 




1.9. XBP1 is a transcription factor involved in immunity and 
cellular stress 
 
 XBP1 is a transcription factor involved in a number of physiological processes 
and diseases which include MHC class II gene regulation, B cell development and the 
unfolded protein response (UPR) 38. Two variants of XBP1 exist, an unspliced variant 
(XBP1u) and the spliced variant (XBP1s) with a 26 nucleotide unconventional intron 
spliced out. XBP1 activity is upregulated via the conversion of XBP1u to XBP1s, 
which is the active form. The aforementioned processes such as B cell development 
and the UPR, activate this splicing. 
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1.10. GPR41 and GPR43 mediate the physiological effects of SCFAs 
 
 As receptors specific for SCFAs, the activation of GPR41 and GPR43 may 
account for some of the physiological effects of the SCFAs. This is consistent with 
the findings of some recent knockout mice studies that have implicated GPR41 and 
GPR43 in the etiology of SCFA-associated chronic inflammatory diseases such as 
obesity, colitis, asthma and arthritis in mice 39–47 [Table 1.1]. While these studies 
generally agree upon the importance of GPR41 and GPR43, there is a lack of 
agreement as to whether GPR43 is pro- or anti- inflammatory, with contradictory 
findings from different studies. For example, while Maslowski et al. 2009 39 and 
Smith et al. 2013 42 reported that GPR43 reduces the severity of colitis, Sina et al. 
2009 40 and Kim et al. 2013 41 on the other hand, reported the opposite. There is also a 
lack of agreement on the cell type responsible for the effect of GPR43. The cell type 
mainly responsible for the effect have been variously described to be either 
neutrophils (Sina et al. 2009) 40; gut epithelial cells (Kim et al. 2013) 41; or regulatory 
T cells (Smith et al. 2013) 42. Hence, more studies are required to clarify the roles of 
GPR41 and GPR43. 
 
1.11. GPR41 and GPR43 signaling remains ill-defined in 
monocytes 
 
 Despite the severe phenotypes of GPR43 and GPR41 knockouts [Table 1.1], 
little is known about the signaling pathways activated by these receptors. GPR43 has 
been reported to activate p38 in the human MCF-7 cell line 48 while p38, Akt and 
ERK is activated in mouse bone marrow derived neutrophils 49. Both GPR41 and 
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GPR43 reportedly activate p38 and ERK in mouse intestinal epithelial cells 41. 
However, GPR43 and GPR41 are also upregulated in monocytes, yet the signaling of 
these receptors in monocytes remains to be elucidated. 
 
Table 1.1 | Contradictory findings on the inflammation phenotypes of Gpr43-/- and 
Gpr41-/- mice. 
 
Gpr43-/- mice display increased inflammation 
Maslowski et al. 2009 39 Exacerbated colitis, arthritis and asthma 
Reduced neutrophil recruitment 
Smith et al. 2013 42 Exacerbated colitis 
Reduced Treg cell count 
 
Gpr43-/- mice display reduced inflammation 
Sina et al. 2009 40 Reduced colitis 
Increased neutrophil recruitment 
Kim et al. 2013 41 Reduced colitis 
Reduced ERK and p38 activation in epithelial cells 
 
Gpr43-/- mice display increased obesity markers 
Ge et al. 2008 50 Increased lipolysis and plasma free fatty acids 
Tolhurst et al. 2012 45 Impaired glucagon-like peptide-1 secretion and glucose tolerance 
Kimura et al. 2013 46 Increased fat accumulation and obesity on a normal diet 
 
Gpr43-/- mice display reduced obesity markers 
Bjursell et al. 2011 44 Improved glucose control and reduced body fat mass on a high fat diet 
 
Gpr41-/- mice display increased inflammation 
Trompette et al. 2014 47 Exacerbated asthma 
Impaired dendritic cell generation 
 
Gpr41-/- mice display reduced inflammation 
Kim et al. 2013 41 Reduced colitis 
Reduced ERK and p38 activation in epithelial cells 
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Chapter 2 | Hypothesis, specific aims and study 
design 
 
 Knockout mice studies have confirmed the role of GPR41 and GPR43 in the 
etiology of chronic inflammatory diseases such as obesity, colitis, asthma and arthritis 
39–47
. However, many questions regarding their exact roles and mechanisms remain 
unanswered. Here, we attempt to address some of these questions. 
 
Question 1: What transcription factors are involved in the regulation of GPR43 
transcription/expression?  
 
 The compelling effects of Gpr43 knockout [Table 1.1] suggest that GPR43 
expression may be pertinent in a wide range of physiological processes 39–47. 
However, while the GPR41 promoter has been studied 35, the GPR43 promoter 
remains unknown. Characterizing the GPR43 promoter may provide novel insights 
into the mechanism by which GPR43 is expressed, and hence how its function may be 
regulated. Indeed, the observations of (i) cell-specific expression of GPR43 mRNA in 
monocytes 16–18, and (ii) the upregulation of GPR43 mRNA expression induced by 
inflammatory stimuli such at LPS and GM-CSF 34, suggest that GPR43 transcription 
is tightly controlled and may be important for regulating its function. Other 
mechanisms such as reduced mRNA stability or microRNA-mediated mRNA 
silencing may also repress GPR43 expression. However, these other mechanisms can 
only occur after the promoter-mediated transcription of GPR43 mRNA occurs. Hence, 
before the role of any of these other mechanisms can be considered, it is necessary to 
first characterize the GPR43 promoter. Here, we formulate our first hypothesis that 
the specific expression of GPR43 is due to promoter-mediated transcriptional 
regulation. To test this hypothesis, our first aim was to characterize the GPR43 
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promoter and its associated transcription factors. The study design is described in 
Figure 2.1 
 
Question 2: Do short chain fatty acids (SCFAs) act via GPR41 and GPR43 to 
modulate monocyte signaling and cytokine expression? 
 
 Since GPR43 expression is upregulated in monocytes by inflammatory stimuli 
such as LPS 34, we proceeded to investigate if this increased GPR43 expression will 
alter monocyte response to SCFAs during inflammation. Efforts were also made to 
investigate GPR41, another SCFA receptor 16–18 expressed by monocytes, that is also 
likely to mediate monocyte SCFA responses. This addresses another question on the 
mechanism of GPR41/43 action, which remained poorly understood despite the 
physiological importance of these receptors in vivo 39–47. Notably, both receptors are 
highly expressed in the monocytes 17,18, but their functions in these cells are unknown. 
Monocytes are a promising target to study GPR41 and GPR43 functions as these cells 
have been found to migrate to the colon and contribute to inflammation in both 
patients 51 and mouse models 52,53. In the colon, monocytes are presumably exposed to 
millimolar concentrations of SCFAs required to activate the receptors. Monocytes 
also constitute the principal source of intestinal macrophages in mice 54,55. The 
CD14+CD16+ monocyte subset is reportedly expanded and is implicated in the disease 
pathology of patients with rheumatoid arthritis 56 and inflammatory bowel disease 
57,58
. Together, these prior observations suggest that GPR41 and GPR43 may 
modulate monocyte function, with implications in monocyte-associated chronic 
inflammatory diseases.  
 One mechanism by which GPR41/43 could modulate monocyte function is by 
modulating monocyte inflammatory cytokine expression. Previous studies have 
shown that SCFAs, the GPR41/43 ligands, can inhibit CCL2 and IL-10 cytokine 
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expression in vitro 59. However, the potential involvement of GPR41 and GPR43 in 
mediating these SCFA effects has not been investigated. Our previous finding that 
CRP and M-ficolin interaction with GPR43 leads to reduced monocyte IL-8 secretion 
60
, hints at the potential ability of GPR43 to modulate cytokine expression. Thus, it is 
conceivable that the SCFAs act via GPR41 and/or GPR43 to modulate cytokine 
expression in monocytes, forming our second hypothesis. To test this hypothesis, our 
second aim was to determine if GPR41/43 modulates cytokine production. 
 If GPR41/43 do indeed alter cytokine expression, a possible mechanism is via 
the modulation of kinase signaling pathways involved in monocyte cytokine 
expression 61,62. It is thus conceivable that GPR41 and GPR43 may modulate kinase 
signaling in monocytes– our third hypothesis. To determine if this is true, our third 
aim was to investigate if GPR41/43 modulates kinase signaling in monocytes.  
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Aim 1: To characterize the GPR43 promoter and its associated transcription factors
1. Determine GPR43 5’-UTR and transcription start site (TSS)
 5’ Rapid Amplification of cDNA Ends (RACE)  Sequence the 5’-UTR 
2. Delineate the GPR43 promoter sequence
 Step-wise deletions of 4000 bp putative GPR43 promoter
 Measure promoter activity via Luciferase reporter assays
3. Identify transcription factor (TF) binding sites within the GPR43 promoter
 Site-directed mutagenesis of predicted DNA binding sites
 Measure promoter activity via Luciferase reporter assays
5. Confirm that XBP1 regulates endogenous GPR43 expression
 SiRNA knockdown, heterologous expression  Measure GPR43 mRNA via Real-time PCR
4. Confirm TF binding to GPR43 promoter
 Chromatin Immunoprecipitation (ChIP) with antibodies targeting TFs
 Measure percipitated GPR43 promoter DNA abundance via Real-time PCR
Cells: U937 promonocytic leukocytes, A549 alveolar basal epithelial cells
 
Figure 2.1 | Study design to characterize the GPR43 promoter and its associated 
transcription factors. 
To characterize the GPR43 promoter, we first determine the 5'-UTR sequence of the GPR43 
mRNA which follows immediately after the transcription start site (TSS). By comparing the 
5'-UTR with the human genome, we can determine the location of the GPR43 TSS. Since the 
core promoter elements of genes are typically around 10 to 30 bp upstream of the TSS, 
locating the TSS allowed us to ensure that the putative GPR43 promoter is defined to include 
this likely core promoter site. The GPR43 putative promoter is then cloned upstream of a 
luciferase reporter, allowing us to measure promoter activity in U937 cells. By step-wise 
deletions, we identify portions of the putative promoter sequence are involved in its activity. 
These shorter promoter sequences are then analyzed computationally for potential 
transcription factor (TF) binding sites, which were then null mutated to investigate their 
importance. Upon identifying important TFs, we use ChIP to confirm their binding to the 
GPR43 endogenous promoter. Finally, heterologous expression and siRNA knockdown is 
used to modulate TF activity, to confirm the altered TF activity lead to altered endogenous 
GPR43 expression. 
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Aim 3: To investigate if GPR41/43 
modulates kinase signaling in monocytes
Measure kinase activity via:
- Proteome arrays
- Western Blot
- Luciferase reporter assay




Aim 2: To determine if GPR41/43 
modulates cytokine production
Cells:
- A549 alveolar basal epithelial cells
- Human peripheral blood monocytes
- Mouse bone marrow monocytes (WT and KO)

Method: Gpr41/43 knockout (KO), small molecule inhibitors, heterelogous expression

GPR41 ligand: Acetate, AR420626 synthetic agonist
GPR43 ligand: Acetate, CFMB synthetic agonist
 
Figure 2.2 | Study design to investigate the role of GPR41/43 in monocyte response to 
SCFAs. 
This is complicated by the fact that the SCFAs may activate/inhibit other targets besides 
GPR41/43. For example, both butyrate and propionate reportedly inhibit histone deacetylases 
20
 while butyrate also activates GPR109A 21. Acetate, on the other hand, has no other known 
targets and would appear to act exclusively via GPR41/43. Thus, to more specifically activate 
GPR41/43, we use acetate instead of propionate or butyrate. While acetate may be more 
specific for GPR41/43, the fact that it activates both receptors means that we are still unable 
to determine if a specific receptor or both are involved. We additionally cannot rule out the 
possibility that acetate may modulate other yet-to-be-determined targets. The synthetic 
agonists, AR420626 and CFMB, allow us to specifically activate GPR41 and GPR43 
respectively 23,24. To further confirm the necessity of either receptor, we use GPR41 or GPR43 
knockout mice.  
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Chapter 3 | Materials and methods 
 
3.1 Animal work 
 
 All experiments were performed in compliance with guidelines approved by 
the Institutional Animal Care and Use Committee (IACUC Protocol Ref: 049/11, 
BR14/11). Gpr41 and Gpr43 knockout mice were kindly provided by Takeda 
Cambridge Ltd., as part of an ongoing collaboration. The knockout mice were 
generated as previously described 45 and maintained in the 129/SvEv background. 
Briefly, a linearized targeting vector containing homology arms (Gpr41, 1,250 base 
pairs [bp] 5′ and 3,914 bp 3′; Gpr43, 1,761 bp 5′ and 4,199 bp 3′), internal ribosomal 
entry site β-gal reporter gene, neomycin selection marker, and two thymidine kinase 
negative selection markers; was electroporated into embryonic stem cells (129/SvEv). 
Cells positive for homologous recombination were screened via PCR and Southern 
blot before being injected into the blastocyst to generate chimeras. Knockout and wild 
type animals were maintained inbred in the 129/SvEv background and kept in a 
Specific Pathogen Free (SPF) colony. Work on Gpr43-/- mice were carried out at NUS 
while work on Gpr41-/- mice were performed at Takeda Cambridge, UK through a 
research attachment.  
 
3.2. Plasmid constructs 
 
The myristoylated human Akt1 (myr-Akt) was cloned into pcDNA3 vector or 
the empty pcDNA3 expression vector as control. The coding regions (CDS) of human 
GPR41 (NM_005304), human GPR43 (NM_005306), murine Gpr41 
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(NM_001033316), and murine Gpr43 (NM_001168509) were cloned into the 
pcDNA3.1/V5-His A (Invitrogen) expression vector. 
To generate promoter deletion constructs, primary monocyte genomic DNA 
was extracted from the interphase and phenol layer using Trizol Reagent (Life 
Technologies). To obtain 5’ end promoter deletion products, primers (Table 2.1) 
flanking the desired promoter regions were used for PCR amplification, using the 
purified genomic DNA as template. PCR was performed using iProof High Fidelity 
DNA Polymerase (Bio-rad) under the following parameters: initial denaturation at 98 
oC; 40 cycles of amplification, denaturation at 98 oC for 10 s, annealing at Tm of 
primer pair + 3 oC for 30 s, elongation at 72 oC for 2.5 min; followed by a final 
extension at 72 oC.  
The isolated promoter lengths were separately cloned into pGL4.20 vector 
(Promega) using standard molecular cloning techniques. The full-length sequence of 
each promoter construct was confirmed by sequencing using Big Dye Terminator 
cycle sequencing kit and ABI Prism 3100 Genetic Analyzer (Life Technologies). 
 
3.3. Primary cell isolation 
 
 Human peripheral blood monocytes were isolated from buffy coat of healthy 
adult donors (National University Hospital, Blood Donation Centre, Singapore). This 
work was approved by the National University of Singapore (NUS) Institutional 
Review Board (IRB), NUS-IRB B-14-063E. Briefly, the buffy coat was diluted four 
times with PBS containing 2% FBS and 1 mM EDTA, and the mononuclear fraction 
was obtained via density gradient centrifugation (4000 g for 40 min at 23oC) with 
Ficoll-Paque Premium 1.073 (GE Healthcare). From the mononuclear fraction, the 
monocyte population was enriched with the Human Monocyte Enrichment Kit 
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(Stemcell). For mouse monocytes, the bone marrow from 10-14 week old mice was 
harvested and the monocyte fraction was enriched with the Mouse Monocyte 
Enrichment Kit (Stemcell).  
 
3.4. Cell culture conditions 
 
The enriched primary human peripheral blood monocytes and primary 
129SvEv mouse bone marrow monocytes were cultured in RPMI media (with 10% 
FBS and 1% v/v penicillin and streptomycin) at 37oC for 2 h before being used in 
assays. The A549 adenocarcinomic human lung alveolar basal epithelial cells and 
U937 human promonocytic cell line were routinely cultured in RPMI media (with 
10% FBS and 1% v/v penicillin and streptomycin) at 37oC. The primary neonatal 
human fibroblasts (Life Technologies) were routinely grown in medium 106 (Life 
Technologies). 
 
3.5. 5’-Rapid Amplification of cDNA Ends (5’ RACE) 
 
Amplification of 5’ cDNA ends of mature GPR43 was performed with the 
GeneRacerTM kit (Life Technologies, Cat. #L1-502-02), following the standard 
protocol provided. Briefly, 5 µg of U937 total RNA was dephosphorylated with Calf 
Intestinal Phosphatase (CIAP) and ligated with a sequence specified RNA 
oligonucleotide at 37oC for 1 h. Following ligation, the 5’ ends of GPR43 mRNA 
were reverse transcribed and amplified using nested PCR primers (Supplementary 
Table S1). The PCR product was then analyzed on a 1.5% agarose gel. The sequence 
of the GPR43 5’ end was confirmed using Big Dye Terminator cycle sequencing kit 
and ABI 3100 Genetic Analyser (Life Technologies).  
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3.6. NF-κB luciferase reporter assays 
 
 For A549 cells, luciferase assays were performed in 24-well plates. 
Transfections were performed at ~80% confluency using the TurboFect Transfection 
Reagent (Thermo Scientific), and according to the manufacturer’s protocol. A 
combination of 0.8 µg expression/control vector + 0.2 µg pNFκB_Luc (Stratagene) + 
0.02 µg pRL-CMBV (Promega) was used. For experiments involving the exogenous 
expression of multiple proteins, an equal mass of each expression vector was used to 
make up 0.8 µg. Following ligand induction, the luciferase activities were measured 
with the Dual-Luciferase® Reporter Assay kit (Promega). 
 
3.7. Electroporation of primary human monocytes 
 
 Freshly isolated peripheral blood monocytes were electroporated with 5 µg 
plasmid or 200 nM siRNA per electroporation cell, on a Nucleofector II Device 
(Program Y-001) (Lonza), using the Amaxa Human Monocyte Nucleofector Kit 
(Lonza). The monocytes were then cultured in RPMI media (with 10% FBS and 1% 
v/v penicillin and streptomycin) at 37oC. 
 
3.8. Measuring promoter activity in U937 cells with luciferase 
reporter assay 
 
The full-length promoter, deletion and mutant constructs were transiently 
transfected into differentiated U937 cells at 48 h after removal of PMA, with X-
tremeGENE HP DNA Transfection Reagent (Roche) according to the manufacturer’s 
standard protocol. Promoter-pGL4.20 vector constructs and pRL-CMV control 
Renilla luciferase vector (Promega) were transfected in the molar ratio of 10:1. 
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Luciferase reporter activities were assessed using the Dual Luciferase Reporter Assay 
System (Promega) 24 h after transfection [Figure 3.1]. Relative light units were 
calculated using readouts from the pGL4.20-Basic (promoter-less) vector or the wild 
type promoter as baseline for deletion and mutation constructs, respectively. 
 
Luciferase genePutative GPR43 promoter region
Exon GPR43 CDS hChr19
















Figure 3.1 | Assay for putative GPR43 promoter activity with luciferase reporter system. 
The putative GPR43 promoter sequence (spanning -4560 to +68 bp relative to the TSS) was 
cloned into the reporter plasmid immediately upstream of the luciferase gene, where the 
cloned sequenced would act as the promoter for the luciferase gene expression. This plasmid 
was then transfected in PMA-differentiated U937 monocytes. By measuring the 
luminescence, the expression level of the luciferase enzyme and hence the promoter activity 
of the cloned sequence can be quantified. 
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3.9. XBP1s siRNA knockdown and heterologous expression 
 
For transient knockdown, negative control scrambled siRNA (Life 
Technologies, #4390843) was purchased from Life Technologies while XBP1-
sequence specific siRNA targeting  sequences,  Sense: 5’-
AAAGACAGCAAGTGGTAGATTTA-3’; Anti-sense: 5’-
AAAATAAATCTACCACTTGCTGT-3’ 48 was synthesized. siRNA was 
nucleofected into undifferentiated U937 cells with Amaxa Cell Line Nucleofector Kit 
C (Lonza) using the Amaxa Nucleofector II device and the accompanying protocol 
optimized for U937. The U937 cells were PMA-differentiated right after 
nucleofection. GPR43 mRNA was determined at 72 h after siRNA knockdown. The 
culture medium was refreshed at 24 h after nucleofection.  
For stable knockdown of XBP1, siRNA sequences  
Sense: 5’-AAAGACAGCAAGTGGTAGATTTA-3’; Anti-sense: 5’-
AAAATAAATCTACCACTTGCTGT-3’ 131 was cloned into pFIV-H1/U6 vector 
(System Biosciences), while a non-targeting sequence was cloned as the negative 
control vector. The resulting siRNA vector construct or pFIV-H1/U6-copGFP vector 
(System Biosystems), which contains CopepodGFP coding sequence in replacement 
of the puromycin selection marker, was co-transfected with lentiviral packaging 
vectors pFIV-34N and pVSV-G into HEK-293T cells with TurboFect transfection 
reagent (Thermo Scientific). Culture supernatant was collected after 48 h and used to 
resuspend U937 cells, with the addition of polybrene to a final concentration of 8 
µg/mL. The resulting suspensions were then centrifuged at 1000 g for 2 h at 37 oC, 
after which the transduced cells were re-suspended in 2 mL of fresh complete RPMI 
media and seeded into 6 well plates. Successfully transduced cells were selected with 
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1 µg/mL puromycin (Life technologies) in culture medium 48 h after transduction, for 
1.5 weeks. 
For XBP1s overexpression, XBP1s coding sequence (NM_001079539.1) was 
cloned into pcDNA3.1A (Invitrogen) and transfected into A549 cells using X-
tremeGENE HP DNA Transfection Reagent (Roche) according to the manufacturer’s 
instructions. 
 
3.10. Cell treatments 
 
 Acetate treatments were applied as sodium acetate (Sigma-Aldrich) solution. 
To specifically activate GPR43 or GPR41 in both human and mice, cells were treated 
with 10 µM of the synthetic agonists, CFMB ((2S)-2-(4-chlorophenyl)-3,3-dimethyl-
N-(5-phenylthiazol-2-yl)butanamide) (Calbiochem) (ChemSpider ID: 24656891) 
(EC50 of ~0.7 µM) 23 and AR420626 (N-(2,5-Dichlorophenyl)-4-(furan-2-yl)-2-
methyl-5-oxo-1,4,5,6,7,8-hexahydro-quinoline-3-carboxamide) (Glixx Laboratories) 
(EC50 of ~0.7 µM) respectively 24. Inflammatory stimuli used include 100 ng/mL 
Escherichia coli 055:B5 LPS (Sigma), 10 ng/mL TNF (Gibco), 200 nM 12-O-
Tetradecanoylphorbol-13-acetate (TPA) (Sigma) and 100 ng/mL PAM3CSK4 
(Invivogen). To inhibit Gi/G0, 500 ng/mL of Pertussis Toxin (PT) (Invitrogen) was 
used while Gq/11 was inhibited with 10 µM YM254890 84. Akt was inhibited with 2 
µM Wortmannin (Sigma). ERK was inhibited with 10 µM U0126 (Cell Signaling). 
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3.11. Proteome array and Western blot analysis of MAPKs and 
cytokines 
 
 The Human Phospho-MAPK Array Kit (R&D Sytems, ARY002B), Mouse 
Cytokine Antibody Array (R&D Systems, ARY006) and Human Cytokine Array Kit 
(R&D Systems, ARY005) were used. The array chemiluminescent signals were 
captured with ImageQuant™ LAS 4000 mini (GE Healthcare). Densitometric analysis 
was performed using the ImageQuant TL Software (GE Healthcare) as described 
above. Optical densities were standardized to the mean positive control (reference 
spots 1 to 3) readings and displayed as a heat map generated using the matrix2png 
program 132. 
 Total cell lysates were resolved on a denaturing SDS PAGE gel (10-12 %) and 
transferred onto Immuno-Blot PVDF membranes (Biorad). These were then probed 
according to the manufacturer’s recommended incubation conditions, with antibodies 
against XBP1 (Abcam, ab37152), β-actin (Sigma, a2066), against phospho-p38 
(Thr180/Tyr182) (Cell Signaling, 4511), p38 (Cell Signaling, 8690), phospho-Akt 
(Ser437) (Cell Signaling, 4060), Akt (Cell Signaling, Cat. #9272), phospho-ERK1/2 
(Thr202/Tyr204) (Cell Signaling, 4370), or ERK1/2 (Cell Signaling, Cat. #9107). 
These primary antibodies were then probed with the respective HRP-conjugated 
secondary antibodies: Goat anti-Rabbit (Dako, P00448) or Goat Anti-Mouse (Dako, 
P0447). Western blots were developed in WesternBright ECL chemiluminescent 
substrate (Advansta) and the chemiluminescent signals captured with an 
ImageQuant™ LAS 4000 mini (GE Healthcare). Densitometric analysis was 
performed on biological triplicates using the ImageQuant TL Software (GE 
Healthcare. These PVDF blots were then stripped as described by Yueng and Stanley 
133
 before further reprobing.  
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3.12. ChIP assay. 
 
ChIP assay was performed as described previously 134. Differentiated U937 
cells were cross-linked with 1% formaldehyde for 10 min at room temperature and 
then quenched with 0.2 M of glycine. Chromatin extracts from lysed cells were 
sonicated to an average DNA fragment length of 350 bp and immunoprecipitated with 
Santa Cruz Biotechnology antibodies, anti-XBP1 (sc-7160) or IgG isotype control 
(sc-2027). Following de-crosslinking, quantitative PCR was performed with multiple 
ChIP primers to quantify the relative occupancy of the GPR43 promoter region. Fold 
enrichment was obtained by normalizing the amount of precipitated DNA to that of 
the input sample and then expressed relative to the GPR43 negative control coding 
region.  
 
3.13. Real-time quantitative PCR analysis of cytokine mRNA. 
 
 RNA was extracted using the Trizol Reagent (Ambion). The resulting RNA 
was subjected to an additional round of Trizol extraction to further remove any 
protein/DNA contamination. The purified RNA was reverse transcribed with the 
SuperScript® III First-Strand Synthesis System (Invitrogen) with both the oligo(dT) 
and random hexamer primers used. The resulting cDNA was analyzed by real-time 
qPCR using the GoTaq® qPCR Master Mix (Promega) and a LightCycler® 480 
(Roche). Primers, all with an annealing temperature of 60oC, are listed in Table 2.1. 
Spliced XBP1 mRNA was quantified using the Taqman gene expression assay (Life 
Technologies, Hs03929085_g1) and Light Cycler Probes Master (Roche). Each 
condition was performed in biological triplicates and each biological triplicate was 
run in technical triplicates. The mean fold change of the treatment condition relative 
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to the reference condition was calculated using the Relative Expression Software Tool 
(REST MCS ©  - version 2) 135,136.  
 
3.14. In silico predictions of transcription factor binding sites and 
site-directed mutagenesis. 
 
Transcription factor binding sites (TFBS) along the delineated promoter 
regions were identified using the MatInspector program available online at 
http://www.genomatix.de/ 69. Analysis of the sequences was performed using the 
MatInspector TFBS, weight matrix library version 9.0. Only predicted TFBS with a 
core matrix similarity of ≥ 0.95 and an overall matrix similarity of ≥ 0.90, were 
considered significant.  
Promoters containing the specific mutated TFBS were synthesized by 
Integrated DNA technologies. The mutated promoters were cloned into pGL4.20 
vector and confirmed by sequencing as described above.  
 
3.15. Statistical analysis. 
 
 Data are presented as means ± SEM of triplicate conditions/samples tested and 
are representative of at least 3 independent experiments. Differences between 
averages were analyzed by two-tailed Student's t-test. Significance was set at a P-
value of <0.05. *P<0.05; **P<0.005; ***P<0.0005. 
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5’-GRN;GGACACTGACATGGACTGAAGGAGTA;Nested forward primer 
317-5;TCGATGCTGATGCCCGCCAG;Reverse primer 
265-5;AGCCAAAACTCGTGAGGGCG;Nested reverse primer 
394R-5;CCAGAGCTGCAATCACTCCA;GPR43 gene specific reverse transcription 













































Chapter 4 | Results 
 
4.1.  An XBP1 core promoter element regulates GPR43 
expression while CREB, CHOP, NFAT and STAT5 are 
enhancers. 
 
 The transcriptional control of GPR43 is pertinent in a range of crucial 
physiological processes [Table 1.1] 39–47. However, the GPR43 promoter remains 
unknown. Here, we characterize the GPR43 promoter, identifying transcription 
factors and pathways that regulate the expression of GPR43. 
 
 
4.1.1.  PMA-differentiated U937 monocytes are a suitable model 
for GPR43 expression. 
 
 To investigate the mechanisms underlying the specific expression of GPR43, 
we first confirmed the cells with high GPR43 expression, which would presumably 
have high GPR43 promoter activity. Consistent with previous studies 16–18, we found 
human peripheral blood monocytes and neutrophils to express the highest level of 
GPR43 mRNA [Figure 4.1]. Monocytes, as leukocytes, are a functionally relevant cell 
type to study GPR43 promoter activity. This is supported by Maslowski et al 2009 39 
who have demonstrated, through bone transplants, that leukocytes play a key role in 
the inflammatory effects of GPR43. In addition to primary cells, GPR43 expression 
was also assessed in the human U937 promonocytic cell line. Phorbol 12-myristate 
13-acetate (PMA)-mediated monocytic differentiation of the human U937 cell line 
63,64
 led to a 100-fold increase in the transcription of GPR43, yielding mRNA levels 
that was comparable to the peripheral blood monocytes and neutrophils [Figure 4.1]. 
This suggests that the U937 cell line would be a suitable model to study GPR43 




















































perform luciferase reporter assays to characterize the GPR43 promoter. This would 
not be feasible with primary monocytes that are recalcitrant towards transfection with 
the luciferase reporter plasmids. Hence, our GPR43 expression analysis has confirmed 
primary human monocytes and PMA-induced U937 monocytes as suitable cells for 
the characterization of the GPR43 promoter.  
 
Figure 4.1 | GPR43 mRNA is up-regulated in 
primary human monocytes, neutrophils and 
PMA differentiated U937 cells. 
Results shown are real-time PCR measurements 
standardized to undifferentiated U937 cells and 
error bars represent the mean ± SEM of three 
independent cell cultures. Measurements were 




4.1.2. Troubleshooting  the Western blot detection of GPR43. 
 
 Since mRNA expression levels may not correlate with protein expression 65, 
we attempted to confirm the expression of GPR43 at the protein level through western 
blot, which would additionally allow for the confirmation of the molecular weight of 
the detected product. A lack of correlation between GPR43 mRNA and protein would 
suggest that, in addition to transcriptional control, other factors such as the rate of 
GPR43 translation or degradation may also be involved in regulating GPR43 
expression. With no prior reports on the western blot detection of GPR43, we first 
attempted to confirm if some commercially available GPR43 antibodies were able to 
detect, the increase in GPR43 protein expression in A549 adenocarcinomic human 
alveolar basal epithelial cells transfected with GPR43 expression vectors. The 
expression of mCherry-tagged GPR43 [Figure 4.2A] and the functional up-regulation 
of GPR43 activity (leading to a greater reduction in cAMP upon acetate treatment) 
[Figure 4.2B] in these cells were confirmed. However, we failed to detect any specific 
increase in the western blot signal intensities at the corresponding molecular masses 
(37 kDa for GPR43; and 66 kDa for GPR43-mcherry fusion) when probing with the 
GPR43 antibodies [Figure 4.2 C, D and E]. Efforts to obtain a more specific western 
blot detection have yet to succeed. With the lack of specificity of the GPR43 western 
blots in question, we are thus limited to real-time quantitative PCR assays, which 











































Amino  acids  281-330 of human GPR43PolyclonalRabbitab131003Abcam
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Figure 4.2 | GPR43 antibodies failed to detect specific bands at the predicted 27 kDa 
molecular weight of human GPR43. 
(A) The expression of GPR43 with a C-terminal mCherry tag in A549 cells. (B) A549 cells 
transfected to overexpress GPR43 display a greater reduction in cAMP upon acetate treatment 
as measured with Promega cAMP-Glo assay. The data shown are the means of three 
independent cultures for each treatment condition and is standardized to the to the untreated 
controls (0 mM NaAc); ± SEM; n = 3. (C) Western blot analysis of GPR43 protein levels, 24 
h after A549 cell were transfected with indicated expression plasmids. Calculated molecular 
masses: 37 kDa for GPR43; and 66 kDa for GPR43-mcherry. The representative blot shown 
was probed using rabbit anti-GPR43 (Santa Cruz, sc-32806). (D) Detail of the GPR43 
antibodies used. (E) GPR43 amino acids sequences used as the antigen for antibody 
generation. 
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4.1.3. GPR43 transcription start site is located at 1459 bp 
upstream of the ATG start codon 
 
From PMA-differentiated U937 monocytes, we performed a 5'-RACE of the 
GPR43 transcript, to determine the yet unknown 5'-UTR sequence of GPR43. This 
was done to allow us to identify the transcription start site (TSS) and the likely 
position of the core promoter that is usually a few dozen base pairs upstream of the 
TSS. 5'-RACE of the GPR43 transcript generated an approximately 450 bp product 
[Figure 4.3A] which was sequenced to reveal a 124 bp 5'-UTR upstream of the GPR43 
ATG start codon [Figure 4.3B]. Mapping of this sequence with the human genome 
database (NCBI Ref Seq: NC_000019.10) revealed the presence of a 1335 bp intron 
flanked by the GPR43 5'-UTR and the start codon [Figure 4.3B]. This more complete 
GPR43 mRNA sequence has been uploaded to genbank [Figure 4.3C]. Thus, the 
transcription start site (TSS) is located 1459 bp upstream of the ATG start codon. 
While it was difficult to judge the presence of other 5'-RACE products [Figure 4.3A, 
Lane 1], we note that a previously reported northern blot analysis [Senga et al., 2003 
34
, Figure 3.3h], detected two GPR43 transcripts, with the shorter (~2.3 kb) product 
being many times more abundant than the longer transcript (~3.5 kb). It is possible 
that the two transcript sizes described by Senga et al., 2003 34 are due to different 
lengths of the 5'-UTR, which can possibly result from alternate splicing 66 or 
promoters 67. Interestingly, the ~3.5 kb transcript matches the length of a hypothetical 
GPR43 transcript containing the 1335 kb intron, which may conceivably be present 
due to alternate splicing. The transcript detected by the 5' RACE here is likely the 
shorter, more abundant, transcript. Our attempts to detect the presence of other 
possible 5'-UTR species via RACE were thus far unsuccessful [data not shown], 
presumably due to the low abundance. Overall, these results characterize the 5’ region 
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of the human GPR43 gene and allow the putative core promoter to be identified for 
subsequent analysis of transcriptional elements. 
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Figure 4.3 | The GPR43 transcription start site is mapped to 1459 bp upstream of the 
ATG start codon. 
(A) 5’-RACE of GPR43 transcripts from U937 cells. Total RNA from U937 cells was 
extracted and full-length GPR43 mRNA was reverse transcribed using a gene specific primer 
complementary to its open reading frame. The resulting cDNA was ligated to a known 
oligonucleotide sequence at the 5’ end. Nested PCR using primers flanking the 5’ end was 
then performed to procure an approximately 450 bp product encompassing the 5’ untranslated 
region (5’-UTR) and part of the GPR43 coding sequence (lane 1). As positive controls, 
amplification of 246 bp of the GPR43 coding region (lane 2), as well as a 900 bp-long 5’ end 
of the β-actin gene (lane 3) were performed. (B) Schematic mapping the GPR43 5’-UTR 
region and protein coding region on the human chromosome 19. The PCR product from (a, 
lane 1) was sequenced to reveal a 124 bp long 5'-UTR exon upstream of the GPR43 ATG 
start codon. (C) Sequence of GPR43 5'-UTR or exon 1. 
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4.1.4. The core and proximal promoter of GPR43 are located 
within a 500 bp region that is 30 bp upstream of the 
transcriptional start site (TSS) 
 
 With the TSS identified, we cloned a putative promoter region (spanning -
4560 to +68 bp relative to the TSS) from genomic DNA isolated from the primary 
human monocyte, and analyzed its promoter activity using dual luciferase reporter 
system as described in the materials and methods section. The sequence cloned was 
selected based on cross-species sequence alignment identifying short stretches of 
alignment with greater than 70 % sequence identity to the corresponding mouse 
sequence [Figure 4.4A], suggesting conservation due to involvement in transcriptional 
regulation 68. This region should also contain the likely position of the core promoter, 
which is generally a few dozen base pairs upstream of the TSS, as well as any 
potential enhancer/repressor elements, up to 4.5 kb upstream of the TSS.  
 The putative GPR43 promoter (-4560 to +68 bp relative to the TSS), raised the 
luciferase reporter activity by > 100-fold as compared to the promoter-less control 
vector [Figure 4.4B]. Deletion from positions -4560 to -451 revealed no significant 
change (p-values > 0.05) in luciferase activity [Figure 4.4B], implying that this region 
lacks regulatory elements, which is consistent with the general lack of sequence 
conservation observed [Figure 4.4A]. Although two short sequence alignments do 
appear in this region, we note that the corresponding mouse sequences are much 
further away from the mouse Gpr43 gene (0.6 Mbp and 1.7 Mbp, respectively), 
suggesting a lack of involvement in mouse Gpr43 transcriptional control. Deletion 
from positions -451 to -182 resulted in a marked drop (p-value = 0.07) in activity 
while further deletions downstream of position -182 resulted in near abrogation in 
activity (p values < 0.005), suggesting that the region spanning -451 to -58 might 
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contain crucial activator elements [Figure 4.4B]. This is consistent with the observed 
interspecies sequence conservation [Figure 4.4A]. Strikingly, the near abrogation of 
promoter activity upon deletion of -58 to -33 suggests that the core promoter 
element(s) lies within this 25 bp region [Figure 4.4B]. Thus, the step-wise deletions 
define the core and proximal promoter of GPR43 within -451 to -33 from the TSS. 
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Figure 4.4 | Deletions define a 519-bp putative GPR43 promoter containing the core and 
proximal promoter. 
(A) ECR Browser plot spanning -4560 bp upstream of the transcription start site (+1), the 
entire GPR43 gene and 2000 bp after the gene. The plot represents sequence homology of the 
mouse chromosome 7 (Ref Seq ID: NC_000073.6 ) region flanking the murine Gpr43 (Entrez 
Gene ID: 233079) in comparison to the corresponding region on the human chromosome 19 
(RefSeq ID: NC_000019.9; positions: 35934599 - 35942669), which is acting as the baseline. 
Sequence lengths of >100 bp with 70 % sequence conservation are shown as peaks. (B) 
Luciferase reporter activities of 5’ deletion constructs from a 4628 bp putative GPR43 
promoter in differentiated U937 cells 22 h after transfection. Analysis of the homology with 
mouse sequence was used to approximate the deletion sites. Results represent the average 
Firefly luciferase read-outs of three independent transfections normalized to Renilla luciferase 
activity and relative to the basic (empty) luciferase vector, which is arbitrarily set as 1. Error 
bars represent mean ± SEM; n=3. The data shown are representative of three independent 
experiments. Two tailed Students’ T-test was used to determine the statistical significance of 
the difference between promoter constructs and is annotated as: * < 0.05 and ** < 0.005. 
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4.1.5. XBP1 is part of the GPR43 core promoter while CREB, 
CHOP, NFAT and STAT5 act as enhancers. 
 
 Upon defining the core and proximal promoter of GPR43 to within a 510 bp 
region, we attempted to identify the promoter elements. By in silico predictions using 
the MatInspector program 69, we predicted 8 transcription factor (TF) recognition sites 
with high matrix similarity of ≥ 90% within the 519 bp putative promoter [Figure 4.5]. 
The validity of these predictions were then tested by site-directed mutagenesis of the 
TF binding site sequence to produce null mutants that were no longer predicted by 
MatInspector to bind TFs. Of the 8 predicted TFs, the null mutations of Tax/CREB, 
CHOP, NFAT and STAT5/5B resulted in significant losses in activity compared to 
the wild type (WT) promoter [Figure 4.5B], indicating that these TFs may be 
important enhancers for the control of GPR43 expression. Conversely, no significant 
loss in activity was found for mutations in the IRF4, PU.1 and c-Rel recognition sites. 
Mutation of the XBP1 recognition site resulted in near abrogation of promoter 
activity, hence identifying it as a crucial core cis element. Notably, this XBP1 
recognition site resides within the 25 bp region that was deleted from the 126 bp 
promoter [Figure 4.4B]. XBP1 binding also appears to be required for the low level 
GPR43 expression observed in A549 adenocarcinomic human alveolar basal 
epithelial cells since the XBP1 null mutation also led to near abrogation in promoter 
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Figure 4.5 | In silico predictions and null mutations of the 519 bp promoter region, 
identify transcription factors (TFs) and pathways regulating GPR43 expression. 
(A) Predicted TF binding sites by MatInspector software with corresponding WT and mutant 
sequences and their relative positions indicated above each TF binding site. The core 
recognition sequences are underlined while mutated bases are indicated in red. (B) Relative 
luciferase reporter activities of 519-bp promoter mutated at indicated sites were measured in 
differentiated U937 monocytes and A549 cells. The multiple binding sites of PU.1 or NFAT 
residing within the 519 bp promoter were simultaneously mutated in their respective 
constructs. Wild type (WT) promoter is arbitrarily set to 1 luciferase unit. The error bars 
represent the mean of triplicate transfections ± SEM. The data shown are representative of 
three independent experiments. The two tailed Students’ T-test was used to determine 
statistical significance. p-value * < 0.05 and ** < 0.005. 
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4.1.6. The activities of p38 and PLC are required for GPR43 
transcription. 
 
 A number of the predicted TFs are known to be regulated by MAPK and 
PLC/PKC pathways 70–72 [Figure 4.6A]. To determine if these pathways are involved 
in the modulation of GPR43 expression, we blocked the putative pathways with small 
molecule inhibitors [Figure 4.6 B and C]. Both SB203580 and U73122, inhibitors of 
p38 and PLC, respectively, attenuated GPR43 transcription in LPS-challenged 
monocytes [Figure 4.6B] while only SB203580 attenuated GPR43 transcription in 
unchallenged monocytes [Figure 4.6C]. This suggests that the p38 pathway is required 
for basal transcription of GPR43, which is active with or without LPS-challenge while 
the PLC-PKC pathway is important only during LPS-mediated upregulation of 
GPR43. This may be due to p38 pathway activation of XBP1 72, which is part of the 
core promoter regulating basal transcription [Figure 4.6B]; while the PLC-PKC 
pathway activates NFAT 71, which we find to act as an enhancer [Figure 4.6B]. The 
p38 pathway also activates CHOP 70. Separately, the proteasome inhibitor, MG132, 
reduced GPR43 mRNA levels with or without LPS treatment while Wortmannin, an 
inhibitor of the PI3K/Akt pathway, increased GPR43 transcript levels. The increase in 
GPR43 expression observed suggests that there was a relief of suppression that is 
mediated by the PI3K/Akt pathway. However, the current information is insufficient 
to deduce whether this is a direct or indirect effect from PI3K/Akt signaling. 
Nevertheless, it should be noted that activation of the PI3K/Akt pathway may lead to 
the inhibition of p38 73, suggesting that the increase may be due to the recovery of p38 
causing an indirect activation of GPR43 expression. Overall, our findings indicate that 
activation of the GPR43 expression is mediated by the p38 and PLC/PKC pathways, 
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and transcriptional regulation may also involve the proteasome degradation and 
PI3/Akt pathways. 
 
4.1.7. ChIP analysis confirmed XBP1 binding to GPR43 promoter 
in vivo. 
 
 Since the XBP1 binding sites were found to be essential for promoter activity, 
we investigated XBP1 binding to the endogenous GPR43 promoter.  Chromatin 
immunoprecipitation (ChIP) was performed with antibodies against XBP1. The 
GPR43 promoter XBP1 binding site was significantly enriched in the resulting 
immunoprecipitate, consistent with strong association of XBP1 to that site [Figure 
4.7]. The pull down appears specific as no significant enrichment was detected for the 
negative control genomic regions and no GPR43 promoter enrichment was observed 
and when the isotype control antibody was used. Thus, we confirmed XBP1 binding 
to the endogenous GPR43 promoter, further substantiating the role of XBP1 in 
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LPS + + + + + + - - +
SB203580 (p38) - + - - - - - - -
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Wortmannin (Akt) - - - - + - - - -
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Figure 4.6 | The p38 and PLC-PKC pathways are involved in regulating GPR43 
expression. 
(A) Known interactions between protein kinases and transcription factors. P38 activates 
XBP1 72 and CHOP 70; PLC-PKC activates NFAT 71; Akt 74 and PKC 75 activates CREB; 
cAMP activates CREB 76; MG132 inhibits NF-kB 77. (B) Quantitative PCR analysis of 
GPR43 mRNA levels upon modulation of signaling pathways after 1 h pre-treatment with 
activators / inhibitors followed by immune challenge for 3 h with 100 ng/mL LPS. (C) 
Quantitative PCR analysis of GPR43 mRNA levels upon 4 h treatment of monocytes with 
inhibitor / activator or 12 h treatment with inhibitor. (B and C) Inhibitor / Activator + 
(Targeted signaling proteins) are shown: SB203580, 10 µM | p38; U73122, 5 µM | 
phospholipase C (PLC); MG132, 10 µM | Proteasome; Wortmannin, 2 µM | PI3kinase 
(PI3K); BisI, 4 µM | protein kinase C (PKC); Forskolin, 20 µM  Adenylyl cyclase (AC). 
Expression levels of two reference genes, beta-2-microglobulin (B2M) and cyclophilin B 
(CYPB) were also measured and presented below. All measurements were standardized to the 
RPL27 as the reference gene. Error bars represent the mean of triplicate transfections or 
treatments ± SEM. The data shown are representative of three independent experiments. The 
two tailed Students’ T-test was used to determine statistical significance. p-value * < 0.05. 


























































































Figure 4.7 | XBP1 binds to the GPR43 promoter in vivo. 
(A) Schematic showing the relative regions of GPR43 promoter amplified by quantitative 
PCR following ChIP assay with anti-XBP1 antibody. The P1 to P6 PCR products span ~ 1200 
bp surrounding the XBP1 binding site on the GPR43 promoter. Only promoter regions, P3 
and P4 contain the XBP1 binding site. The GPR43 enhancer region and coding sequence, 
located more than 3 kb and 2.5 kb up- and downstream of the XBP1 binding site respectively, 
were also amplified as negative controls. (B) Quantitative PCR analysis of GPR43 promoter 
regions following ChIP assay on U937 cells using anti-XBP1 antibody or IgG isotype control 
antibody. Results are expressed as fold enrichment relative to GPR43 coding sequence 
(GPR43_CDS) negative control region and error bars represent the mean ± s.d. of three 
independent pull-down. p-value * < 0.05 and ** < 0.005. The data shown are representative 
of two independent experiments. 
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4.1.8. GPR43 expression is altered by XBP1-siRNA knockdown or 
overexpression. 
 
 Next, we investigated the effect of XBP1 knockdown and heterologous 
expression, on the endogenous expression of GPR43. Measuring endogenous GPR43 
expression allows us to account for additional regulatory mechanisms such as DNA 
methylation and chromatin remodeling, which are not evaluated by the promoter 
luciferase assays used previously. 
 We attempted to knockdown XBP1 expression in U937 cells via 
electroporation of XBP1-siRNA which resulted in a ~70 % drop in XBP1 mRNA at 
24 h after electroporation [Supplementary Figure 1]. A 50% knockdown persisted up 
to 96 h post-electroporation. A corresponding reduction in GPR43 expression would 
have confirmed that XBP1 activity is required for endogenous GPR43 transcription. 
However, no significant decrease in GPR43 mRNA was detected.  
 This lack of an observable reduction in GPR43 during transient XBP1 
knockdown [Supplementary Figure 1] may be due to the 50% knockdown being 
insufficient to produce a detectable reduction in GPR43 expression. The low 
knockdown efficiency may be a consequence of a low transfection rate as the Amaxa 
Cell Line Nucleofector Kit C (Lonza) used is reported by the manufacturer to produce 
only up to 70% transfection rate under optimized conditions. Another possibility is 
that the knockdown time was insufficient. Some time is required following mRNA 
knockdown before XBP1 protein levels are reduced, leading to reduced XBP1 
activity. Following this, additional time is required before the difference in GPR43 
promoter activity leads to a measurable difference in GPR43 mRNA levels. To 
improve transfection efficiency and to allow for a lengthier knockdown time, we 
performed a stable knockdown of XBP1 in U937 cells via lentiviral transduction. This 
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led to a reduction in GPR43 expression levels relative to the control siRNA [Figure 
4.8 A and B]. Conversely, in the A549 cell line, which expresses low levels of GPR43 
mRNA [Figure 4.1], the heterologous expression of the active spliced form of XBP1 
(XBP1s) raised GPR43 expression levels [Figure 4.8 C and D]. Collectively, we have 
confirmed that XBP1 modulates endogenous GPR43 expression. 
 Additional attempts were also made to investigate the effect of XBP1 
knockdown during LPS-mediated induction of GPR43 expression in U937 cells. 
However, XBP1 knockdown was lost during PMA-mediated monocytic 
differentiation of U937 [Supplementary Figure 2], which is required to render the cells 
LPS responsive 63,64. Consistently, without XBP1 knockdown, the repression of 
GPR43 expression was also lost. Efforts to identify a more potent XBP-1 siRNA 

































































































A. U937 C. A549
 
Figure 4.8 | XBP1 is critical for the expression of GPR43. 
(A) Real time PCR analysis of U937 cell stably transduced with XBP1-siRNA showing 
reduced XBP1s and GPR43 mRNA relative to cells transduced with the negative control (non-
targeting) siRNA (which is arbitrarily set as 1).  (B) Western blot analysis showing reduced 
unspliced XBP1 (XBP1u) protein levels in XBP1-stable knockdown U937 cells. XBP1s 
levels were undetectable. (C) Real time PCR analysis of A549 cells after 48 h overexpression 
of XBP1s showing increased XBP1 and GPR43 mRNA relative to the pcDNA empty vector 
(which is set arbitrarily as 1). (D) Western blot analysis of XBP1s protein levels after 48 h 
overexpression of XBP1s in A549 cells. (B and C) Measurements were standardized to 
RPL27 as the reference gene. (A and C) Results shown are the average of three independent 
transductions (for stable knockdown) or transfections (for overexpression), with error bars 
representing the mean ± SEM. The data shown are representative of two independent 
experiments. Two tailed Students’ T-test was used to calculate statistical significance. p-value 
* < 0.05. 
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4.1.9. GPR43 expression is up-regulated by XBP1 activators. 
 
 The XBP1-mediated transactivation of GPR43 prompted us to examine 
whether GPR43 expression might be increased by known activators of XBP1. LPS 
acts via the TLR4 pathway to increase XBP1 splicing into the functional transcript, 
thereby increasing XBP activity 78. GM-CSF is a known positive regulator of 
dendritic cell development 79, a process which requires XBP1 80. We found that LPS 
treatment increased the GPR43 transcription by at least 7-fold while GM-CSF raised 
transcription by 5-fold [Figure 4.9A]. Both stimuli were previously reported to induce 
GPR43 expression via an unknown mechanism 34. Our results now reveal this to be 
attributable to XBP1 activation since an  increase in the expression of the active 
spliced form of XBP1 (XBP1s) is detected [Figure 4.9B]. Besides LPS, treatment with 
TNF also up-regulated GPR43 transcription by 5-fold. TNF is another inducer of 
XBP1 activity, acting via the induction of the UPR which then enhances XBP1 
mRNA splicing to the active spliced form 81. Thus, we have demonstrated that 


































































Figure 4.9 | Human monocyte GPR43 expression is up-regulated by LPS, TNF and GM-
CSF treatment. 
(A) Quantitative PCR analysis of GPR43 mRNA and (B) spliced XBP1 (XBP1s) mRNA 
levels under 3 h treatment with either 100 ng/mL LPS; 10 ng/mL TNF or 100 ng/mL GM-
CSF. (A and B) The results represent average fold change of the treated samples relative to 
the non-treated control (NT) and error bars represent the mean ± SEM of three independent 
treatment wells. Measurements were standardized to RPL27 as the reference gene. Two tailed 
Students’ T-test was used to determine the statistical significance of the difference between 
treated and NT samples. p-value * < 0.05 and ** < 0.05. The data shown are representative of 
at least two independent experiments. 
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4.2. Acetate acts via GPR43 and GPR41 to repress 
inflammatory signaling and cytokine expression in human 
monocytes 
 
 Our findings thus far revealed that GPR43 mRNA expression is upregulated in 
monocytes by the XBP1 transcription factor, which is further inducible by 
inflammatory stimuli such as LPS and TNF. This suggests that GPR43 may play an 
important role in monocyte response to SCFAs during inflammation. However, the 
role of GPR43 in monocytes remains ill-defined, which is the next subject of our 
investigation. 
 
4.2.1. Human monocyte cytokine expression is reduced by the 
GPR43 ligand, acetate. 
 
 A potential role for GPR43 in monocytes is the modulation of inflammatory 
cytokine expression. The ability of GPR43 to modulate cytokine expression is hinted 
at in our previous finding that the CRP and M-ficolin interaction with GPR43 leads to 
reduced monocyte IL-8 secretion 60. Previous studies have also shown that GPR43 
SCFA ligands can inhibit CCL2 and IL-10 cytokine expression in vitro 59. However, 
how GPR43 mediates these SCFA effects has not been studied. To determine if 
GPR43 plays such a role, we first indentified the cytokines that are altered in 
monocytes by treatment with the GPR43 SCFA ligand, acetate. Among the known 
GPR43 SCFA ligands (acetate, propionate and butyrate), we utilized acetate for the 
SCFA treatments to be more specific as both butyrate and propionate reportedly 
inhibit histone deacetylases 20 while butyrate also activates GPR109A 21. To 
reproduce conditions in the colon, where low milimolar concentrations of acetate have 
been detected 9,10, a 5 mM concentration of acetate was applied during treatment. Cell 
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cytokine mRNA levels were quantified at 4 h and 12 h post LPS challenge while 
protein levels were measured at 6 h and 12 h post LPS challenge. This is based on 
available literature 82,83 on the kinetics of monocyte cytokine expression during LPS 
challenge where cytokines such as TNF, IL-1α and IL-1β will show peak expression 
at 4 to 6 h while others such as IL-8 and IL-10 peak after 12 h. 
 In LPS-activated human monocytes, acetate treatment caused a 
downregulation of C5, CCL1, CCL2, GM-CSF, IL-1α, IL-1β, sICAM-1 and TNF 
cytokine expression [Figure 4.10]. These changes in the cytokine level were also 
detected at the transcript level [Figure 4.11 A and D][ Figure 4.12C], suggesting that the 
altered protein levels are a consequence of the mRNA changes. The cytokine 
inhibition is not specific to the LPS-induced pathway as both naive and activated 
monocytes were similarly susceptible [Figure 4.12B]. Overall, we have identified 
several key cytokines that may be potentially regulated by GPR43 signaling. 
 
4.2.2. siRNA-mediated knockdown of GPR43 in primary human 
monocytes. 
 
 To investigate if GPR43 signaling is required for the cytokine inhibition by 
acetate, we attempted to knockdown GPR43 expression in primary human monocytes 
via electroporation of GPR43 specific siRNA. The nucleofection of cyclophilin B 
gene-specific siRNA (positive control), led to a 90% knockdown in cyclophilin B 
mRNA [Supplementary Figure 3A]. This suggests that the siRNA nucleofection 
protocol was efficient in introducing siRNA into monocytes for knockdown. 
However, nucleofection of GPR43 gene-specific siRNAs, failed to produce efficient 
knockdown, even with multiple different sequences tested, [Supplementary Figure 
3B]. Thus far, we have been unable to efficiently knockdown GPR43 expression. 
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4.2.3. Acetate-mediated cytokine inhibition is absent in U937, HT-
29 and 3T3-L1 cell lines. 
 
 To produce a more efficient knockdown of GPR43, we attempted the stable 
transduction of GPR43-siRNA. Before that can be done, a suitable cell line that 
reproduces human monocyte response to acetate must be found. We performed the 
same combined acetate and LPS treatments on U937 promonocytic cell lines that are 
found to upregulate GPR43 mRNA. However, acetate treatment did not significantly 
reduce the cytokine expression of U937 cells [data not shown]. In addition to U937 
cells, the HT-29 (human colorectal adenocarcinoma) and differentiated 3T3-L1 
(mouse adipocytes) cells also displayed upregulated GPR43 mRNA. These cells were 
pretreated with acetate followed by the activation of cytokine expression with TNF. 
Again, acetate treatment of HT-29 and 3T3-L1 did not reduce cytokine expression 
[data not shown]. Thus, it would appear that the acetate-mediated suppression of the 
cytokine expression does not occur in the cell lines tested, and may be specific to 
primary human monocytes. 
 
4.2.4. The GPR43-specific synthetic agonist, CFMB, repressed 
human monocyte cytokine expression.  
 
 While we were unable to investigate GPR43 via siRNA-mediated knockdown, 
the recent development of synthetic agonists enabled us to specifically activate 
GPR43 23. Human monocytes treated with the GPR43 agonist, (2S)-2-(4-
chlorophenyl)-3,3-dimethyl-N-(5-phenylthiazol-2-yl)butanamide [abbreviated as 
CFMB], displayed reduced CCL1, CCL2, GM-CSF, IL1a, IL1b, ICAM1 and TNF 
mRNA at 4 h post-LPS [Figure 4.11B] and -PAM3CSK4 [Figure 4.12B] challenge, 
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mirroring the inhibition by acetate [Figure 4.11A] [Figure 4.12 B and C]. Only 
reductions in C5 at 6 and 12 h post-LPS challenge, and CCL2 at 6 h post-LPS 
challenge [Figure 4.10 A and B], were observed at the protein level. This may be due to 
the purported instability of CFMB 23, which may not sustain the inhibition long 
enough for a drop to be observed at the protein level. Consistent with this instability, 
while acetate-mediated cytokine mRNA inhibition persisted at 12 h post-LPS 
challenge [Figure 4.11D], the CFMB-mediated cytokine mRNA inhibition at the same 
time point was abated [Figure 4.11E].  Additionally, monocytes pretreated with acetate 
for 12 h prior to a 4-h LPS challenge, continued to display suppressed cytokine 
mRNA expression, while monocytes pretreated with CFMB for 12 h did not [Figure 
4.12A], possibly due to CFMB degradation. On the whole, the results here suggest that 
the acetate-mediated cytokine downregulation may be due to the activation of GPR43 
since similar downregulations are observed during specific activation of GPR43 by 
synthetic agonists. 
 
4.2.5. Human monocyte cytokine expression is reduced by the 
GPR41-specific synthetic agonist, AR420626. 
 
 With the finding that specific activation of GPR43 with CFMB leads to 
repressed cytokine expression, there is a possibility that GPR41, another GPCR 
expressed in monocytes that is activated by SCFAs 16–18, may also share similar 
functions. Specific activation of human monocyte GPR41 (via the synthetic agonist, 
AR420626) under LPS induction, led to reduced expression of C5, CCL1, CCL2, 
GM-CSF, sTREM-1 and IL-1β, at either the protein level [Figure 4.10 A and B] or the 
mRNA level [Figure 4.11 C and F][Figure 4.12C]. This accounts for the reduction of a 
subset of the cytokines observed during acetate treatment [Figure 4.10 A and B][Figure 
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4.11 A and D][ Figure 4.12C], and represents a smaller subset than that observed for the 
GPR43 agonist. Thus, it appears that the human monocyte response to acetate is 
mediated by both GPR41 and GPR43. 
Non-detectable: CCL1,CXCL11,GM-CSF, IFN-
g,IL-10,IL-12, p70, IL-17, IL-17E, IL-1α, IL-2, IL-
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Figure 4.10 | GPR41 and GPR43 agonists repress cytokine expression in human 
monocytes. 
(A and B) Cytokine proteome arrays of human monocytes treated with either 5 mM acetate or 
10 µM CFMB (GPR43 agonist) or 10 µM AR420626 (GPR41 agonist) or the respective 
solvent controls (NT, 0.1% v/v DMSO) for 15 min followed by 100 ng/mL LPS challenge for 
6 h and 12 h. When compared to the respective solvent controls, a reduction in C5, CCL1, 
CCL2, GM-CSF, IL-1α, IL-1β and ICAM-1 protein expression was observed for the acetate 
treated monocytes. Monocytes treated with either CFMB or AR420626 displayed reduced C5 
and CCL2 expression. Two independent cultures for each treatment condition is shown; n = 2. 
(C) Acetate and CFMB- mediated inhibition of CCL2 was confirmed by ELISA. Monocytes 
were challenge with 100 ng/mL LPS challenge for 6 h. The data shown are the means 
concentration from three independent cultures for each treatment condition ± SEM; n=3. The 
data shown are representative of three independent experiments. The two tailed Students’ T-
test was used to determine the statistical significance of this fold change and is annotated as 













































































































































































































Figure 4.11 | GPR41 and GPR43 agonists repress human monocyte cytokine mRNA. 
(A - C) The expression of CCL1, CCL2, CCL3, GM-CSF, IL1α, IL1β and ICAM1 mRNA was 
repressed in both acetate- and CFMB- treated monocytes at 4 h post-LPS induction, while IL8 
and TNF levels remain unchanged. AR420626 treated monocytes show reduced CCL2 
mRNA. (D - F) Cytokine mRNA at 12 h post-LPS challenge as determined by real time 
qPCR analysis. (A - F) Unless otherwise indicated, human monocytes were treated with either 
5 mM acetate, 10 uM CFMB, 10 uM AR420626 or the respective solvent control for 15 min 
followed by a 4 h activation with LPS before the cytokine mRNA levels were measured by 
real-time PCR analysis. The data shown are the means of three independent cultures for each 
treatment condition and is presented as the fold change of the acetate/CFMB/AR420626 
treated samples relative to the respective solvent controls ± SEM; n = 3. Measurements were 
standardized to RPL27 as the reference gene. The data shown are representative of three 
independent experiments. n.d: non-detectable. The two tailed Students’ T-test was used to 
determine the statistical significance of this fold change and is annotated as: * < 0.05, ** < 















































































































































































































































Figure 4.12 | GPR41/43 agonists repress human monocyte cytokine mRNA in a dose 
dependent manner, even in the absence of inflammatory stimuli. 
(A) Cytokine inhibition is observed in monocytes pretreated for 12 h with acetate followed by 
4 h LPS induction but not for 12 h with CFMB. (B) Acetate- and CFMB-mediated cytokine 
repression is observed in both naive and activated monocytes after 4 h of induction. (C) 
Acetate-, CFMB-, and AR420626-mediated cytokine inhibition is dose-responsive as 
determined through real-time qPCR analysis. (A - C) Unless otherwise indicated, human 
monocytes were treated with either 5 mM acetate, 10 uM CFMB, 10 uM AR420626 or the 
respective solvent control for 15 min followed by a 4 h activation with LPS before the 
cytokine mRNA levels were measured by real-time analysis. The data shown are the means of 
three independent cultures for each treatment condition and is presented as the fold change of 
the acetate/CFMB/AR420626 treated samples relative to the respective solvent controls ± 
SEM; n = 3. Measurements were standardized to RPL27 as the reference gene. The data 
shown are representative of three independent experiments. n.d: non-detectable. The two 
tailed Students’ T-test was used to determine the statistical significance of this fold change 
and is annotated as: * < 0.05, ** < 0.005, and *** < 0.0005.  
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4.2.6. GPR43 activates p38 signaling in human monocytes via the 
Gq/11 pathway. 
 
 Monocyte cytokine expression is regulated by the p38, Akt and ERK pathways 
61,62
. These pathways also control other crucial monocyte functions such as 
chemotaxis. Thus, we investigated if GPR41/43 modulated these signaling pathways 
in monocytes. Treatment of human monocyte with either acetate or CFMB (GPR43 
agonist) led to a transient increase in p38 phosphorylation that peaked at 3 min post-
induction [Figure 4.13A]. During this period, Akt was only weakly activated and ERK 
remained unaffected [Supplementary Figure 5]. Since GPR43 has been shown to 
couple to both Gq/11 and Gi/G0 G proteins, we investigated if these pathways were 
involved 16–18. GPR43-mediated activation of p38 persisted during Gi inhibition by 
Pertussis toxin (PT) but was abolished during Gq/11 inhibition by YM254890 84, 
suggesting that Gq/11 signaling is required for the activation of p38 [Figure 4.13B]. 
Taken together, these results indicate that acetate induces GPR43 to transiently 
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Figure 4.13 | GPR43 agonists activates human monocyte p38 in a Gq/11 dependent 
manner. (A) Elevated phosphorylation of p38 was detected in human monocytes at 3 min 
post-induction with either 5 mM acetate (top) or 10 µM CFMB (bottom) through Western 
blots. Each lane represents an independent culture for each treatment condition. (B) 
Phosphorylation of p38 by 5 mM acetate is abolished in human monocytes treated with either 
YM254890 (Gq/11 inhibitor) alone or in combination with Pertussis toxin (PT, Ga inhibitor), 
but is retained in the solvent control (NT) monocytes and monocytes treated with PT alone. 
Results shown are from western blots. Cells were pretreated with PT for 2 h and/or 
YM254890 for 30 min before acetate induction. (A - B) The corresponding optical density 
(OD) is shown as the mean ± SEM; n = 3. The solvent controls (NT and 0.1% v/v DMSO) 
have been arbitrarily assigned the value of 1. The two tailed Students’ T-test was used to 
determine statistical significance and is annotated as: * < 0.05 and *** < 0.0005. The data 
shown is representative of three independent experiments. 
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4.2.7. GPR43 agonists inhibit Akt and ERK phosphorylation in 
human monocytes. 
 
 Next, using proteome array analysis, we determined whether acetate-mediated 
activation of GPR41/43 would alter human monocyte kinase activity during LPS-
induced inflammation. Compared to LPS-treatment alone, combined treatment with 
acetate led to attenuated Akt2 and ERK2 phosphorylation [Figure 4.14A]. 
Consistently, acetate treatment also attenuated the phosphorylation of MSK2 (which 
is activated by ERK and p38 signaling) while the mTOR phosphorylation (a target of 
Akt inhibition) was enhanced. This inhibitory effect was strongest during early 
activation of Akt and ERK2 by LPS [Figure 4.14C]. The Akt and ERK2 inhibition 
was not observed during AR420626 (GPR41 agonist) treatment of human monocytes 
[Supplementary Figure 6], excluding the involvement of GPR41. This inhibition was 
instead, mediated by GPR43 as Western blot analysis confirmed the inhibition of 
ERK2 and Akt during acetate or CFMB treatment while the levels of phosphorylated 
p38 remained unaffected. Thus, we showed that GPR43 inhibits Akt and ERK in 
human monocytes. 
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Figure 4.14 | GPR43 agonists inhibit Akt and ERK2 phosphorylation in LPS-activated 
human monocytes. 
(A) Proteome array analysis of human monocytes treated with both acetate and LPS 
displaying reduced Akt2, ERK2 and MSK2 phosphorylation, as well as elevated TOR 
phosphorylation, when compared to monocytes treated with LPS alone. This experiment was 
performed with two independent cultures for each treatment condition. (B) Western blot 
assays of LPS-activated human monocytes. Akt and ERK2 phosphorylation was inhibited in 
cells pretreated with the GPR43 agonists, acetate and CFMB. (C) Time course analysis 
showing that the acetate-mediated inhibition is more pronounced during the early stages of 
Akt and ERK activation by LPS in human monocytes. (A - C) Unless otherwise indicated, 
Monocytes were treated for 15 min with either 5 mM acetate or 10 µM CFMB (GPR43 
agonist) or 10 µM AR420626 (GPR41 agonist), followed by 100 ng/mL LPS for 8 min. Each 
lane represents an independent culture for each treatment condition. The corresponding 
optical density (OD) is shown as the mean ± SEM; n = 3. The solvent controls (NT and 0.1% 
v/v DMSO) have been arbitrarily assigned the value of 1. The two tailed Students’ T-test was 
used to determine statistical significance and is annotated as: * < 0.05, ** < 0.005, and *** < 
0.0005. The data shown are representative of three independent experiments. 
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4.2.8. ERK2 inhibition requires Gq/11 while Akt inhibition is 
independent of both Gi/G0 and Gq/11. 
 
 In human monocytes, acetate-mediated Akt inhibition persisted during Gi/G0 
and Gq/11 signaling inhibition by PT and YM254890 [Figure 4.15A] while the ERK2 
inhibition required Gq/11 signaling and was abolished by YM254890 but not by PT 
treatment [Figure 4.15B]. In summary, GPR43 inhibits Akt via a GiG0 and Gq/11 
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Figure 4.15 | ERK2 inhibition is dependent on Gq/11 while Akt inhibition is independent 
of both Gi/G0 and Gq/11. 
(A - B) Combined treatment with PT and YM254890 abolished ERK2 inhibition but does not 
affect Akt inhibition. YM254890 treatment alone abolished ERK2 inhibition while PT has no 
effect. Results shown are from western blots. Cells were pretreated with PT for 2 h and/or 
YM254890 for 30 min before acetate induction. Unless otherwise indicated, monocytes were 
treated for 15 min with 5 mM acetate followed by 100 ng/mL LPS for 8 min. Each lane 
represents an independent culture for each treatment condition. The corresponding optical 
density (OD) is shown as the mean ± SEM; n = 3. The solvent controls (NT and 0.1% v/v 
DMSO) have been arbitrarily assigned the value of 1. The two tailed Students’ T-test was 
used to determine statistical significance and is annotated as: * < 0.05, ** < 0.005, and *** < 
0.0005. The data shown are representative of three independent experiments. 
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4.2.9. Repression of Akt may account for the cytokine inhibition. 
 
 GPR43 likely mediates the cytokine inhibition via the attenuation of Akt and 
ERK, which our inhibitor studies demonstrate to be required for the expression of 
CCL2, IL-1α and IL-1β in human monocytes [Figure 4.16A]. By contrast, the 
inhibition of p38 (which is instead activated by GPR43 [Figure 4.13], did not reduce 
cytokine expression.  Treatment with PTX (Gi/G0 inhibitor) and YM254890 (Gq/11 
inhibitor) [Figure 4.16B], which were required for GPR43-mediated modulation of 
ERK2 [Figure 4.15B] and p38 activity [Figure 4.13B], failed to rescue human monocyte 
cytokine expression from acetate-mediated inhibition. Finally, Akt activity in human 
monocytes was restored via the expression of a constitutively active myristoylated 
Akt (myr-Akt), which led to a recovery in cytokine expression [Figure 4.16C], thus 
confirming the role of Akt in acetate-mediated attenuation of cytokine expression. 
Taken together, these results suggest that the repression of Akt may account for the 


















































































































Figure 4.16 | Acetate inhibits cytokine expression via repression of Akt. 
(A) The Akt and ERK pathways are required for transcription of CCL2, IL-1α and IL-1β. 
Human monocytes were pretreated with either the solvent control, Wortmannin (PI3K-Akt 
pathway inhibitor), U0126 (ERK inhibitor) or SB203580 (p38 inhibitor) followed by 100 
ng/mL LPS activation for 4 h. (B) Inhibition of Gi/G0 and Gq/11 signaling with Pertussis 
toxin (PT) and YM254890, respectively, did not rescue cytokine expression from acetate-
mediated inhibition. Human monocytes were treated with PT for 2 h and/or YM254890 for 30 
min.  This was followed by 15 min treatment with 5 mM acetate and 12 h treatment with 100 
ng/mL LPS. (C) Acetate mediated inhibition of CCL1, CCL2 and GM-CSF, is significantly 
diminished upon expression of the constitutively active myristoylated Akt construct (myr-
Akt) in human monocytes. Human monocytes were electroporated with the myr-Akt 
expression vector (myrAkt-pcDNA) or the empty vector (pcDNA) as a control. 12 h after 
electroporation, the cells were treated with 5 mM acetate followed by 12 h with 100 ng/mL 
LPS. (A - C) Real time PCR analysis of mRNA expression. The data shown are the means of 
three independent cultures for each treatment condition and is presented as the fold change of 
the treated samples relative to the solvent controls ± SEM; n = 3. n.d: non-detectable. 
Measurements were standardized to RPL27 as the reference gene. The data shown are 
representative of three independent experiments. The two tailed Students’ T-test was used to 
determine the statistical significance of this fold change and is annotated as: * < 0.05, ** < 




4.3. Mouse monocytes display distinct GPR43 and GPR41 
signaling and cytokine expression in response to acetate 
 
 Upon confirming the importance of GPR43 and GPR41 in mediating human 
monocyte response to SCFAs ex vivo, we investigated if such GPR43 and GPR41 
functions were also found in mouse monocytes. The mouse model would allow us to 
further characterize these functions in vivo via knockout animals. 
4.3.1. Acetate modulates cytokine expression in mouse monocytes 
independently of GPR43 and GPR41.  
 
 While investigating mouse monocyte response to SCFAs, we confirmed that 
like human monocytes, 129SvEv mouse monocytes display acetate-mediated cytokine 
modulation. However, the cytokine profile produced was distinct from that of the 
human monocytes. In mouse monocytes, treatment with acetate was found to 
downregulate CXCL10, IL-1rα, TIMP-1 and CCL2, but upregulate CXCL1, IL-1α 
and IL-1β at both protein [Figure 4.17A] and mRNA [Figure 4.17C] levels. 
Surprisingly, specific activation of GPR43 (with CFMB) or GPR41 (with AR420626), 
did not affect cytokine expression [Figure 4.18], suggesting that these pathways are 
not involved in mouse monocyte response to acetate. Indeed, the acetate-mediated 
cytokine modulation persisted in Gpr43-/- and Gpr41-/- mouse monocytes [Figure 4.17 
A and B] consistent with a GPR43/41-independent mechanism. Collectively, our 
results suggest that the modulation of mouse monocyte cytokine expression by acetate 
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Figure 4.17 | Acetate treatment alters the cytokine expression of LPS-activated mouse 
monocytes, independent of GPR43 and GPR41. 
(A) Cytokine proteome arrays revealed reductions in CXCL10, IL-1ra, TIMP-1 and CCL2 
and increases in CXCL1, IL-1α and IL-1β in WT, Gpr43-/-, and Gpr41-/- monocytes upon 
acetate treatment. Two independent cultures for each treatment condition is shown; n = 2. (B - 
C) Real-time qPCR analysis showing changes in cytokine mRNA in mouse monocytes (WT, 
Gpr41-/- and Gpr43-/-) treated with acetate. The data shown are the means of three 
independent cultures for each treatment condition and is presented as the fold change of the 
acetate treated samples relative to the solvent controls ± SEM; n = 3. n.d: non-detectable. 
Measurements were standardized to Rpl27 as the reference gene. The data shown are 
representative of three independent experiments.  
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Figure 4.18 | CFMB (GPR43 agonist) and AR420626 (GPR41 agonist) did not reproduce 
acetate-mediated cytokine modulation in mouse monocytes. 
Mouse monocytes treated with either CFMB or 10uM AR420626 followed by 100 ng/mL 
LPS challenge for the indicated times, show no obvious change in cytokine expression as 
determined through real-time qPCR analysis. The data shown is the mean of three 
independent cultures for each treatment condition and is presented as the fold change of the 
acetate/CFMB/AR420626 treated samples relative to the respective solvent controls ± SEM; n 
= 3. Measurements were standardized to Rpl27 as the reference gene. The data shown are 




4.3.2. GPR43 knockout abolishes mouse monocyte p38 activation 
during acetate treatment. 
 
 The lack of GPR43/41-mediated cytokine modulation in mouse monocytes is 
not due to a lack of GPR43 activity as treatment with GPR43 agonist led to p38 
phosphorylation in mouse monocytes, which was abolished upon GPR43 knockout 
(Gpr43-/-) [Figure 4.19], consistent with GPR43 mediating acetate activation of p38. 
The activation of GPR41 alone, which is present in the Gpr43-/- monocytes [data not 
shown], did not lead to p38 phosphorylation. This suggests that unlike GPR43, GPR41 
signaling does not activate p38. 
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Figure 4.19 | GPR43 expression is required for acetate-induced phosphorylation of p38 
in mouse monocytes. 
Phosphorylation of mice monocyte p38 by acetate and CFMB treatment is abolished upon 
GPR43 knockout (Gpr43-/-) as determined through Western blots. Monocytes were induced 
with 5 mM acetate or 10 µM CFMB for 3 min. Each lane represents an independent culture 
for each treatment condition. The corresponding optical density (OD) is shown as the mean ± 
SEM; n = 3. The solvent controls (NT and 0.1% v/v DMSO) have been arbitrarily assigned 
the value of 1. The two tailed Students’ T-test was used to determine statistical significance 




4.3.3. Mouse monocytes display no apparent reduction in Akt and 
ERK2 phosphorylation upon GPR43 agonist treatment 
 
 Consistent with the apparent lack of GPR43 and GPR41 involvement in 
mouse monocyte cytokine expression during acetate treatment, we also failed to 
detect any reduction in Akt and ERK2 phosphorylation in LPS-activated mouse 
monocytes upon acetate or CFMB treatments [Figure 4.20]. The lack of Akt and ERK2 
repression may possibly account for the distinct cytokine expression pattern observed 
in mice monocytes, where IL-1α and IL-1β is upregulated [Figure 4.17]. In human 
monocytes treated with GPR43 agonists, the attenuation of Akt and ERK2 [Figure 
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Figure 4.20 | Acetate pretreatment does not decrease Akt and ERK phosphorylation in 
LPS-activated mouse monocytes. 
Western blot of mouse monocytes treated with 5 mM acetate for 15 min followed by 100 
ng/mL LPS challenge. No change in Akt and ERK phosphorylation levels was detected 





4.4. Heterologous expression of GPR43 and GPR41. 
 
 To determine if the species specific effects were due to functional differences 
between human and mouse GPR43 and GPR41, we evaluated the function of these 
receptors via heterologous expression in human adenocarcinoma lung alveolar basal 
epithelial cell line, A549 (which has low endogenous levels of GPR41 and GPR43 
[data not shown]). 
4.4.1. Heterologously expressed GPR43 is constitutively active. 
 
 Heterologous expression of both human and mouse GPR43 led to the 
constitutive phosphorylation of p38 [Figure 4.21]. This p38 phosphorylation occurred 
in the absence of GPR43 ligands, which suggests that GPR43 is in a constitutively 
active state when overexpressed. Further treatment with TNF did not increase p38 
phosphorylation further. Constitutive activity has been reported in some GPCRs 85, 
including GPR43 17,86. Heterologous expression of GPR41 on the other hand, did not 
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Figure 4.21 | Heterologous expression of GPR43 leads to the constitutive 
phosphorylation of p38 in A549 cells. 
Western blot shows that heterologous expression of GPR43 leads to the constitutive 
phosphorylation of p38. A549 cells were transfected with GPR43-pcDNA or GPR41-pcDNA 
or the pcDNA control vector. 24 h later, the cells were induced with 5 ng/mL TNF. The data 
shown is representative of three independent experiments. 
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4.4.2. Heterologous expression of GPR43 attenuated Akt-mediated 
activation of NF-κB. 
 
 By constitutively activating GPR43 signaling in A549 cells through 
heterologous expression [Figure 4.21], we further investigated GPR43-mediated 
inhibition of Akt. We found that GPR43 expression led to attenuation of NF-κB 
activation by TNF [Figure 4.22 A and B], which is dependent on Akt 87, as shown by 
the partial rescue during combined expression with myristoylated Akt (myr-Akt) 
[Figure 4.22C]. The basal NF-κB activity (without TNF treatment), which is a 
pathway reportedly activated by certain GPCRs 88, was only moderately raised by 
GPR43 expression [Figure 4.22]. Consistent with the constitutive activation of GPR43, 
the attenuation of NF-κB was proportional to the expression levels of GPR43 [Figure 
4.22B] and it was not increased by acetate ligand treatment [Figure 4.22A]. 
Surprisingly, heterologous expression of GPR41, albeit to a lesser extent than GPR43, 
also attenuated NF-κB activity [Figure 4.22E]. Collectively, these heterologous 
expression studies confirmed that GPR43 mediates the inhibition of Akt. 
 
4.4.3. NF-κB activity inhibition is also observed during the 
heterologous expression of mouse GPR43. 
 
 Similar to the human receptor variant, the expression of mouse GPR43 in 
A549 cells also led to the inhibition of NF-κB activity [Figure 4.22E]. This suggests 
that the lack of GPR43-mediated inhibition in mouse monocytes may be due to 
known differences in signaling pathways between human and mouse monocytes 89. 
Depending on the cell context, such as in A549, mouse GPR43 may also display Akt 
inhibitory activity. Such cell context-dependent signaling outcomes have been 
 71 
reported for other GPCRs 90. On the other hand, if the different signaling outcomes 
were due to species variations in GPR43 amino acid sequence leading to species-
specific receptor functions, we would expect to observe inhibitory activity from 
human but not murine GPR43. Therefore, species-specific signaling of GPR43 in 
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Figure 4.22 | Heterologous expression of GPR43 attenuates TNF activation of NF-κB 
which  requires Akt activity. 
(A) A549 cells overexpressing GPR43 show attenuated NF-κB activation upon TNF 
induction as measured by NF-κB luciferase assay. (B) Inhibition of NF-κB activity is 
proportional to GPR43 expression levels as measured by NF-κB luciferase assay. (C) 
Expression of a constitutively active form of Akt (myrAkt) rescues NF-κB activity. (D) 
Among human and mouse GPR41 and GPR43, overexpression of human GPR43 in A549 
inhibits NF-κB activation by TNF the most. (E) GPR43 constitutive activation of NF-κB is 
inhibited by BisI, a PKC inhibitor, while PKC appears to have no effect on GPR43 inhibition 
of NF-κB activation by TNF. A549 cells were treated with BisI during transfection for 24 h. 
(A - C) Cells were transfected with either the GPR43/41-pcDNA or the pcDNA control vector 
together with the NF-κB dual luciferase reporter plasmids. 24 h after transfection, cells were 
treated with 5 ng/mL TNF for 6 h before the luciferase reporters were assayed. NF-κB 
activity values are standardized to the untreated control cells that have been transfected with 
mock plasmid. Values shown are the average of three independent cultures (n=3) with the 
error bars representing mean ± SEM. The two tailed Students’ T-test was used to determine 




Chapter 5 | Discussion 
 In this thesis, we have demonstrated the essential role the SCFA receptors, 
GPR41 and GPR43 in mediating human monocyte response to acetate. Firstly, we 
characterized the GPR43 promoter, revealing that XBP1 acts as a core cis promoter 
element. XBP1 is activated by inflammatory stimuli such as TNF and LPS, to induce 
GPR43 expression in monocytes. Next, we show that this increased GPR43 
expression may facilitate monocyte anti-inflammatory signaling. GPR43, and the 
related SCFA receptor, GPR41, were found to mediate human monocyte response to 
SCFAs by suppressing inflammatory signaling and the resulting cytokine expression. 
Surprisingly, the mouse monocyte response to acetate was independent of GPR41 and 
GPR43, resulting in a cytokine profile that is distinct from acetate-treated human 
monocytes. These findings [which are summarized in Figure 5.1] have many 
implications for our understanding of the interaction between our gut microbiota, diet-


















































Figure 5.1 | Model of the transcriptional regulation of GPR43 expression and the 
GPR43- and GPR41- mediated regulation of human monocyte response to SCFA. 
The expression of GPR43 in monocytes is induced by inflammatory stimuli such as TNF and 
LPS, that activate the XBP1 core promoter element. This increased GPR43 expression may 
enhance monocyte anti-inflammatory signaling in response SCFAs. The related SCFA 
receptors, GPR43 and GPR41, were found to mediate human monocyte response to SCFAs 
by suppressing inflammatory signaling and the resulting cytokine expression. Surprisingly, 
the mouse monocyte response to acetate was independent of GPR41 and GPR43, resulting in 
a cytokine profile that is distinct from acetate-treated human monocytes. 
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5.1. Inflammatory stimuli upregulate GPR43 expression via the 
XBP1 transcription factor 
 
 Our studies on elucidating the promoter of GPR43, revealed the importance of 
the XBP1 transcription factor in enabling GPR43 transcription. The knowledge 
gained has provided new insights into the roles of GPR43. 
 
5.1.1. The GPR43 promoter elements may be conserved across 
species. 
 
 Firstly, we provide the first description of the 5'-UTR of the human GPR43 
gene, identifying an intron between the 5'-UTR and the start codon [Figure 4.2]. Our 
findings present a new perspective on the human GPR43 gene, which was initially 
described as being intronless, downstream of the ATG start codon 91. Notably, this 
gene organization is also seen in the bovine GPR43 gene, the only other GPR43 
homolog which has its 5'-UTR sequenced 92. Such cross-species similarities in the 
gene organization and high sequence conservation of the entire core promoter across 
human and mouse [Figure 4.4A] suggests that the same regulatory elements are 
conserved in the bovine and murine promoters. Indeed, bovine and murine tissue 
specific expression of GPR43 have been found to be highly similar to that of the 
human counterpart 16–18,92. Thus, these findings suggest that GPR43 transcriptional 
regulation is conserved among mammals. 
 
5.1.2. Previous reports failed to consider the GPR43 5'-UTR. 
 
 Sequencing the 5'-UTR of GPR43 has also allowed us to locate the GPR43 
TSS (transcription start site), which has provided a novel perspective on some 
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previous reports. A recent study documented transcriptional activity from a luciferase 
assay of a 500 bp sequence immediately upstream of the human GPR43 start codon in 
mouse RAW264.7 macrophages 93. Interestingly, these researchers predicted an NF-
κB binding site within this 500 bp sequence, although the mutation was reported to 
cause only 10% reduction in the promoter activity. Perhaps, inclusion of the GPR43 
TSS (located more than 1 kb upstream of the predicted NF-κB binding site as reported 
by our study) would offer a more complete analysis of the effect of this putative 
enhancer. Additionally, we were unable to detect GPR43 expression in RAW 264.7 
macrophages via real-time PCR. This, along with the fact that RAW264.7 are cells 
derived from the mouse, casts doubts on the suitability of the cell line when used to 
study the human GPR43 promoter. 
 
5.1.3. Inducers of XBP1 activity may also enhance GPR43 
expression. 
 
 Upon identification of the TSS, we characterized the core and proximal 
promoter located upstream of the TSS, and identified XBP1 to be part of the core 
promoter [Figure 4.5]. This finding implies that pathways that increase XBP1 activity 
are also expected to raise GPR43 transcription. Known inducers of XBP1 activity 
include the endoplasmic reticulum (ER) stress 38 and TLR activation 78. While we 
have shown that the activation of TLR4 with LPS induces GPR43 transcription via 
XBP1 [Figure 4.9], it stands to reason that the other TLR pathways are also expected 
to induce GPR43 transcription. Likewise, ER stress may also up-regulate GPR43 
expression. ER stress is caused by the accumulation of unfolded proteins due to 
processes such as hypoxia, ER–Ca2+ depletion, viral infections, or agents that affect 
Ca2+ balance (i.e., thapsigargin), protein glycosylation (i.e., tunicamycin), and ER–
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Golgi vesicular transport (i.e., brefeldin A) 94,95. Confirming if such processes induce 
GPR43 transcription and the role of GPR43, if any, in these processes, will be an 
interesting subject for further investigation.  
 
5.1.4. The etiology of XBP1-associated diseases may be due to 
reduced GPR43 expression. 
 
 The indispensability of XBP1 for GPR43 promoter activity [Figure 4.5] has 
important implications since XBP1 is involved in a number of physiological processes 
and diseases which include MHC class II gene regulation, B cell development and the 
unfolded protein response (UPR) 38. It now appears likely that these physiological 
processes may engage the expression and function of GPR43. Notably, mutations in 
the XBP1 gene locus of human patients has been associated with increased risk of 
inflammatory bowel disease (IBD), Crohn’s disease and ulcerative colitis, while 
Xbp1-/- mice have increased susceptibility to colitis 96. Xbp1-/- mice also display 
impaired glucose and insulin tolerance upon high fat diet-induced obesity 97. The 
association of XBP1 with gut inflammation and obesity may be partially attributable 
to the disrupted expression of GPR43, since Gpr43-/- mice are similarly more 
susceptible to colitis 39–42 as well as exhibiting impaired glucose tolerance and 
increased obesity 45,46. Considering the implications of XBP1 and GPR43 in 
inflammation and obesity, it might be pertinent to further investigate if GPR43 
expression is reduced in Xbp1-/- mice, and if the rescue of GPR43 expression in these 
mice would reduce disease severity. 
 
5.1.5. Multiple enhancers may fine-tune GPR43 expression. 
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 While XBP1 activity may be essential, other factors may also be involved in 
the transcription of GPR43. This is suggested by the observation that while XBP1 is 
ubiquitously expressed 98, GPR43 expression is more specific, with the highest 
expression found in immune cells such as monocytes and neutrophils 16–18. Besides 
XBP1, the GPR43 promoter was also found to be upregulated by Tax/CREB, CHOP, 
NFAT and STAT5 [Figure 4.5]. Tax/CREB is a heterodimer consisting of viral 
oncoprotein, Tax, and the host derived CREB 99. NFAT and STAT5 have been 
extensively implicated in immunity and cancer, through regulating cell development, 
growth and cytokine production 100–103. CHOP plays a role in ER stress-induced 
apoptosis and cytokine production 104. However, in comparison with XBP1, null 
mutations of the promoter binding sites for the aforementioned four TFs only resulted 
in relatively modest inhibition of ~30-40% in the promoter activity [Figure 4.5]. It is 
hence likely that these TFs are involved in fine-tuning the expression levels of GPR43 
in monocytes, or, they may be more active in upregulating the gene under the 
appropriate external stimuli (e.g. cytokine stimulation, ER stress or viral infection). 
Following the same line of argument, we cannot rule out the potential involvement of 
other predicted transcription factors, e.g. IRF4, c-Rel (component of NF-κB), and 
Pu.1, in the expression of GPR43 under the appropriate immune contexts. Future 
studies may include performing these studies (luciferase assays or TF knockdown) 
under different inflammatory stimuli. This would allow us to determine if the 
enhancers identified play a greater role under such conditions 
 
5.1.6. The mechanism by which PMA induces GPR43 expression 
in U937 cells remains unclear. 
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 In addition to known XBP1 activators such as LPS 78 and TNF 81 [Figure 4.9], 
treatment with PMA was also found to up-regulate GPR43 transcription in U937 cells 
by 100-fold [Figure 4.1] The mechanism by which PMA induces GPR43 transcription 
remains unclear. Since PMA is a transient activator of PKC, this would suggest that 
some downstream targets of PKC are involved in GPR43 transcription in U937 cells. 
Depending on the stimuli and cell type, PKC has been shown to enhance the activities 
of multiple signaling pathways including AP-1, NF-κB and ERK 105. However, in 
human peripheral blood monocytes, our data suggests that PKC activity is not 
essential for maintaining GPR43 transcription as treatment of these cells with the 
PKC inhibitor, BisI, did not reduce GPR43 mRNA levels [Figure 4.6], while treatment 
with PMA led to an increase in GPR43 mRNA [data not shown]. Since U937 is a 
promonocytic cell line which undergoes monocytic differentiation upon PMA 
treatment 63,64, perhaps the up-regulation of GPR43 is the result of the U937 cells 




5.1.7. GPR43 transcription regulation is distinct from that of 
GPR40 and GPR41. 
 
 Having characterized the GPR43 promoter, we can now perform a comparison 
with earlier reports on the transcriptional control of the related GPR40 and GPR41 
receptors . All three receptor genes are located side-by-side on human chromosome 
19 16–18. While GPR41 and GPR43 are specific for SCFAs, GPR40 detects medium to 
long chain fatty acids. Surprisingly, while the receptor amino acid sequences share at 
least 30% sequence identity, very little similarity is observed in their regulatory 
sequences. Consistent with the distinct tissue expression patterns of these receptors, 
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the transcriptional regulatory mechanism of GPR40 and GPR41 are also distinct from 
the XBP1-mediated transcriptional control observed in GPR43 [Figure 5.2]. The 
GPR40 promoter is bound by β cell-specific PDX1 and BETA2 transcription factors 
106
. GPR41 protein is translated from the bicistronic mRNA encoding GPR40 and 
GPR41 35. Thus, the distinct transcriptional control of GPR43, GPR41 and GPR40– 
may account for the distinct tissue specificities. 
 
TSS (+1)















Exon Intron Transcription factor
 
Figure 5.2 | Transcriptional regulation of the free fatty acid receptors: GPR40, GPR41 
and GPR43. 
The GPR40 promoter contains binding sites for the β cell-specific PDX1 and BETA2 
transcription factors 106. GPR41 protein is translated from the bicistronic mRNA encoding 
GPR40 and GPR41 35. GPR43 transcription is regulated by a XBP1 core promoter element. 
 
5.1.8. The GPR43 promoter elements identified may regulate its 
expression in multiple cell types. 
 
 While the findings on the GPR43 promoter are mostly obtained from human 
monocytes in this study, it would be interesting to explore if the promoter elements 
identified, regulate GPR43 in other cell types. Our findings on A549 cells suggest that 
this may indeed be the case. In A549 cells, the 519 bp GPR43 promoter construct up-
regulated luciferase expression; this was abrogated by XBP1 null mutation [Figure 
4.5C]. These findings mirror those of U937 cells [Figure 4.5B] although differences are 
also noted. Notably, while a 50% knockdown of XBP1 mRNA led to an 80% drop in 
expression of GPR43 in the U937 cell [Figure 4.8A], a 100-fold increase in XBP1 
mRNA only resulted in a 2-fold increase in A549 expression of GPR43 [Figure 4.8B]. 
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This discrepancy in effect may be due to a variety of factors. XBP1 activity in A549 
may already be near saturation and hence further increases in XBP1 expression will 
not proportionally increase GPR43 expression. Another possibility is that XBP1 may 
require further activation, such as by the p38 pathway 72, to become fully activated. 
Such pathways may be more active in monocytes. The GPR43 promoter in A549 cells 
may also be epigenetically silenced through DNA methylation or chromatin 
remodeling, such that further increases in XBP1 expression may not fully overcome 
this silencing. Despite these differences, our findings confirm that XBP1 can serve as 
a regulator involved in controlling GPR43 expression in other cell types. Notably, 
both GPR43 17,107,108 and XBP1 109 are found to be upregulated in adipocytes and 
adipocyte-derived cell lines, suggesting that XBP1 may also be involved in regulating 
the expression of GPR43 in adipocytes, an interaction that may have implications in 
adipocyte function. 
 
5.1.9. GPR43 expression may be induced during inflammation. 
 
 The ability of inflammatory stimuli such as LPS, TNFα and GM-CSF [Figure 
4.9] to up-regulate GPR43 expression infers a number of interesting possibilities. Our 
findings imply that the positive correlation between GPR43 expression and 
inflammation at the fetal cell membranes 110 or TNF levels in adipocytes 108, is likely 
due to the induction of GPR43 transcription by the inflammatory stimuli present. 
Notably, GM-CSF has been found to be beneficial for the treatment of IBD 111,112. 
Since GPR43 is also implicated in the etiology of IBD 39–42, it would be interesting to 
investigate whether GM-CSF exerts any beneficial therapeutic effects through 




5.1.10. Confirming the expression of GPR43 at the protein level 
 
 A major challenge towards the further characterization of GPR43 is the lack 
reliable antibodies for the detection of GPR43 protein expression. In our studies as 
well, multiple commercial antibodies were tested but none seemed to be able to detect 
GPR43 expression via Western blot [Figure 4.2], despite claims to the contrary by the 
manufacturers. To the best of our knowledge, there are no prior reports on the 
Western blot detection of GPR43. There are however, reports on the 
immunhistochemistry (IHC) detection of GPR43 in human and mouse colon epithelial 
cells using polyclonal antibodies that were either produced within the authors’ labs 
113,114
 or from a commercial source (Novus biologicals) 115. However, these studies 
failed to include sufficient controls to validate the specificity of the antibodies. The 
controls used include a Western blot 113,114, which does not demonstrate specificity 
during IHC as the non-specifically bound epitope confirmations may differ between 
the two methods. Another control used was the absorption test 113,114, whereby the 
epitope used to raise the antibody is applied in excess to block binding by the antigen 
recognition site. However, this method fails to account for non-specific binding by the 
antigen recognition site. For future studies, we believe the use of GPR43 knockout 
mice tissues will demonstrate the specificity of the IHC stain on mouse tissues. While 
for human tissues, two GPR43 antibodies targeting different epitopes can be used to 
cross-validate each other as the antigen binding sites from both antibodies are unlikely 
to bind the same non-specific targets. 
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5.2.  Acetate induces distinct inflammatory cytokine profiles in 
human and mouse monocytes due to species-specific 
signaling of GPR41 and GPR43. 
 
 Besides revealing that inflammatory stimuli upregulate GPR43 expression via 
XBP1 [Figure 4.9], we also show that this increased GPR43 expression may affect the 
monocyte inflammatory response. Our findings demonstrate that GPR43 and the 
related SCFA receptor, GPR41, mediate human monocyte response to SCFAs by 
repressing Akt and ERK, and reducing cytokine expression [Figure 5.1]. 
5.2.1 The expression regulation of anti-inflammatory GPR43 by 
inflammatory stimuli suggests possible feedback regulation. 
 
 Our findings suggest a 
possible feedback mechanism 
between inflammatory stimuli and 
GPR43 signaling [Figure 5.3]. 
Notably, TNF, which induces GPR43 
expression, is also a target of 
GPR43-mediated inhibition. Under 
one possible feedback scenario, 
inflammation and the consequent 
release of inflammatory stimuli, may 
induce the expression of GPR43. The 
increased expression of GPR43 in 
peripheral blood monocytes by inflammatory stimuli, may compensate for the low 
plasma levels of SCFA (< 200 µM) 9,10 and low potencies of the ligands in activating 
GPR43 (generally in the mid micromolar range) 16–18. With increased GPR43 













Figure 5.3 | A hypothetical 
GPR43-TNF feedback loop. 
Inflammatory cytokines would 
induce GPR43 expression, which 
would in turn repress the expression 
of inflammatory cytokines. 
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regulation and subsequent resolution of inflammation. In the resulting non-
inflammatory state, a lack of inflammatory stimuli would return GPR43 expression to 
low levels and thus the monocytes would again be ready to mount an immune 
response 
 
5.2.2. GPR43 modulates cell response to SCFAs through the 
activation of p38. 
 
 Among the monocyte functions altered by the increased expression of GPR43 
is the p38 pathway. We found that GPR43 acts via the Gq/11 pathway to 
phosphorylate p38 in both human [Figure 4.13] and mouse monocytes [Figure 4.19]. 
This is consistent with previous reports on GPCRs activating p38 via the Gq/11 
pathway 116,117. In fact, GPR43-induction of p38 has been reported in multiple cell 
types including human MCF-7 cell line 48 and mouse neutrophils 49, with differing 
sensitivities to PT-mediated inhibition of Gi/G0 signaling. Our finding that GPR43 
phosphorylation of p38 is PT-insensitive, is in agreement with Yonezawa et al. 48. 
Here, we reveal that the inhibition 
occurs via a YM254890-sensitive 
Gq/11 pathway [Figure 4.13B][Figure 
5.4A]. This difference may be due to 
cell-specific signaling 90, but we 
reasoned that Gq/11 is the more 
likely candidate since only GPR43 
acts via Gq/11 while both GPR43 
and GPR41 couple to Gi/G0 protein 
16–18










Figure 5.4 | The possible G protein-
coupled pathways leading to the 
activation of p38. 
(A) GPR43 activation of p38 via the Gq/11 
pathway is consistent is consistent with the 
inability of GPR41 to activate p38 as the 
Gq/11 pathway is not activate by GPR41. 
(B) GPR41 is also expected to activate p38 
if the activation is mediated by the Gi/G0 
pathway.  
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5.4B], GPR41 should phosphorylate p38 in the Gpr43-/- monocytes, which was not 
observed [Figure 4.19].  Surprisingly, while both acetate and LPS induced p38 
phosphorylation, the simultaneous treatment with both ligands did not lead to an 
additive effect on p38 phosphorylation [Supplementary Figure 4]. This may be due to 
the much weaker GPR43-mediated phosphorylation of p38 [Figure 4.13] that was 
undetectable beyond 7 min of ligand addition, which may not measurably enhance the 
much stronger LPS-mediated p38 phosphorylation that was sustained up to 42 min. 
Hence, we have demonstrated that GPR43 phosphorylates p38 in both the human and 
mouse monocytes, the functional outcome of which is unclear at this juncture, and 
warrants future studies. 
 
5.2.3. Acetate acts through GPR43 to inhibit Akt and ERK2 
signaling in human but not mouse monocytes. 
 
 While GPR43 activates p38 in both human [Figure 4.13] and mouse [Figure 
4.19] monocytes, the attenuation of Akt and ERK2 signaling by acetate activation of 
GPR43 was only observed in human monocytes [Figure 4.14][Figure 4.20]. The 
inhibition of these pathways is characteristic of certain GPCRs. One example is the 
P2Y(2) GPCR-mediated inhibition of ERK activation by growth factor in 
keratinocytes 118, which similar to GPR43 [Figure 4.15], is also sensitive to Gq/11 
inhibitor (YM254980). GPR43-mediated inhibition of Akt is also observed during 
insulin-induced activation of adipocytes 46 and is abolished by the Gi/G0 inhibitor 
(PT). On the other hand, the GPR43-mediated attenuation of monocyte Akt observed 
here, was neither PT- nor YM254890-sensitive [Figure 4.15]. Since different stimuli 
were used to activate Akt, it is plausible that different inhibitory pathways are 
involved leading to the different G protein specificities. The implications of GPR43-
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mediated inhibition of Akt and ERK2 will be an important subject of future study, as 
the consequences may extend beyond cytokine inhibition. 
 
5.2.4. Acetate modulates human monocyte cytokine expression via 
GPR41 and GPR43. 
 
 Consistent with the role of Akt and ERK in monocyte cytokine expression 
61,62
, GPR43-mediated inhibition of Akt and ERK [Figure 4.14] led to attenuated 
human monocyte cytokine expression while GPR41 inhibited a smaller subset of 
cytokines [Figure 4.10][Figure 4.11][Figure 4.16]. These findings reveal that the 
inhibition of CCL2 by acetate treatment of human monocytes observed previously by 
Cox et al. (2009) 59, is attributable to GPR41 and GPR43 activation as the synthetic 
agonists for these receptors also inhibited CCL2 expression [Figure 4.10][Figure 4.11]. 
Interestingly, the same study 59 also reported a decrease in IL-10 expression upon 
acetate treatment which were undetectable by our assays. We note that the potency of 
IL-10 inhibition reported by Cox et al. (2009) 59, is much lower than that for CCL2, 
with a 20% reduction for IL-10 versus an 80% reduction for CCL2 during 2 mM 
acetate treatment. Thus, it is possible that the concentrations of acetate used in this 
study (up to 10 mM) did not produce an inhibitory effect on IL-10 that would be 
strong enough to be detected. Nevertheless, SCFAs may also act via other pathways, 
which is likely the case for mouse monocytes where the acetate-mediated modulation 
of cytokine expression is independent of GPR41 and GPR43 [Figure 4.17][Figure 4.18]. 
The abolishment of SCFA-mediated cytokine modulation by the specific inhibition of 
GPR41 or GPR43 with antagonists, when available, would further confirm that the 
inhibition is dependent on GPR41 and/or GPR43 in human monocytes. 
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5.2.5. GPR41 may inhibit cytokine expression via the repression of 
the Akt pathway. 
 
 Surprisingly, despite not detecting any GPR41-mediated modulation of 
MAPK activity in monocytes (which was observed for GPR43), we nonetheless found 
that GPR41 activation led to the inhibition of a smaller subset of cytokines [Figure 
4.10][Figure 4.11]. The mechanism by which GPR41 modulates these cytokines 
remains uncertain. The rescue of CCL1, CCL2 and GM-CSF from acetate-mediated 
inhibition by the expression of constitutively-active myristoylated Akt [Figure 4.16C], 
suggests that both GPR41 and GPR43 modulate cytokine expression via inhibition of 
Akt. It is thus possible that GPR41 does in fact inhibit Akt activity in a manner that 
was not detected by our Western blot assays, such as during a specific time-point that 
was not covered. This is consistent with the finding that TNF mediated activation of 
NF-κB is also inhibited in A549 cells during the heterologous expression of GPR41 
[Figure 4.22E]. Nevertheless, it is possible that additional pathways may be involved. 
 
5.2.6. Elucidating the role of GPR43 and GPR41 via siRNA 
knockdown 
 
 During the course of this thesis, we have encountered a number of challenges 
in siRNA-mediated gene knockdown. Unexpectedly, the reduction in XBP1 mRNA 
achieved during the stable transduction of U937 cells [Figure 4.8] was lost when these 
cells were treated for 24 h with PMA [Supplementary Figure 2]. This may be due to the 
induction of XBP1 mRNA transcription by PMA, which overcame the knockdown 
effect of siRNA treatment. In such a case, utilizing a more potent XBP1 siRNA 
sequence may allow the knockdown to be maintained even during PMA treatment. 
The knockdown of GPR43 mRNA in primary human monocytes was also 
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challenging. This task was complicated by the lack of reliable methods to efficiently 
transfect primary human monocytes, which are notoriously resistant to uptake of 
foreign DNA. The most efficient method available to us was electroporation using the 
Amaxa® Human Monocyte Nucleofector Kit (Lonza), that is reported by the 
manufacturer to achieve a 50% transfection rate of the pmaxGFP® vector. While this 
transfection rate was sufficient for a knockdown in CYPB mRNA to be observed 
when electroporating the CYPB positive control siRNA [Supplementary Figure 3], we 
were unable to successfully knockdown GPR43. The GPR43-siRNAs tested may not 
have been as potent, requiring a higher transfection efficiency for the knockdown to 
be observed. For both XBP1 and GPR43, the identification of highly potent siRNA 
sequences may aid in overcoming some of these challenges. 
 Even if the efficient knockdown of GPR43 mRNA is achieved, the question 
remains on whether primary monocytes can be kept in vitro long enough for GPR43 
protein levels to be reduced. Monocytes reportedly show signs of differentiation after 
just two to three days of culture in vitro 119,120. Thus, rather than the knockdown of 
GPR43, perhaps a different approach to modulating GPR43 activity should be 
considered in future. Nevertheless, our success with utilizing synthetic agonist to 
specifically elucidate the roles of GPR43 and GPR41 [Chapter 4.2], suggests that a 
pharmacological approach is feasible. The generation of specific and potent GPR43 
and GPR41 synthetic antagonists, will allow for further studies into the role of these 
receptors. 
 




 The low millimolar concentrations of acetate [Figure 4.12C] required to induce 
monocyte GPR43 and GPR41 signaling pathways would suggest that the 
concentrations of SCFAs found in the peripheral blood (reported at 5 µM for 
propionate and butyrate, and around 100 µM for acetate 9,10) are expected to be too 
low to fully activate GPR43 and GPR41. This means that the majority of the GPR43 
and GPR41 effects on monocyte function may be restricted to the colon where SCFA 
concentrations are found in the mid millimolar (mM) range 9,10. Whether the 
microbiota of other mucosal surfaces such as in the respiratory canal would produce 
SCFA concentrations high enough to activate GPR43 and GPR41, is currently 
unclear. Additionally, it may be possible that while SCFA concentrations are only 
high in the gut, the effects of monocyte GPR43 and GPR41 activation may extend 
beyond the gut. It would be hard to determine such a function in mice, since mice 
monocyte GPR43 and GPR41 do not display inhibitory function [Chapter 4.3]. Perhaps 
if the GPR43 and GPR41 inhibitory functions are observed in the monocytes of other 
model organisms such as those from primates, such a possibility can be investigated. 
 
5.2.8. The mouse may not reliably model human-gut microbiome 
interactions. 
 
 Our findings reveal that the human monocyte response to acetate is mediated 
by GPR41 and GPR43, resulting in the inhibition of inflammatory signaling [Figure 
4.14] and cytokine expression [Figure 4.10][Figure 4.11]. By contrast, the mouse 
monocyte response to SCFA is independent of GPR41 and GPR43 [Figure 4.20], 
showing a distinct cytokine profile [Figure 4.17][Figure 4.18]. That the mouse model 
does not fully replicate human disease pathologies is hardly a new revelation 121. For 
example, mutations in the retinoblastoma tumor suppressor gene (RB) in humans are 
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causative of, as the name suggests, retinoblastoma. On the other hand, Rb+/- mice 
show no increased incidence of retinoblastoma 122. Another notable example is in the 
null mutation of the dystrophin gene, which reduces the lifespan of individuals with 
Duchenne muscular dystrophy (DMD) by ~75%; while dystrophin deficient mice 
display minimal clinical symptoms and only a ~25% reduction in lifespan 123. Here, 
our findings offer a novel perspective on the limitations of using the mouse model to 
study human diseases. To our knowledge, this is the first report of differences 
between human and mouse monocyte response to SCFA. Such differences may not be 
restricted to monocytes since GPR43 agonists have been reported to induce the 
differentiation of mouse 107 but not human 108 adipocytes. Thus our findings reveal 
that the mouse models, which are widely used in gut microbiota studies, may not fully 
replicate the distinct responses of human monocyte to SCFAs. This may also explain 
why current mouse models are unable to fully replicate human IBD symptoms 124,125. 
We propose that host-microbiota interaction studies, when performed on human cells 
ex vivo or in mice with humanized immune systems 126, may uncover unexpected and 
novel findings. 
 
5.2.9. The species-specific functions of GPR41 and GPR43 may 
explain some controversies in earlier reports. 
 
  The species-specific function of GPR41 and GPR43 in response to SCFA 
may shed light on some intriguing earlier controversies. Previously, Masui et al 
(2013) 43 reported that acetate treatment reduced TNF expression in both human and 
mouse peripheral blood mononuclear cells (PBMCs), an effect that was abolished in 
human monocytes by a GPR43 antibody (discontinued antibody (cat. KX448) from 
Cosmo Bio), but persisted in Gpr43-/- mouse PBMCs. Our findings could possibly 
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explain this dichotomy; that GPR43 inhibitory activity is human monocyte-specific 
and therefore the inhibition of human GPR43 activity (possibly by antibody binding) 
is expected to abolish the acetate-mediated cytokine inhibition. In mouse monocytes 
on the other hand, acetate appears to act independently of GPR43, to modulate 
cytokine expression, thus Gpr43 knockout did not abolish the inhibition. 
 
5.2.10. SCFAs may act on other cellular targets 
 
 While the activation of GPR43 and GPR41 may account for some of the 
apparent effects of acetate on monocytes [Chapter 4.2], the possibility remains that the 
SCFAs may act on other cellular targets. This is most likely the case in mouse 
monocytes where synthetic agonist activation of GPR43 and GPR41 in these cells did 
not lead to the cytokine or MAPK inhibition observed in the human monocytes 
[Chapter 4.3]. As to what cellular pathways are involved in the cytokine modulation 
observed in mice monocytes and whether these pathways are present to some extent 
in humans, will require further elucidation. In fact, the findings based on the synthetic 
agonists, does not rule out that in addition to GPR43 and GPR41, acetate may also act 
on other targets in human monocytes to induce the signaling and cytokine inhibition 
observed. The complete ablation of acetate-mediated signaling and cytokine inhibition 
during treatment with hypothetical synthetic agonists or inhibitors specific for GPR43 
and GPR41 will confirm that the effects of acetate on human monocytes are indeed 
dependent on GPR43 and GPR41. 
 
5.2.11. Human monocyte GPR41 and GPR43 may play a role in 
many inflammatory diseases. 
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 Many of the inflammatory cytokines (C5, CCL1, CCL2, GM-CSF, IL-1α, IL-
1β, ICAM-1 and TNF) attenuated by human monocyte GPR41 and GPR43 signaling 
[Figure 4.10][Figure 4.11], are associated with IBD 127. For example, the CCL2 gene 
has been identified as an IBD susceptibility loci 128 while IL-1 is essential in the 
initiation of colonic inflammation 127. Another study found that monocytes from 
Crohn's disease patients had increased IL-1β and CCL2 secretion 129. In light of the 
similar cytokine profiles, the potential involvement of monocyte GPR41 and GPR43 
in human IBD is hard to ignore. Further investigations to: (i) determine if the cytokine 
inhibition activities of GPR41 or GPR43 are non-functional in IBD patients, and (ii) 
query whether this abnormality is involved in the disease pathology– may reveal 
novel insights on IBD and its treatment. 
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Chapter 6 | Concluding Remarks 
 
 This thesis presents the first full characterization of the human GPR43 
promoter, and reveals that GPR43 expression is regulated by XBP1 as a core cis 
element while CREB, CHOP, NFAT and STAT5 act as enhancers [Figure 5.1]. With 
this newfound insight, it may be possible to identify pathways or stimuli that are 
likely to modulate GPR43 expression based on whether or not those pathways are 
known to modulate the XBP1 transcriptional activity. We demonstrated the feasibility 
of this approach by accurately predicting the ability of TNF to regulate GPR43 
expression based on its known ability to activate XBP1 81 [Figure 4.9]. With GPR43 
being implicated in the etiology of chronic inflammatory diseases such as obesity, 
colitis, asthma and arthritis 39–47 – there is increasing interest towards the 
pharmacological modulation of GPR43 function 130. Our characterization of the 
GPR43 promoter and the pathways leading to its activation, may allow for 
pharmacological modulation of GPR43 function through its expression levels. 
 Modulating the expression of GPR43 may also facilitate monocyte anti-
inflammatory signaling in response SCFAs as GPR43 and the related SCFA receptor, 
GPR41, are found to mediate human monocyte response to SCFAs. Here, our study 
offers a first glimpse into the functions of GPR41 and GPR43 in human monocytes, 
where these receptors repress Akt and ERK, resulting in reduced cytokine expression 
[Figure 5.1]. These findings hint at a potentially important role for GPR41 and GPR43 
in mediating the interaction between the SCFA-producing gut bacteria and 
monocytes, with possible implications in monocyte-associated chronic inflammatory 
diseases 56–58, in particular in IBD 51. In mouse monocytes, where GPR41- and 
GPR43-mediated cytokine expression does not occur, acetate treatment produces a 
distinct cytokine profile. This implies that the roles of GPR41 and GPR43 in human 
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physiology may not be fully represented by mouse models. With the growing interest 
on these SCFA receptors as potential therapeutic targets 130, our newfound insight will 
allow for potential differences between human and mouse monocyte responses to 
pharmacological compounds to be accounted for. In particular, the repressive effect of 
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Supplementary Figure 1 | Electroporation of XBP1 siRNA 
leads to XBP1 mRNA knockdown, but does not affect 
GPR43 mRNA. 
U937 cells were electroporated with XBP1 or control 
siRNA and the mRNA levels were measured via real 
time PCR at the indicated time points. Measurements 
were standardized to RPL27 as the reference gene. 
Results shown are the average of three independent 
electroporations with error bars representing the mean ± 





Supplementary Figure 2 | XBP1 knockdown 
was not detected during PMA-induced 
monocytic differentiation of U937 cells. 
Real time PCR analysis of U937 cells 24 h 
after PMA-induction. These cell have 
previously been stably transduced with 
either XBP1- or control-siRNA. Results 
shown are the average of three 
independent transductions with error bars 
representing the mean ± SEM. The data 
shown are representative of two 
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Supplementary Figure 3 | Real time PCR analysis reveal no significant knockdown in 
GPR43 mRNA after electroporation of GPR43-siRNA. 
Electoporation of XBP-siRNA as a positive control led to a significant drop in XBP1 mRNA. 
All siRNA utilized were from Dharmacon: Control-siRNA (D-001810-10), CYPB-siRNA (D-
001610-01), and GPR43-siRNA Pool (D-005574). The GPR43 siRNA 1 and GPR43 siRNA 2 
are previously reported sequences 48  (5' CCAUCGUGAUCAUCGUUCAtt and 
5'CCGAUAACCAGUUGGACGUtt respectively) also synthesized by Dharmacon. The data 
shown are the means of three independent primary human monocyte ± SEM; n = 3. 
Measurements were standardized to RPL27 as the reference gene. The data shown are 
representative of two independent experiments. n.d: non-detectable. The two tailed Students’ 
T-test was used to determine the statistical significance of this fold change and is annotated as 










Supplementary Figure 4 | Acetate treatment did not enhance p38 phosphorylation in 
LPS-activated monocytes 
Monocytes were treated for 15 min with 5 mM acetate followed by 100 ng/mL LPS for 8 min. 
Each lane represents an independent culture for each treatment condition. The corresponding 
optical density (OD) is shown as the mean ± SEM; n = 3. The solvent controls (NT and 0.15 
v/v DMSO) have been arbitrarily assigned the value of 1. The two tailed Students’ T-test was 
used to determine statistical significance and is annotated as: * < 0.05, ** < 0.005, and *** < 




















Supplementary Figure 5 | GPR43 agonist treatment of human monocytes. 
Human monocytes were treated with 5 mM acetate (top) or 10 µM CFMB 
(bottom) and the Akt and ERK phosphorylation levels were measured via 
western blots at the indicated time-points. Each lane represents an independent 
culture for each treatment condition. The corresponding optical density (OD) is 
shown as the mean ± SEM; n = 3. The solvent controls (NT and 0.1% v/v 
DMSO) have been arbitrarily assigned the value of 1. The two tailed Students’ 
T-test was used to determine statistical significance and is annotated as: * < 
















Supplementary Figure 6 | GPR41 agonist, 
AR420626, failed to inhibit Akt and ERK2 
phosphorylation in LPS-activated human 
monocytes. 
Monocytes were treated for 15 min with 10 µM 
AR420626 (GPR41 agonist), followed by 100 
ng/mL LPS for 8 min. Each lane represents an 
independent culture for each treatment condition. 
The corresponding optical density (OD) is shown 
as the mean ± SEM; n = 3. The solvent controls 
(NT and 0.1% v/v DMSO) have been arbitrarily 
assigned the value of 1. The two tailed Students’ 
T-test was used to determine statistical 
significance and is annotated as: * < 0.05, ** < 
0.005, and *** < 0.0005. The data shown are 
representative of three independent experiments. 
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The short-chain fatty acid receptorGPR43
is transcriptionally regulated by XBP1 in
human monocytes
Zhiwei Ang1,2*, Jun Zhi Er1,2* & Jeak Ling Ding1,2
1Department of Biological Sciences, National University of Singapore, Singapore 117543, 2NUS graduate School for Integrative
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G-protein coupled receptor 43 (GPR43) recognizes short chain fatty acids and is implicated in obesity,
colitis, asthma and arthritis. Here, we present the first full characterization of the GPR43 promoter and
59-UTR. 59-RACE of the GPR43 transcript identified the transcription start site (TSS) and a 124 bp 59-UTR
followed by a 1335 bp intron upstream of the ATG start codon. The sequence spanning -4560 to 168 bp
relative to the GPR43 TSS was found to contain strong promoter activity, increasing luciferase reporter
expression by .100-fold in U937 monocytes. Stepwise deletions further narrowed the putative GPR43
promoter (2451 to168). Site-directed mutagenesis identified XBP1 as a core cis element, the mutation of
which abrogated transcriptional activity. Mutations of predicted CREB, CHOP, NFAT and STAT5 binding
sites, partially reduced promoter activity. ChIP assays confirmed the binding of XBP1 to the endogenous
GPR43 promoter. Consistently, GPR43 expression is reduced in monocytes upon siRNA-knockdown of
XBP1, while A549 cells overexpressing XBP1 displayed elevatedGPR43 levels. Based on its ability to activate
XBP1, we predicted and confirmed that TNFa induces GPR43 expression in humanmonocytes. Altogether,
our findings form the basis for strategic modulation of GPR43 expression, with a view to regulate
GPR43-associated diseases.
S
tudies on knockout mice have identified Free Fatty Acid Receptor 2 (FFAR2 or GPR43) as a critical gene in
the prevention of obesity, colitis, asthma and arthritis1–8. GPR43 is a G protein coupled-receptor that is
activated by mid-micromolar concentrations of short-chain fatty acids (SCFAs) - namely acetate, propion-
ate and butyrate. While the liver metabolism of ethanol can generate micromolar concentrations of acetate in the
blood, by far the most abundant source of SCFAs in the human body is the colonic lumen, where hundreds of
millimolars are continuously being produced during the anaerobic fermentation of dietary fibre by saccarolytic
gut bacteria9,10. These gut SCFAs have been found to beneficially modulate blood glucose and lipid levels, the
colonic environment, and immune functions11–13. As an SCFA receptor, GPR43 has already been shown to
mediate some of these beneficial effects, with knockout mice studies confirming a role in obesity and inflam-
mation (Table 1).
Consistent with its role as an SCFA receptor,GPR43 expression is found in cells that are exposed to the highest
concentrations of SCFAs. These include the cells of the distal ileum, colon and adipose tissue, with the highest
expression found in immune cells such asmonocytes and neutrophils14–16. In addition,GPR43 expression appears
to be modulated during inflammation since immune challenge by lipopolysaccharide (LPS) or treatment with
granulocyte-macrophage colony stimulating factor (GM-CSF) raises GPR43 transcript levels in human mono-
cytes17. This tissue-specificity suggests that GPR43 expression is tightly regulated and may be important for its
function. Indeed, the compelling outcomes of Gpr43 knockout (Table 1) imply that proper regulation of GPR43
expression is pertinent to the normal functioning of a range of physiological processes, and consequently,
targeting of GPR43 expression in diseases would provide new therapeutic potential. Thus, details on the factors
involved in cell-type specific expression of the GPR43 gene under pathophysiological conditions remain an
unexplored and intriguing area of investigation. Here, we characterized the human GPR43 gene, identifying
the promoter and enhancer sequence elements, as well as the critical transcription factors and signalling pathways
that regulate GPR43 expression.



















SCIENTIFIC REPORTS | 5 : 8134 | DOI: 10.1038/srep08134 1
Results
PMA-differentiated U937 monocytes are a suitable model for
GPR43 expression. To understand the mechanisms underlying the
specific expression ofGPR43, we first confirmed the cell type with the
highest level of GPR43mRNA. Consistent with previous studies14–16,
we found human peripheral blood monocytes and neutrophils to
express the highest level of GPR43 mRNA (Fig. 1). PMA-mediated
monocytic differentiation of the human promonocytic cell line,
U93718,19, led to a 100-fold increase in the transcription of GPR43,
yielding mRNA levels that was comparable to the peripheral blood
monocytes and neutrophils. Hence, we reasoned that the U937 cell
line would be a suitable model to study GPR43 transcriptional
regulation in leukocytes.
GPR43 transcription start site is located at 1459 bp upstream of
the ATG start codon. To define the GPR43 putative promoter site,
we first performed a 59-RACE of theGPR43 transcript, generating an
approximately 450 bp product which was sequenced to reveal a
124 bp 59-UTR upstream of the GPR43 ATG start codon (Fig. 2a).
Mapping of this sequence with the human genome database (NCBI
Ref Seq: NC_000019.10) revealed the presence of a 1335 bp intron
flanked by theGPR43 59-UTR and the start codon (Fig. 2b). Thus, the
transcription start site (TSS) is located 1459 bp upstream of the ATG
start codon. While it was difficult to judge the presence of other 59-
RACE products (Fig. 2a, Lane 1), we note that a previously reported
northern blot analysis (Senga et al., 200317, Fig. 2h), detected two
GPR43 transcripts, with the shorter (by about a few hundred bases)
product beingmany timesmore abundant than the longer transcript.
It is possible that the two transcript sizes described by Senga et al.,
200317 are due to different 59-UTR lengths, which can possibly result
from alternate splicing20 or promoters21. The transcript detected by
the 59 RACE here is likely the shorter, more abundant, transcript.
Our attempts to detect the presence of other possible 59-UTR species
via RACE were thus far unsuccessful (data not shown), presumably
due to the low abundance. Overall, these results characterize the 59
region of the human GPR43 gene and allow the putative core
promoter to be identified for subsequent analysis of transcriptional
elements.
The core and proximal promoter of GPR43 are located within
2451 to 233 from the TSS. Upon identification of the TSS, we
cloned a putative promoter region (spanning 24560 to 168 bp
relative to the TSS) from primary human monocyte genomic DNA
and analyzed its promoter activity using dual luciferase reporter
system. This putative promoter contained aligned sequences with
greater than 70% sequence identity to the corresponding mouse
sequence (Fig. 3a), suggesting conservation with involvement in
transcriptional regulation22. Indeed, compared to the vector alone,
the promoter insert raised the luciferase reporter activity by .100-
fold (Fig. 3b). Deletion from positions 24560 to 2451 revealed no
significant change (p-values . 0.05) in luciferase activity, implying
that this region lacks regulatory elements, which is consistent with the
general lack of sequence conservation observed (Fig. 3a). Although
two short sequence alignments do appear in this region, we note that
the corresponding mouse sequences are much further away from the
mouse Gpr43 gene (0.6 Mbp and 1.7 Mbp, respectively), suggesting a
lack of involvement in mouse Gpr43 transcriptional control. Deletion
from positions 2451 to 2182 resulted in a marked drop (p-value 5
0.07) in activity while further deletions downstream of position 2182
resulted in significant reductions in activity (p values , 0.005),
suggesting that the region spanning 2451 to 258 might contain
crucial activator elements. This is consistent with the observed inter-
species sequence conservation (Fig. 3a). Strikingly, the near abrogation
of promoter activity upon deletion of 258 to 233 suggests that the
core promoter element(s) lies within this 25 bp region.
XBP1 is part of the core promoter while CREB, CHOP, NFAT and
STAT5 act as enhancers. By in silico predictions using the Mat-
Inspector program23, we identified 8 transcription factor (TF) recog-
nition sites with high matrix similarity of $90% within the 519 bp
putative promoter (Fig. 4a). The null mutations of Tax/CREB, CHOP,
NFAT and STAT5/5B resulted in significant losses in activity com-
pared to the wild type (WT) promoter (Fig. 4b), indicating that these
TFs may be important enhancers for the control ofGPR43 expression.
Conversely, no significant loss in activity was found for mutations
in the IRF4, PU.1 and c-Rel recognition sites. Mutation of the XBP1
recognition site resulted in near abrogation of promoter activity
(Fig. 4b), hence identifying it as a crucial core cis element. Notably,
Table 1 | Known phenotypes of GPR43 knockout mice
Publication: Gpr43 knockout mice phenotype:
Maslowski et al. 20091 Exacerbated colitis, arthritis and asthma
Reduced neutrophil recruitment
Sina et al. 20092 Reduced colitis
Increased neutrophil recruitment
Kim et al. 20133 Reduced colitis
Reduced ERK and p38 activation in epithelial cells
Smith et al. 20134 Exacerbated colitis
Reduced Treg cell count
Ge et al. 200853 Increased lipolysis and plasma free fatty acids
Bjursell et al. 20116 Improved glucose control and reduced body fat mass on a high fat diet
Tolhurst et al. 20127 Impaired glucagon-like peptide-1 secretion and glucose tolerance
Kimura et al. 20138 Increased fat accumulation and obesity on a normal diet
Figure 1 | GPR43 mRNA is up-regulated in primary human monocytes,
neutrophils and PMA differentiated U937 cells as determined by
quantitative PCR. Results shown are standardized to undifferentiated
U937 cells and error bars represent the mean 6 s.d. of three independent
cell cultures.
www.nature.com/scientificreports
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this XBP1 recognition site resides within the 25 bp region that was
deleted from the 126 bp promoter (Fig. 3b). XBP1 binding also
appears to be required for the low level GPR43 expression observed
in A549 adenocarcinomic human alveolar basal epithelial cells
(Supplementary Fig. S1) since the XBP1 null mutation also led to
near abrogation in promoter activity in the A549 cells.
The activities of p38 and PLC are required forGPR43 transcription.
A number of the identified TFs are known to be regulated by MAPK
and PLC/PKC pathways24–26. To determine if these pathways are
involved in the modulation of GPR43 expression, we blocked the
putative pathways with small molecule inhibitors (Fig. 4c, 4d). The
relative expression of housekeeping genes was not markedly affected
(Supp. Fig. 2). Both SB203580 and U73122, inhibitors of p38 and
PLC respectively, attenuated GPR43 transcription in LPS-challenged
monocytes while only SB203580 attenuated GPR43 transcription
in unchallenged monocytes (Fig. 4c, 4d). This suggests that the
p38 pathway is required for basal transcription of GPR43 which is
active with or without LPS-challenge while the PLC-PKC pathway is
important only during LPS-mediated up-regulation of GPR43. This
may be due to p38 pathway activation of XBP126, which is part of the
core promoter regulating basal transcription (Fig. 4b); while the PLC-
PKC pathway activates NFAT25, which we find to act as an enhancer
(Fig. 4b). The p38 pathway also activates CHOP24. Separately, the
proteasome inhibitor, MG132, reduced GPR43 mRNA levels with
or without LPS treatment while Wortmannin, an AKT inhibitor,
increased GPR43 transcript levels. Overall, our findings indicate that
activation of the GPR43 expression is mediated by the p38 and PLC/
PKC pathways, and transcriptional regulation may possibly also
involve the proteasome degradation and PI3/Akt pathways.
ChIP analysis confirmed XBP1 binding to GPR43 promoter in
vivo. Since the XBP1 binding sites were found to be necessary for
promoter activity, we investigated XBP1 binding to the endogenous
GPR43 promoter. Chromatin immunoprecipitation (ChIP) was per-
formed with antibodies against XBP1. The GPR43 promoter XBP1
binding site was significantly enriched in the resulting immunopre-
cipitate, consistent with strong association of XBP1 to that site (Fig. 5).
The pull down appears specific as no significant enrichment was
detected for the negative control genomic regions and no GPR43
promoter enrichment was observed when the isotype control anti-
body was used.
XBP1-siRNA knockdown or overexpression altersGPR43 expression.
Next, we sought to confirm that XBP1 activity is required for the
endogenous transcription of GPR43. Stable knockdown of XBP1 in
U937 cells led to a reduction in GPR43 expression levels relative
to the control siRNA (Fig. 6a, b). Conversely, in the A549 adenocar-
cinomic human alveolar basal epithelial cell line, which expresses low
levels of XBP1-dependent GPR43mRNA (Fig. 1 and Supplementary
Fig. S1), the overexpression of the active spliced form of XBP1
(XBP1s) raised GPR43 expression levels (Fig. 6c, d). Thus, we have
confirmed that XBP1 modulates endogenous GPR43 expression.
GPR43 expression is up-regulated by XBP1 activators. The XBP1-
mediated transactivation ofGPR43 prompted us to examine whether
GPR43 expression is increased by known activators of XBP1. LPS is
a known activator of XBP127 while GM-CSF is a known positive
regulator of dendritic cell development28, a process which requires
XBP129. We found that LPS treatment increased the GPR43 trans-
cription by at least 7-fold while GM-CSF raised transcription by 5-
fold (Fig. 7a). Both stimuli were previously reported to induceGPR43
expression via an unknown mechanism17. However, our results
now revealed this to be attributable to XBP1 activation. Besides
LPS, treatment with TNFa, another known activator of XBP130,
also up-regulated GPR43 transcription by 5-fold. Thus, we have
demonstrated that pathways leading to the activation of XBP1
consistently up-regulate GPR43 transcription.
Discussion
In this study, we identified and characterized the GPR43 promoter,
revealing that XBP1 acts as a core cis promoter element while CREB,
CHOP, NFAT and STAT5 act as enhancers (Fig. 2, 4a, 4b). Based
on its known ability to activate XBP1, we accurately predicted
that TNFa up-regulates GPR43 expression (Fig. 7b). This suggests
that other regulators of XBP1 activity may likewise be involved in
the regulation of GPR43 expression. We also showed that GPR43
expression was altered by inhibition of pathways involved in the
activation of CHOP and NFAT (Fig. 4c, 4d). Our identification of
the pathways known to activate these GPR43 promoter elements
would facilitate the application of stimuli and conditions to alter
GPR43 expression and its subsequent functions, with a view to thera-
peutic developments.
The indispensability of XBP1 for GPR43 promoter activity has
important implications since XBP1 is involved in a number of
Figure 2 | The GPR43 transcription start site is mapped to 1459 bp upstream of the ATG start codon. (a) 59-RACE of GPR43 transcripts from U937
cells. Total RNA from U937 cells was extracted and full-length GPR43 mRNA was reverse transcribed using a gene specific primer complementary to
its open reading frame. The resulting cDNAwas ligated to a known oligonucleotide sequence at the 59 end. Nested PCR using primers flanking the 59 end
was then performed to procure an approximately 450 bp product encompassing the 59 untranslated region (59-UTR) and part of the GPR43 coding
sequence (lane 1). As positive controls, amplification of 246 bp of the GPR43 coding region (lane 2), as well as a 900 bp-long 59 end of the b-actin gene
(lane 3) were performed. (b) Schematic mapping theGPR43 59-UTR region and protein coding region on the human chromosome 19. The PCR product
from (a, lane 1) was sequenced to reveal a 124 bp long 59-UTR exon upstream of the GPR43 ATG start codon.
www.nature.com/scientificreports
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physiological processes and diseases which include B cell develop-
ment and the unfolded protein response (UPR)31. It now appears
likely that these physiological processes may engage the expression
and function ofGPR43. Notably,mutations in the XBP1 gene locus of
human patients has been associated with increased risk of inflam-
matory bowel disease (IBD), Crohn’s disease and ulcerative colitis,
whileXbp12/2 mice have increased susceptibility to colitis32.Xbp12/2
mice also display impaired glucose and insulin tolerance upon high
fat diet-induced obesity33. The association of XBP1 with gut inflam-
mation and obesity may be partially attributable to the disrupted
expression of GPR43, since Gpr432/2 mice are similarly more sus-
ceptible to colitis1–4 as well as exhibiting impaired glucose tolerance
and increased obesity7,8. Considering the implications of XBP1 and
GPR43 in inflammation and obesity, it might be pertinent to further
investigate this hypothetical link.
Besides XBP1, the GPR43 promoter was also found to be up-regu-
lated by Tax/CREB, CHOP, NFAT and STAT5 (Fig. 4). Tax/CREB is
a heterodimer consisting of viral oncoprotein, Tax, and the host
derived CREB34. NFAT and STAT5 have been extensively implicated
in immunity and cancer, through regulating cell development,
growth and cytokine production35–38. CHOP plays a role in ER
stress-induced apoptosis and cytokine production39. However, in
comparison with XBP1, mutations of the promoter binding sites
for the aforementioned four TFs only resulted in relatively modest
decrease of ,30–40% in the promoter activity (Fig. 4b). It is hence
likely that these TFs are involved in fine-tuning the expression
levels of GPR43 in monocytes, or, they may be more active in up-
regulating the gene under the appropriate external stimuli (e.g.
cytokine stimulation, ER stress or viral infection). Following the
same line of argument, we cannot rule out the potential involve-
ment of other predicted transcription factors, e.g. IRF4, c-Rel
(component of NF-kB), and Pu.1 (Fig. 4b), in the expression of
GPR43 under the appropriate immune contexts. This will be a
subject of future investigation.
Figure 3 | Deletions define a 519-bp putative GPR43 promoter containing the core and proximal promoter. (a) ECR Browser plot spanning 24560 bp
upstream of the transcription start site (11), the entire GPR43 gene and 2000 bp after the gene. The plot represents sequence homology of the mouse
chromosome 7 (Ref Seq ID: NC_000073.6 ) region flanking the murine Gpr43 (Entrez Gene ID: 233079) in comparison to the corresponding region
on the human chromosome 19 (RefSeq ID: NC_000019.9; positions: 35934599–35942669), which is acting as the baseline. Sequence lengths of.100 bp
with 70% sequence conservation are shown as peaks. (b) Luciferase reporter activities of 59 deletion constructs from a 4628 bp putativeGPR43 promoter
in differentiated U937 cells 22 h after transfection. Analysis of the homology with mouse sequence was used to approximate the deletion sites. Results
represent the average Firefly luciferase read-outs of three independent transfections (n 5 3) normalized to Renilla luciferase activity and relative to
the basic (empty) luciferase vector, arbitrarily set as 1. Error bars represent the mean 6 s.d.. The data shown are representative of three independent
experiments. Two tailed Students’ T-test was used to determine the statistical significance of the difference between promoter constructs and is annotated
as: * ,0.05, ** ,0.01, and *** ,0.001.
www.nature.com/scientificreports
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The ability of inflammatory stimuli such as LPS, TNFa and GM-
CSF (Fig. 7a) to up-regulate GPR43 expression infers a number of
interesting possibilities. Our findings imply that the positive correla-
tion between GPR43 expression and inflammation at the fetal cell
membranes40 or TNFa levels in adipocytes41, is likely due to the up-
regulation of GPR43 by the inflammatory stimuli present. Notably,
GM-CSF has been found to be beneficial for the treatment of IBD42,43.
Since GPR43 is also implicated in the etiology of IBD1–4, it would be
Figure 4 | In silico predictions, null mutations of the 519 bp promoter region and signalling pathway modulation identify transcription factors (TFs)
and pathways regulating GPR43 expression. (a) Predicted TF binding sites byMatInspector software with correspondingWT andmutant sequences and
their relative positions indicated above each TF binding site. The core recognition sequences are underlined while mutated bases are indicated in red.
(b) Relative luciferase reporter activities of 519-bp promoter mutated at indicated sites were measured in differentiated U937 monocytes. The multiple
binding sites of PU.1 or NFAT residing within the 519 bp promoter were simultaneously mutated in their respective constructs. Wild type (WT)
promoter is arbitrarily set to 1 luciferase unit. (c)Quantitative PCR analysis ofGPR43mRNA levels uponmodulation of signalling pathways after 1 h pre-
treatment with activators/inhibitors followed by immune challenge for 3 h with 100 ng/mL LPS. (d) Quantitative PCR analysis of GPR43mRNA levels
upon 4 h treatment of monocytes with inhibitor/activator or 12 h treatment with inhibitor. (c) and (d) Inhibitor/Activator 1 (Targeted signalling
proteins) are shown: SB203580, 10 mM —| p38; U73122, 5 mM —| phospholipase C (PLC); MG132, 10 mM —| Proteasome; Wortmannin, 2 mM —|
PI3kinase (PI3K); BisI, 4 mM—| protein kinase C (PKC); Forskolin, 20 mMR Adenylyl cyclase (AC). Expression levels of two reference genes, beta-2-
microglobulin (B2M) and cyclophilin B (CYPB) were also measured and presented as Supplementary Figure S2. All measurements were standardized to
the RPL27 as the reference gene. Experiments were performed in triplicate transfections or treatments, where error bars represent the mean 6 s.d.
In (b), Dunnett’s test (a 5 0.05) was performed while in (c) and (d), the two tailed Students’ T-test was used to determine statistical significance.
p-value * ,0.05, ** ,0.01, and *** ,0.001. The data shown are representative of three independent experiments.
www.nature.com/scientificreports
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interesting to investigate whether GM-CSF exerts any beneficial
therapeutic effects through modulating GPR43 expression. In view
of the low plasma levels of SCFA (,200 mM)9,10 and low potencies of
the ligands in activating GPR43 (generally in the mid micromolar
range)14–16, the higher levels of expression ofGPR43 in the peripheral
blood monocytes might thus enhance the potency of SCFAs on the
GPR43-mediated inflammation.
The increase inGPR43 expression observed in phosphoinositide-3
kinase (PI3K) inhibition under basal or immune-challenged condi-
tions (Fig. 4c, 4d) suggests that there was a relief of suppression that is
mediated by the PI3K/Akt pathway. However, the current informa-
tion is insufficient to deduce whether this is a direct or indirect effect
from the PI3K/Akt signalling. Nevertheless, it should be noted that
activation of the PI3K/Akt pathway may lead to the inhibition of
p3844. Hence, the increase may be due to the recovery of p38, causing
an indirect activation of GPR43 expression.
In addition to characterizing the promoter, we provide the first
description of the 59-UTR of the human GPR43 gene, identifying an
intron between the 59-UTR and the start codon. Our findings present
a new perspective on the human GPR43 gene, which was initially
described as being intronless, downstream of the ATG start codon45.
Notably, this gene organization is also seen in the bovine GPR43
gene, the only other GPR43 homolog which has its 59-UTR
sequenced46. Such cross-species similarities in the gene organization
and high sequence conservation of the entire core promoter across
human and mouse (Fig. 2a) suggests that the same regulatory ele-
ments are conserved in the bovine and murine promoters. Indeed,
bovine and murine tissue specific expression of GPR43 have been
found to be highly similar to that of the human counterpart14–16,46. A
recent study reported transcriptional activity from a luciferase assay
of a 500 bp sequence immediately upstream of the human GPR43
start codon in mouse RAW264.7 macrophages47. Interestingly, these
researchers predicted an NF-kB binding site within this 500-bp
sequence, although the mutation was reported to cause only 10%
reduction in the promoter activity. Perhaps, inclusion of the
GPR43 TSS (located more than 1 kb upstream of the predicted
NF-kB binding site as reported by our study) would offer a more
complete analysis of the effect of this putative enhancer.
While the findings on the GPR43 promoter are mostly obtained
from human monocytes in this study, it would be interesting to
explore if the promoter elements identified, regulate GPR43 in other
cell types. Our findings on A549 cells suggest that this may indeed be
the case. In A549 cells, the 519 bp GPR43 promoter construct up-
regulates luciferase expression; an up-regulation that is abrogated by
XBP1 null mutation (Supp. Fig. S1). These findings mirror those of
U937 cells (Fig. 4b) although differences are also noted. Notably,
while a 50% knockdown of XBP1 mRNA led to an 80% drop in
expression of GPR43 in the U937 cell, a 100-fold increase in XBP1
mRNA only resulted in a 2-fold increase in A549 expression of
GPR43. This discrepancy in effect may be due to a variety of factors.
XBP1 activity in A549 may already be near saturation and hence
further increases in XBP1 expression will not proportionally increase
GPR43 expression. Another possibility is that XBP1 may require
further activation, such as by the p38 pathway26, to become fully
activated. Such pathways may be more active in monocytes. The
GPR43 promoter in A549 cells may also be epigenetically silenced
Figure 5 | XBP1 binds to the GPR43 promoter in vivo. (a) Schematic showing the relative regions of GPR43 promoter amplified by quantitative PCR
following ChIP assay with anti-XBP1 antibody. P1–P6 spans a region of ,1200 bp surrounding the XBP1 binding site on the GPR43 promoter.
Only promoter regions, P3 and P4 contain the XBP1 binding site. The GPR43 enhancer region and coding sequence, located more than 3 kb and 2.5 kb
up- and downstream of the XBP1 binding site respectively, were also amplified as negative controls. (b) Quantitative PCR analysis of GPR43 promoter
regions following ChIP assay onU937 cells using anti-XBP1 antibody or IgG isotype control antibody. Results are expressed as fold enrichment relative to
GPR43 coding sequence (GPR43_CDS) negative control region and error bars represent the mean 6 s.d. of three independent pull-down. p-value
* ,0.05, ** ,0.01, and *** ,0.001. The data shown are representative of two independent experiments.
www.nature.com/scientificreports
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through DNA methylation or chromatin remodeling, such that fur-
ther increases in XBP1 expression may not fully overcome this silen-
cing. Despite these differences, our findings confirm that XBP1 can
serve as a regulator involved in controlling GPR43 expression in
other cell types. Notably, both GPR4315,41,48 and XBP149 are found
to be up-regulated in adipocytes and adipocyte-derived cell lines,
suggesting that XBP1may also be involved in regulating the express-
ion of GPR43 in adipocytes, an interaction that may have implica-
tions in adipocyte function.
In conclusion, we present the first full characterization of the
human GPR43 promoter, revealing that GPR43 expression is regu-
lated by XBP1 as a core cis element while CREB, CHOP, NFAT and
STAT5 act as enhancers. We show that by distinguishing pathways
known to activate these GPR43 promoter elements, it is possible to
predict stimuli and conditions that may alter GPR43 expression and
function, thus providing novel drug targets for the treatment of
GPR43-associated diseases such as obesity, colitis, asthma and
arthritis.
Methods
Isolation of peripheral blood monocytes, cell culture and differentiation of U937
cells. Peripheral blood mononuclear cells were isolated from the buffy coat of healthy
adult donors (National University of Singapore Blood Donation Centre). Ficoll-
Paque PREMIUM (GEHealthcare) gradient centrifugation was performed according
to the manufacturer’s instructions. Briefly, the mononuclear cell layer was isolated
and washed with PBS supplemented with 2% FBS (GE healthcare) and 1 mM EDTA,
to remove platelets.Monocytes were subsequently purified by negative selection using
the Human Monocyte Enrichment Kit (StemCell Technologies) according to the
manufacturer’s instructions.
Figure 6 | XBP1 is critical for the expression of GPR43. (a) Quantitative PCR analysis of GPR43 and spliced XBP1 (XBP1s) mRNA in XBP1-stable
knockdown U937 cells relative to the negative control (non-targeting) siRNA expression plasmid, arbitrarily set as 1. (b) Western blot analysis of
unspliced XBP1 (XBP1u) protein levels in XBP1-stable knockdown U937 cells. XBP1s levels were undetectable. (c) Quantitative PCR analysis of GPR43
and XBP1 mRNA after 48 h overexpression of XBP1s in A549 cells, relative to the pcDNA empty vector which is set arbitrarily as 1. (d) Western blot
analysis of XBP1s protein levels after 48 h overexpression of XBP1s in A549 cells. (b) and (c) Measurements were standardized to RPL27 as the reference
gene. (b) to (d) Results shown are the average of three independent transductions (for stable knockdown) or transfections (for overexpression), with error
bars representing the mean 6 s.d.. Two tailed Students’ T-test was used to calculate statistical significance. p-value * ,0.05, *** ,0.001.
Figure 7 | Humanmonocyte GPR43 expression is up-regulated by LPS, TNFa andGM-CSF treatment. (a) Quantitative PCR analysis ofGPR43mRNA
and (b) spliced XBP1 (XBP1s) mRNA levels under 3 h treatment with either 100 ng/mL LPS; 10 ng/mL TNFa; 100 ng/mL GM-CSF or 10 mM Acetate
(Ac). (a) and (b) The results represent average fold change of the treated samples relative to the non-treated control (NT) and error bars represent
the mean 6 s.d. of three independent treatment wells. Measurements were standardized to RPL27 as the reference gene. Two tailed Students’ T-test was
used to determine the statistical significance of the difference between treated and NT samples. p-value * ,0.05, ** ,0.01, and *** ,0.001. The
data shown are representative of at least two independent experiments.
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Primary monocytes and U937 cell line were cultured in RPMI (Life Technologies)
while A549 cells were cultured in DMEM (Life Technologies) supplemented with
10% FBS and 1% (v/v) penicillin and streptomycin (Life Technologies). The cells were
grown at 37uC and 5%CO2. For differentiation of U937 intomonocytes, 53 105 cells/
mL of pre-differentiated cells were induced with 30 ng/mL phorbol 12-myristate 13-
acetate (PMA) (Sigma-Aldrich) for 24 h, before changing to fresh media. The cells
were cultured for another 48 h to allow for full differentiation and thereafter used for
downstream assays.
The primary neonatal human fibroblasts (Life Technologies) were routinely grown
in medium 106 (Life Technologies) before RNA extraction.
59-Rapid Amplification of cDNA Ends (59 RACE). Amplification of 59 cDNA ends
of mature GPR43 was performed with the GeneRacerTM kit (Life Technologies, Cat.
#L1-502-02) following manufacturer’s instructions. Briefly, 5 mg of U937 total RNA
was dephosphorylated with Calf Intestinal Phosphatase (CIP) and ligated with a
sequence specified RNA oligonucleotide at 37uC for 1 h. Following ligation, the 59
ends of GPR43 mRNA were reverse transcribed and amplified using nested PCR
primers (Supplementary Table S1). The PCR product was then analyzed on a 1.5%
agarose gel. The sequence of the GPR43 59 end was confirmed using Big Dye
Terminator cycle sequencing kit and ABI 3100 Genetic Analyser (Life Technologies).
Construction of GPR43 promoter and deletion mutants. To generate promoter
deletion constructs, primary monocyte genomic DNA was extracted from the
interphase and phenol layer using TRIzol reagent (Life Technologies), according to
the manufacturer’s instructions. To obtain 59 end promoter deletion products,
primers (Supplementary Table S1) flanking the desired promoter regions were used
for PCR amplification, using the purified genomic DNA as template. PCR was
performed using iProofHigh Fidelity DNAPolymerase (Bio-rad) under the following
parameters: initial denaturation at 98uC; 40 cycles of amplification, denaturation at
98uC for 10 s, annealing at Tm of primer pair 13uC for 30 s, elongation at 72uC for
2.5 min; followed by a final extension at 72uC.
The isolated promoter lengths were separately cloned into pGL4.20 vector
(Promega) using standard molecular cloning techniques. The restriction enzymes
used were XhoI and HindIII (Thermo Fisher Scientific). T4 DNA ligase was from
Roche. For small-scale purification of plasmids, AxyPrep Plasmid Miniprep kit
(Axygen Biosciences) was used. Large-scale purification of plasmids intended for
transfection was carried out using PureLink HiPure Plasmid Filter Purification kit
(Invitrogen). The full-length sequence of each promoter construct was confirmed by
sequencing using Big Dye Terminator cycle sequencing kit and ABI Prism 3100
Genetic Analyzer (Life Technologies).
In silico predictions of transcription factor binding sites and site-directed
mutagenesis. Transcription factor binding sites (TFBS) along the delineated
promoter regions were identified using theMatInspector programme available online
at http://www.genomatix.de/23. Analysis of the sequences was performed using the
MatInspector TFBS, weight matrix library version 9.0. Only predicted TFBS with a
core matrix similarity of $0.95 and an overall matrix similarity of $0.90, were
considered significant.
Promoters containing the specific mutated TFBS were synthesized by Integrated
DNA technologies. The mutated promoters were cloned into pGL4.20 vector
(Promega) and confirmed by sequencing as described above.
Transient transfection and luciferase reporter assay. The full-length promoter,
deletion and mutant constructs were transiently transfected into differentiated U937
cells at 48 h after removal of PMA, with X-tremeGENE HP DNA Transfection
Reagent (Roche) according to the manufacturer’s guidelines. Promoter-pGL4.20
vector constructs and pRL-CMV control Renilla luciferase vector (Promega) were
transfected in the molar ratio of 1051.
Renilla luciferase reporter activities were assessed using the Dual Luciferase
Reporter Assay System (Promega) 22 h after transfection. Luminescence was
detected using the Glomax 20/20 Luminometer (Promega), and the resulting mea-
surements from the Firefly luciferase were normalized to the Renilla luciferase.
Relative light units were calculated using readouts from the pGL4.20-Basic (pro-
moter-less) vector or the wild type promoter as baseline for deletion and mutation
constructs, respectively.
Treatment of cells with inflammatory stimuli and pathway activation/inhibition.
For stimulation of cells, Escherichia coli 055:B5 LPS and sodium acetate were
purchased from Sigma-Aldrich while GM-CSF and TNFa were from Life
Technologies. Purified humanmonocytes were seeded at a density of 43 106 cells/mL
in 24-well plates and cultured in the presence of either LPS (100 ng/mL), PMA
(30 ng/mL), TNFa (10 ng/mL), GM-CSF (100 ng/mL) or sodium acetate (10 mM)
for 3 h before RNA extraction with TRIzol reagent (Life Technologies).
For modulation of signalling pathways, p38 inhibitor SB203580, PKC inhibitor
Bisindolylmaleimide I (BisI) (all from Cell Signalling Technology), PLC inhibitor
U73122, adenylate cyclase activator Forskolin (Tocris Biosciences), proteasome
inhibitor MG132 and PI3K inhibitor Wortmannin (Sigma) were obtained.
Purified human monocytes were pre-treated for 1 h in either 20 mM DMSO
(Merck) as vehicle control, SB203580 (10 mM), U73122 (5 mM), MG132 (10 mM),
Wortmannin (2 mM) or BisI (4 mM). Cells were then challenged in 100 ng/mL LPS
for 3 h before mRNA was extracted for analysis.
To identify regulatory pathways involved in the basal regulation of gene expression,
the same conditions above were applied except that replicate wells of cells treated with
MG132 (10 mM) and Forskolin (20 mM) were lysed and analyzed for mRNA
expression after 4 h without LPS treatment. For treatment with other inhibitors,
monocytes were lysed for RNA extraction and analyzed after 12 h in culture.
Quantitative PCR (qPCR). Total RNA was isolated using the TRIzol reagent
according to the manufacturer’s instructions and the procedure was repeated to
ensure thorough removal of genomic DNA. cDNA synthesis of the extracted RNA
was performed using Superscript III First Strand Synthesis kit (Life Technologies).
Quantitative PCR was performed using GoTaq qPCR Master Mix (Promega) and
forward and reverse primers (Supplementary Table S1) with LightCycler 480 system
(Roche). Spliced XBP1 was detected using the Taqman gene expression assay (Life
Technologies, Hs03929085_g1) and Light Cycler Probes Master (Roche). To obtain
relative target mRNA folds, cycle thresholds (Ct) were normalized to the Ct of
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) or Ribosomal protein L27
(RPL27) reference genes and expressed as fold-change by the 22nnCt method50.
Western Blotting. Cell lysates were separated by SDS-PAGE and transferred onto
PVDF membranes (Bio-rad). The blots were then probed with antibodies against
XBP1 (Abcam, ab37152), GPR43 (Abcam, ab131003) or b-actin (Sigma, a2066)
followed by the corresponding secondary antibodies according to respective
manufacturer’s instructions. Following incubation with WesternBright ECL
chemiluminescent substrate (Advansta), chemiluminescent signals was detected with
an ImageQuantTM LAS 4000 mini (GE Healthcare).
ChIP assay.ChIP assay was performed as described previously51. DifferentiatedU937
cells were cross-linked with 1% formaldehyde for 10 min at room temperature and
then quenched with 0.2 M of glycine. Chromatin extracts from lysed cells were
sonicated to an average DNA fragment length of 350 bp and immunoprecipitated
with Santa Cruz Biotechnology antibodies anti-XBP1 (sc-7160) or IgG isotype
control (sc-2027). Following de-crosslinking, quantitative PCR was performed with
multiple ChIP primers (Supplementary Table S1) to quantitate the relative occupancy
of the GPR43 promoter region. Fold enrichment was obtained by normalizing the
amount of precipitatedDNA to that of the input sample and then expressed relative to
the GPR43 negative control coding region.
siRNA knockdown and XBP1s overexpression. For stable knockdown of XBP1,
siRNA sequences Sense: 59-AAAGACAGCAAGTGGTAGATTTA-39; Anti-sense:
59-AAAATAAATCTACCACTTGCTGT-3952 was cloned into pFIV-H1/U6 vector
(System Biosciences), while a non-targeting sequence was cloned as the negative
control vector. The resulting siRNA vector construct or pFIV-H1/U6-copGFP vector
(System Biosystems), which contains CopepodGFP coding sequence in replacement
of the puromycin selection marker, was co-transfected with lentiviral packaging
vectors pFIV-34N and pVSV-G into HEK-293T cells with TurboFect transfection
reagent (Thermo Scientific). Culture supernatant was collected after 48 h and used to
resuspend U937 cells, with the addition of polybrene to a final concentration of 8 mg/
mL. The resulting suspensions were then centrifuged at 1000 g for 2 h at 37uC, after
which the transduced cells were re-suspended in 2 mL of fresh complete RPMImedia
and seeded into 6 well plates. Successfully transduced cells were selected with 1 mg/
mL puromycin (Life technologies) in culture medium 48 h after transduction, for 1.5
weeks.
ForXBP1s overexpression,XBP1s coding sequence (NM_001079539.1) was cloned
into pcDNA3.1A (Invitrogen) and transfected into A549 cells using X-tremeGENE
HPDNATransfection Reagent (Roche) according to themanufacturer’s instructions.
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Abstract   
The fermentation of fiber by the gut microbiota produces short-chain fatty acids (SCFAs): 
acetate, propionate and butyrate. SCFAs activate the monocyte receptors, GPR41 and 
GPR43. Monocytes participate in gut mucosa immune surveillance but the functions of 
GPR41/43 in these cells remain ill-defined. Here, we employed knockout mice models and 
receptor-specific synthetic agonists to investigate GPR41/43 functions. Acetate activated 
human and mouse monocyte p38 signaling via GPR43. In LPS-challenged mice 
monocytes, acetate treatment repressed CXCL10, IL-1r, TIMP-1, and CCL2; but 
elevated CXCL1, IL-1 and IL-1, independently of GPR41/43. Surprisingly, this 
contrasted with LPS-challenged human monocytes where acetate activated GPR41 and 
GPR43 to produce a distinct cytokine profile– suppressing C5, CCL1, CCL2, GM-CSF, 
IL-1, IL-1, ICAM-1 and TNF. GPR43 mediated this cytokine inhibition through the 
repression of Akt and ERK2 signaling. This species-specific signaling is attributable to the 
cell context and not receptor variation. Collectively, we show that SCFA treatment 
induces distinct inflammatory cytokine profiles in human and mouse monocytes due to 
species-specific GPR41/43 signaling, with implications in chronic inflammatory diseases 
that may not be fully modeled by the mice. 
 
Introduction 
 The human gut microbiota has been linked to a number of beneficial functions, 
including the modulation of immune development, metabolic function, and preventing 
allergies, colon cancer, and inflammatory bowel disease (IBD) 1. Some of these beneficial 
host-microbiome effects are thought to be mediated by short-chain fatty acids (SCFAs), 
which are produced in millimolar concentrations in the colonic lumen during the anaerobic 
fermentation of dietary fiber by saccarolytic gut bacteria 2. In addition to being an 
important energy source, SFCAs also affect the blood glucose and lipid levels, the colonic 
environment and immune functions 3.  
 The exact mechanism by which the SCFAs exert these physiological effects on the 
gut mucosa remains a subject of ongoing investigation. One likely mechanism is via the 
activation GPR41 and GPR43, a pair of G protein-coupled receptors which recognize 
SCFAs as ligands 4–6. The three most abundant SCFAs (namely acetate, butyrate and 
propionate) activate GPR41 and GPR43 with EC50 of ~0.5 mM. GPR41/43 are the only 
known targets of acetate thus far, while both butyrate and propionate reportedly inhibit 
histone deacetylases 7. Additionally, butyrate also activates GPR109A 8. More recently, 
the development of synthetic agonists has enabled the specific activation of either GPR41 
or GPR43 9,10. 
 Increasing evidence suggest that GPR41 and GPR43 are essential mediators of the 
physiological effects of SCFAs. Knockout mice studies have confirmed the role of GPR41 
and GPR43 in the etiology of colitis, asthma and arthritis 11–16. However, despite being 
highly expressed in monocytes 5,6, little is known about the function of GPR41/43 in these 
cells. Monocytes are a promising target to study GPR41/43 functions as these cells 
migrate to the colon mucosa and contribute to inflammation in both patients 17 and mouse 
models 18. Differentiated monocytes also form the principal source of murine intestinal 
macrophages 19. In the colon mucosa, these cells are presumably exposed to the millimolar 
concentrations of SCFAs required to activate the GPR41/43, with potential implications 
on monocyte-associated inflammatory disorders. Notably, the CD14+CD16+ monocyte 
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subset is reportedly expanded and implicated in the disease pathology of patients with 
rheumatoid arthritis 20 and IBD 21. Such implications are of particular interest, in light of 
the emergence of GPR41/43 as potential pharmacological targets 22. 
 Here, we show that treatment with SCFA induces distinct inflammatory cytokine 
profiles in human and mouse monocytes, as a consequence of species-specific GPR41/43 
signaling. We found that GPR41/43 mediate human monocyte response to SCFA (acetate) 
by inhibiting the expression of C5, CCL1, CCL2, GM-CSF, IL-1, IL-1, ICAM-1 and 
TNF. GPR43 modulates this response through the repression of Akt and ERK2. By 
contrast, acetate treatment of mouse monocytes repressed the transcription of CXCL10, 
IL-1r, TIMP-1 and CCL2, but elevated CXCL1, IL-1 and IL-1independently of 
GPR41/43.Furthermore, mouse monocyte GPR43 failed to inhibit Akt and ERK2. In both 
human and mouse monocytes, GPR43 activated p38 signaling. Hence, we have revealed a 
previously undefined role of GPR41/43 specific to the human monocyte inflammatory 
response. These findings suggest that the mouse may not be a dependable model for 
studying human GPR41/43-associated inflammatory disorders. 
 
Results 
GPR43 activates p38 signaling in monocytes via the Gq/11 pathway  
 A subset of GPCRs activate p38, Akt and ERK signaling 23 which are crucial for 
monocyte function 24,25. Thus, we investigated if GPR41/43 modulated these signaling 
pathways in mouse and human monocytes. Activation of human monocyte GPR43 by 
acetate or CFMB (a synthetic agonist) led to a transient increase in p38 phosphorylation 
that peaked at 3 min post-induction [Figure 1A]. During this period, Akt was only weakly 
activated and ERK remained unaffected [Figure S1]. The p38 phosphorylation observed 
in mouse monocytes was abolished upon GPR43 knockout (Gpr43-/-) [Figure 1B], 
consistent with GPR43 mediation. The activation of GPR41 alone, which is present in the 
Gpr43-/- monocytes [data not shown], did not lead to p38 phosphorylation. Consistently, 
heterologous expression of GPR43 in human lung epithelial carcinoma A549 cells (which 
have low endogenous levels of GPR41 and GPR43 [data not shown]), led to the 
constitutive phosphorylation of p38 [Figure 1C]. This p38 phosphorylation was not 
increased by TNF treatment and occurred in the absence of GPR43 ligands, which 
suggests that GPR43 is in a constitutively active state when overexpressed. Constitutive 
activity is reported in some GPCRs 26, including GPR43 5,27. Heterologous expression of 
GPR41 on the other hand, did not up-regulate p38 even after acetate treatment. GPR43-
mediated activation of p38 persisted during Gi inhibition by pertussis toxin (PT) but was 
abolished during Gq/11 inhibition by YM254890 28, suggesting that Gq/11 signaling is 
required for the activation of p38 [Figure 1D]. Taken together, these results indicate that 
acetate induces GPR43 to transiently activate monocyte p38 signaling via Gq/11. 
 
GPR43 inhibits Akt and ERK in human but not mouse monocytes 
 Next, using proteome array analysis, we determined whether acetate-mediated 
activation of GPR41/43 would alter human monocyte kinase activity during LPS-induced 
inflammation. Compared to LPS-treatment alone, combined treatment with acetate led to 
attenuated Akt2 and ERK2 phosphorylation [Figure 2A]. Consistently, acetate treatment 
also attenuated the phosphorylation of MSK2 (which is activated by ERK and p38 
signaling) while the mTOR phosphorylation (a target of Akt inhibition) was enhanced 
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[Figure 2A]. Western blot analysis confirmed that GPR43 mediates ERK2 and Akt 
inhibition during acetate or CFMB treatment [Figure 2B] and not GPR41 during 
AR420626 (synthetic GPR41 agonist) treatment [Figure S3], while the levels of 
phosphorylated p38 remained unaffected [Figure S2]. This inhibitory effect was strongest 
during early activation of Akt and ERK2 by LPS [Figure 2C]. Interestingly, this GPR43-
mediated inhibition of Akt and ERK2 was absent in mouse monocytes where acetate and 
CFMB treatment did not alter Akt and ERK2 phosphorylation [Figure S4]. Thus, we 
showed that GPR43 inhibits Akt and ERK in human but not mouse monocytes, hinting at 
a species-specific signaling response. 
 By constitutively activating GPR43 signaling in A549 cells through heterologous 
expression [Figure 1C], we further investigated GPR43-mediated inhibition of Akt. 
GPR43 expression led to attenuated NF-B activation by TNF [Figure 2 D and E], which 
is dependent on Akt 29 as shown by the partial rescue during combined expression with 
myristoylated Akt (myr-Akt) [Figure 2 F]. The basal NF-B activity (without TNF 
treatment), which is a pathway reportedly activated by certain GPCRs 30, was only 
moderately raised by GPR43 expression [Figure 2E]. Consistent with the constitutive 
activation of GPR43, the NF-B attenuation was proportional to GPR43 expression levels 
[Figure 2E] and not increased by acetate ligand treatment [Figure 3A]. Surprisingly, 
heterologous expression of GPR41, albeit to a lesser extent than GPR43, also attenuated 
NF-B activity [Figure 3A]. Collectively, these heterologous expression studies confirm 
GPR43-mediated inhibition of Akt. 
 Similar to the human receptor variant, the expression of mouse GPR43 in A549 
cells also led to the inhibition of Akt-dependent NF-B activity [Figure 3A]. This suggests 
that the lack of GPR43-mediated Akt inhibition in mouse monocytes may be due to known 
differences in signaling pathways between human and mouse monocytes 31. Depending on 
the cell context, such as in A549, mouse GPR43 may also display Akt inhibitory activity. 
Such cell context-dependent signaling outcomes have been reported for GPCRs 32. On the 
other hand, if the different signaling outcomes were due to species variations in GPR43 
amino acid sequence leading to species-specific receptor functions, we would expect to 
observe inhibitory activity from human but not murine GPR43. Therefore, species-specific 
signaling of GPR43 in monocytes is likely cell context-dependent. 
 
ERK2 inhibition requires Gq/11 while Akt inhibition is independent of both Gi/G0 
and Gq/11 
 In human monocytes, acetate-mediated Akt inhibition persisted during Gi/G0 and 
Gq/11 signaling inhibition by PT and YM254890 [Figure 3C] while the ERK2 inhibition 
required Gq/11 signaling and was abolished by YM254890 but not by PT treatment 
[Figure 3D]. This is largely consistent with observations in A549 cells heterologously 
expressing GPR43. Here, PT and YM254980 treatment also had no effect on NF-B 
inhibition [data not shown]. Gi/G0-mediated suppression of PKA is also not required since 
the combined expression of constitutively active PKA did not restore NF-B activity [data 
not shown]. NF-B activity was also not restored by the SB203590-mediated inhibition of 
the p38 pathway [data not shown], and the BisI-mediated inhibition of PKC [Figure 3B], 
a pathway known to be engaged by GPCRs. BisI did in fact abolish the moderate increase 
in the basal NF-B activity during GPR43 expression, confirming that a negative feedback 
effect is not responsible for the repression observed. In summary, GPR43 inhibits Akt via 
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a GiG0 and Gq/11 independent pathway, and inhibits ERK via a Gq/11 dependent 
pathway. 
 
Acetate modulates cytokine expression in mouse monocytes independently of 
GPR41/43. 
 Since the p38, Akt and ERK pathways are involved in regulating cytokine 
expression 24,25, we investigated whether acetate treatment would modulate cytokine 
expression in mouse monocytes upon LPS challenge. Treatment with acetate was found to 
down-regulate CXCL10, IL-1r, TIMP-1 and CCL2, but up-regulate CXCL1, IL-1 and 
IL-1 [Figure 4A]. These changes in the cytokine level were also detected at the transcript 
level [Figure 4B and 4C][Figure S5A], suggesting that the altered protein levels are a 
consequence of mRNA changes. Notably, this cytokine modulation persisted in the Gpr41-
/- and Gpr43-/- mouse monocytes [Figure 4A and 4C] consistent with a GPR41/43-
independent mechanism. Indeed, specific activation of GPR41 (with AR420626) or 
GPR43 (with CFMB), did not affect cytokine expression [Figure S5B and S5C]. This 
precludes the possibility that one SCFA receptor is compensating for the loss of the other. 
Thus, it appears that the effect of SCFA on mouse monocyte cytokine expression may 
involve GPR41/43-independent mechanisms. 
 
GPR41 and GPR43 modulate cytokine expression in human monocytes 
 Unlike mouse monocytes, the human monocyte response to acetate was mediated 
by GPR41 and GPR43, resulting in distinct cytokine profile. Acetate treatment caused a 
downregulation of C5, CCL1, CCL2, GM-CSF, IL-1, IL-1, sICAM-1 and TNF in LPS-
activated human monocytes, at both the protein [Figure 5A and 5B] and mRNA levels 
[Figure 5C and 6A] [Figure S6]. This cytokine downregulation is likely due to the 
activation of GPR41/43 since similar downregulations are observed during specific 
activation of GPR41/43 by synthetic agonists. Treatment of LPS-induced human 
monocytes with GPR41 agonist (AR420626) reduced the expression of C5, CCL1, CCL2, 
GM-CSF, sTREM-1 and IL-1 at either the protein level [Figure 5A] or the mRNA level 
[Figures 5D, 6 and S6A]. Treatment with the GPR43 agonist (CFMB) reduced CCL1, 
CCL2, GM-CSF, IL1a, IL1b, ICAM1 and TNF mRNA at 4 h post-LPS challenge [Figure 
5E and 6A]. Only reductions in C5 at 6 and 12 h post-LPS challenge, and CCL2 at 6 h 
post-LPS challenge [Figure 5A], were observed at the protein level. This may be due to 
the purported instability of CFMB 9, which may not sustain the inhibition long enough for 
a drop to be observed at the protein level. Consistent with this instability, CFMB-mediated 
cytokine mRNA inhibition abated at 12 h post-LPS challenge [Figure S6].  Additionally, 
monocytes pretreated with acetate for 12 h prior to a 4-h LPS challenge, continued to 
display suppressed cytokine mRNA expression, while monocytes pretreated with CFMB 
for 12 h did not [Figure S7]. The cytokine inhibition is not specific to the LPS-induced 
pathway as both naive and activated monocytes were similarly susceptible [Figure 5F]. 
On the whole, the results here suggest that GPR41/43 activation modulates cytokine 
expression levels in human monocytes. 
 
Repression of Akt may account for the cytokine inhibition 
 GPR43 likely mediates the cytokine inhibition via the attenuation of Akt and ERK, 
which our inhibitor studies demonstrate to be required for the expression of CCL2, IL-
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1and IL-1 in human monocytes [Figure 6B]. By contrast, the inhibition of p38 (which 
is instead activated by GPR43 [Figure 1]), did not reduce cytokine expression. Such a 
scenario is consistent with the acetate-induced upregulation of IL-1 and IL-1 in mouse 
monocytes [Figure 3] where GPR43-mediated inhibition of Akt and ERK is absent [Figure 
S4]. Treatment with Gi/G0 and Gq/11 signaling inhibitors [Figure 6C], which are 
required for GPR43-mediated modulation of ERK2 [Figure 2E] and p38 activity [Figure 
1D], failed to rescue human monocyte cytokine expression from acetate-mediated 
inhibition. Finally, Akt activity in human monocytes was restored via the expression of a 
constitutively active myristoylated Akt (myr-Akt), which led to a recovery in cytokine 
expression [Figure 6D], thus confirming the role of Akt in acetate-mediated attenuation of 
cytokine expression. Hence, we find that the repression of Akt may account for the 
cytokine inhibition in human monocytes. 
 
Discussion 
 In this study, we demonstrate that the human monocyte response to the SCFA, 
acetate, is mediated by GPR41 and GPR43, resulting in the inhibition of several 
inflammatory cytokines [Figure 5]. By contrast, the mouse monocyte response to SCFA is 
independent of GPR41/43 [Figure 4 and S5], showing a distinct cytokine profile. Our 
findings offer a novel perspective on the limitations of using the mouse model to study 
human diseases 33, such as human IBD 34,35. To our knowledge, this is the first report of 
differences between human and mouse monocyte response to SCFA. Such differences 
may not be restricted to monocytes since GPR43 agonists have been reported to induce the 
differentiation of mouse 36 but not human 37 adipocytes. Thus our findings reveal that the 
mouse models, which are widely used in gut microbiota studies, may not fully replicate 
the distinct responses of human monocyte to SCFAs. 
  The species-specific function of GPR43 in response to SCFA may shed light on 
some intriguing earlier controversies. Previously, Masui et al (2013) 15 reported that 
acetate treatment reduced TNF expression in both human and mouse peripheral blood 
mononuclear cells (PBMCs), an effect that was abolished in human monocytes by a 
GPR43 antibody, but persisted in Gpr43-/- mouse PBMCs. Our findings could possibly 
explain this dichotomy; that GPR43 inhibitory activity is human monocyte-specific and 
therefore the inhibition of human GPR43 activity (possibly by antibody binding) is 
expected to abolish the acetate-mediated cytokine inhibition. In mouse monocytes on the 
other hand, acetate appears to act independently of GPR43, to modulate cytokine 
expression, thus Gpr43 knockout did not abolish the inhibition. 
 The GPR43-mediated inhibition of Akt and ERK2 observed here [Figure 2] is a 
characteristic function of certain GPCRs. One example is the P2Y(2) GPCR-mediated 
inhibition of ERK activation by growth factor in keratinocytes 38, which similar to GPR43 
(Figure 3D), is also sensitive to Gq/11 inhibitor (YM254980). GPR43-mediated inhibition 
of Akt is also observed during insulin activation of adipocytes 39 and is PT-sensitive. On 
the other hand, the GPR43-mediated attenuation of monocyte Akt observed here, was 
neither PT- nor YM254890-sensitive [Figure 3C]. Since different stimuli were used to 
activate Akt, it is plausible that different inhibitory pathways are involved leading to the 
different G protein specificities. The implications of GPR43-mediated inhibition of Akt 
and ERK2 will be an important subject of future study, as the consequences may extend 
beyond cytokine inhibition. 
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 While GPR43-mediated inhibition of monocyte Akt and ERK2 is species-specific, 
GPR43-mediated activation of p38 is observed in both human and mouse monocytes 
[Figure 1]. In fact, GPR43-induction of p38 is reported in multiple cell types including 
human MCF-7 cell line 40 and mouse neutrophils 41 with differing PT sensitivities. Our 
finding that GPR43 phosphorylation of p38 is PT-insensitive, is in agreement with 
Yonezawa et al. 40. Here, we reveal that the inhibition occurs via a YM254890-sensitive 
Gq/11 pathway [Figure 1D]. This difference may be due to cell-specific signaling 32, but 
we reasoned that Gq/11 is the more likely candidate since only GPR43 acts via Gq/11 
while both GPR43 and GPR41 couple to Gi/G0 protein 4–6. If Gi/G0 is involved, GPR41 
should phosphorylate p38 in the Gpr43-/- monocytes, which was not observed [Figure 1B]. 
Hence, we have demonstrated that GPR43 phosphorylates p38 in both of the human and 
mouse monocytes, although the functional outcome is unclear at this juncture, and 
warrants future studies. 
 Consistent with the role of Akt and ERK in monocyte cytokine expression 24,25, 
GPR43-mediated inhibition of Akt and ERK led to attenuated monocyte cytokine 
expression while GPR41 inhibited a smaller cytokine subset (Figure 5 and 6). These 
findings reveal that the inhibition of CCL2 by acetate treatment of human monocytes 
observed previously by Cox et al. (2009) 42, is attributable to GPR41/43 activation as 
shown by treatment with synthetic agonist [Figure 4]. Nevertheless, SCFAs may also act 
via pathways independent of GPR41/43, which is likely the case for mouse monocytes 
[Figure 4]. The abolishment of SCFA-mediated cytokine modulation by the specific 
inhibition of GPR41/43 with antagonists, when available, would further confirm that the 
inhibition is dependent on GPR41/43 in human monocytes. 
 Many of the inflammatory cytokines attenuated by GPR41/43 are associated with 
IBD 43. For example, the CCL2 gene has been identified as an IBD susceptibility loci 44 
while IL-1 is essential in the initiation of colonic inflammation 43. Another study found 
that monocytes from Crohn's disease patients had increased IL-1β and CCL2 secretion 45. 
In light of the similar cytokine profiles, the potential involvement of monocyte GPR41/43 
in human IBD is hard to ignore. Further investigations: (i) to determine if the cytokine 
inhibition activities of GPR41/43 are non-functional in IBD patients, and (ii) if this 
abnormality is involved in the disease pathology– may reveal novel insights on IBD and 
its treatment. 
 In conclusion, our study offers a first glimpse into the functions of GPR41/43 in 
human monocytes, where these receptors repress Akt and ERK, resulting in reduced 
cytokine expression. These findings hint at a potentially important role for GPR41/43 in 
mediating the interaction between the SCFA-producing gut bacteria and monocytes, with 
possible implications in monocyte-associated chronic inflammatory diseases 20,21,46, in 
particular in IBD 17. In mouse monocytes, where GPR41/43-mediated cytokine expression 
does not occur, acetate treatment produces a distinct cytokine profile. This implies that the 
role of GPR41 and GPR43 in human physiology may not be fully represented by mouse 
models. With the growing interest on these SCFA receptors as potential therapeutic targets 
22, our newfound insight will allow for potential differences between human and mouse 
monocyte responses to pharmacological compounds to be accounted for. Finally, we 
propose that host-microbiota interaction studies, when performed on human cells ex vivo 
or in mice with humanized immune systems 47, may uncover unexpected and novel 
findings. 




 All experiments were performed in compliance with guidelines approved by the 
Institutional Animal Care and Use Committee (IACUC Protocol Ref: 049/11, BR14/11). 
Gpr41 and Gpr43 knockout mice were generated as previously described 48 and 




 The myristoylated human Akt1 (myr-Akt) was cloned into pcDNA3 vector or the 
empty pcDNA3 expression vector as control. The coding regions (CDS) of human GPR41 
(NM_005304), human GPR43 (NM_005306), murine Gpr41 (NM_001033316), and 
murine Gpr43 (NM_001168509) were cloned into the pcDNA3.1/V5-His A (Invitrogen) 
expression vector. 
 
Cell culture, monocyte isolation and transfection. 
 Human peripheral blood monocytes were isolated from buffy coat of healthy adult 
donors (National University Hospital, Blood Donation Centre, Singapore). This work was 
approved by the Institutional Review Board (IRB), NUS-IRB B-14-063E, National 
University of Singapore (NUS). Briefly, the buffy coat was diluted four times with PBS 
containing 2% FBS and 1 mM EDTA, and the mononuclear fraction was obtained via 
density gradient centrifugation with Ficoll-Paque Premium 1.073 (GE Healthcare). The 
monocyte fraction was enriched with the Human Monocyte Enrichment Kit (Stemcell). 
Freshly isolated peripheral blood monocytes were electroporated with 5 g plasmid, using 
the Amaxa Human Monocyte Nucleofector Kit (Lonza), according to the manufacturer’s 
instructions. For mouse monocytes, the bone marrow from 10-14 week old mice was 
harvested and the monocyte fraction was enriched with the Mouse Monocyte Enrichment 
Kit (Stemcell). The enriched human and mouse monocytes were cultured in RPMI media 
(with 10% FBS and 1% v/v penicillin and streptomycin) at 37oC for 2 h before being used 
in assays.  
 A549 cells were cultured in RPMI (with 10% FBS and 1% v/v penicillin and 
streptomycin) at 37oC. Luciferase assays were performed in 24-well plates. Transfections 
were performed at ~80% confluency using the TurboFect Transfection Reagent (Thermo 
Scientific), and according to the manufacturer's instructions. A combination of 0.8 g 
expression/control vector + 0.2 g pNF-B_Luc (Stratagene) + 0.02 g pRL-CMBV 
(Promega) was used. For experiments involving the exogenous expression of multiple 
proteins, an equal mass of each expression vector was used to make up 0.8 g. Following 
ligand induction, the Dual-Luciferase® Reporter Assay (Promega) was performed 
according to the manufacturer’s instructions. 
 
Cell treatments 
 Acetate treatments were applied as sodium acetate (Sigma-Aldrich) solution. To 
specifically activate GPR43 or GPR41 in both human and mice, cells were treated with 10 
µM of the synthetic agonists, CFMB ((2S)-2-(4-chlorophenyl)-3,3-dimethyl-N-(5-
phenylthiazol-2-yl)butanamide) (Calbiochem) (ChemSpider ID: 24656891) (EC50 of ~0.7 
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µM) 9 and AR420626 (N-(2,5-Dichlorophenyl)-4-(furan-2-yl)-2-methyl-5-oxo-1,4,5,6,7,8-
hexahydro-quinoline-3-carboxamide) (Glixx Laboratories) (EC50 of ~0.7 µM) 
respectively 10. Inflammatory stimuli used include 100 ng/mL Escherichia coli 055:B5 
LPS (Sigma), 10 ng/mL TNF (Gibco), 200 nM 12-O-Tetradecanoylphorbol-13-acetate 
(TPA) (Sigma) and 100 ng/mL PAM3CSK4 (Invivogen). To inhibit Gi/G0, 500 ng/mL of 
Pertussis Toxin (PT) (Invitrogen) was used while Gq/11 was inhibited with 10 M 
YM254890 28. Akt was inhibited with 2 M Wortmannin (Sigma). ERK was inhibited 
with 10 M U0126 (Cell Signaling). 
 
Proteome array of MAPKs and cytokines 
 The Human Phospho-MAPK Array Kit (R&D Sytems, ARY002B), Mouse 
Cytokine Antibody Array (R&D Systems, ARY006) and Human Cytokine Array Kit 
(R&D Systems, ARY005) were run according to the manufacturer instructions. The array 
chemiluminescent signals were captured with ImageQuant™ LAS 4000 mini (GE 
Healthcare). Densitometric analysis was performed using the ImageQuant TL Software 
(GE Healthcare) as described above. Optical densities were standardized to the mean 
positive control (reference spots 1 to 3) readings and displayed as a heat map generated 
using the matrix2png program 49.  
 
Western blot and densitometric analysis of MAPKs 
 Total cell lysates were resolved on a denaturing SDS PAGE gel (10-12 %) and 
transferred onto Immuno-Blot PVDF membranes (Biorad). These were then probed 
according to the manufacturer instructions, with antibodies against phospho-p38 
(Thr180/Tyr182) (Cell Signaling), p38 (Cell Signaling), phospho-Akt (Ser437) (Cell 
Signaling), Akt (Cell Signaling, Cat. #9272), phospho-ERK1/2 (Thr202/Tyr204) (Cell 
Signaling), and ERK1/2 (Cell Signaling). These primary antibodies were then probed with 
the respective HRP-conjugated secondary antibodies: Goat anti-Rabbit (Dako) and Goat 
Anti-Mouse (Dako). Western blots were developed in WesternBright ECL 
chemiluminescent substrate (Advansta) and the chemiluminescent signals captured with an 
ImageQuant™ LAS 4000 mini (GE Healthcare). Densitometric analysis was performed on 
biological triplicates using the ImageQuant TL Software (GE Healthcare. These PVDF 
blots were then stripped as described by Yueng and Stanley 50 before further reprobing.  
 
Real-time quantitative PCR analysis of cytokine mRNA 
 The mean fold change of the treatment condition relative to the reference condition 
was calculated using the Relative Expression Software Tool (REST MCS ©  - version 2) 
51,52.  RNA was extracted using the Trizol Reagent (Ambion) according to the 
manufacturer's instructions. The RNA was reverse transcribed with the SuperScript® III 
First-Strand Synthesis System (Invitrogen) according to the manufacturer's instructions 
with both the oligo(dT) and random hexamer primers added. The resulting cDNA was 
analyzed by real-time qPCR using the GoTaq® qPCR Master Mix (Promega) and a 
LightCycler® 480 (Roche). Primers, all with an annealing temperature of 60oC, are listed 
in Table S1. Each condition was performed in biological triplicates and each biological 
triplicate was run in technical triplicates. The mean fold change of the treatment condition 
relative to the reference condition was calculated using the Relative Expression Software 
Tool (REST MCS ©  - version 2) 51,52.  
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Statistical analysis 
Data are presented as means ± SEM of triplicate conditions/samples tested and are 
representative of at least 3 independent experiments. Differences between averages were 
analyzed by two-tailed Student's t-test. Significance was set at a P-value of <0.05. 
*P<0.05; **P<0.005; *P<0.0005. 
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Figure 1. GPR43 activates p38 in a Gq/11 dependent manner in monocytes as determined 
through Western blots. (A) Elevated phosphorylation of p38 was detected in human monocytes at 
3 min post-induction with either acetate (top) or CFMB (GPR43 agonist) (bottom). (B) 
Phosphorylation of mice monocyte p38 by acetate and CFMB treatment is abolished upon GPR43 
knockout (Gpr43-/-). (C) Western blot shows that GPR43 overexpression leads to the constitutive 
phosphorylation of p38. A549 cells were transfected with GPR43-pcDNA or GPR41-pcDNA or 
the pcDNA control vector. 24 h later, the cells were induced with 5 ng/mL TNF. (D) 
Phosphorylation of p38 by acetate is abolished in human monocytes treated with either YM254890 
(Gq/11 inhibitor) alone or in combination with pertussis toxin (PT, Ga inhibitor), but is retained in 
the solvent control (NT) monocytes and monocytes treated with PT alone. Cells were pretreated 
with PT for 2 h and/or YM254890 for 30 min before acetate induction. (A, B and D) Unless 
otherwise indicated, monocytes were induced with 5 mM acetate or 10 uM CFMB for 3 min for all 
assays. (A - D) Each lane represents an independent culture for each treatment condition. The 
corresponding optical density (OD) is shown as the mean ± SEM; n = 3. The solvent controls (NT 
and DMSO) have been arbitrarily assigned the value of 1. The two tailed Students’ T-test was used 
to determine statistical significance and is annotated as: * < 0.05, ** < 0.005, and *** < 0.0005. 
The data shown is representative of three independent experiments. 
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Figure 2. GPR43 agonists inhibit Akt and ERK2 phosphorylation in LPS-activated human 
monocytes (A) Proteome array analysis of human monocytes treated with both acetate and LPS 
display reduced Akt2, ERK2 and MSK2 phosphorylation, as well as elevated TOR 
phosphorylation, when compared to monocytes treated with LPS alone. This experiment was 
performed with two independent cultures for each treatment condition. (B) Western blots 
confirming the inhibition of Akt and ERK2 by acetate and CFMB (GPR43 agonist) treatment, in 
LPS activated human monocytes. Each lane represents an independent culture for each treatment 
condition. The corresponding optical density (OD) is shown as the mean ± SEM; n = 3. The 
solvent controls (NT and DMSO) have been arbitrarily assigned the value of 1. (C) Time course 
analysis showing that the acetate-mediated inhibition is more pronounced during the early stages 
of Akt and ERK activation by LPS in human monocytes. (D) A549 cells overexpressing GPR43 
show attenuated NF-B activation upon TNF induction as measured by NF-B luciferase assay. 
(E) Inhibition of NF-B activity is proportional to GPR43 expression levels as measured by NF-
B luciferase assay. (F) Expression of a constitutively active form of Akt (myrAkt) rescues NF-B 
activity. (A - C) Unless otherwise indicated, monocytes were treated for 15 min with either 5 mM 
acetate or 10 uM CFMB or 10 uM AR420626 followed by 100 ng/mL LPS for 8 min. (D - F) Cells 
were transfected with either the GPR43/41-pcDNA or the pcDNA control vector together with the 
NF-B dual luciferase reporter plasmids. 24 h after transfection, cells were treated with TNFfor 6 
h before the luciferase reporters were assayed. NF-B activity values are standardized to the 
untreated control cells that have been transfected with mock plasmid. Values shown are the 
average of three independent cultures (n=3) with the error bars representing mean ± SEM. (B - F) 
The two tailed Students’ T-test was used to determine statistical significance and is annotated as: * 
< 0.05, ** < 0.005, and *** < 0.0005. The data shown are representative of three independent 
experiments. 
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Figure 3. ERK2 inhibition is depedent on Gq/11 while Akt inhibition is independent of both 
Gi/G0 and Gq/11 as shown by western blot. (A) Among human and mouse GPR41 and GPR43, 
overexpression of human GPR43 in A549 inhibits NF-B activation by TNF the most. (B) GPR43 
constitutive activation of NF-B is inhibited by Bis I, a PKC inhibitor, while PKC appears to have 
no effect on GPR43 inhibition of NF-B activation by TNF. A549 cells were treated with BisI 
during transfection for 24 h. (A - B) Cells were transfected with either the GPR43/41-pcDNA or 
the pcDNA control vector together with the NF-B dual luciferase reporter plasmids. 24 h after 
transfection, cells were treated with 5 ng/mL TNFfor 6 h before the luciferase reporters were 
assayed. NF-B activity values are standardized to the untreated control cells that have been 
transfected with mock plasmid. Values shown are the average of three independent cultures (n=3) 
with the error bars representing mean ± SEM. (C - D) Combined treatment with PT and 
YM254890 abolished ERK2 inhibition but does not affect Akt inhibition. YM254890 treatment 
alone abolished ERK2 inhibition while PT has no effect. Cells were pretreated with PT for 2 h 
and/or YM254890 for 30 min before acetate induction. Unless otherwise indicated, monocytes 
were treated for 15 min with 5 mM acetate followed by 100 ng/mL LPS for 8 min. Each lane 
represents an independent culture for each treatment condition. The corresponding optical density 
(OD) is shown as the mean ± SEM; n = 3. The solvent controls (NT and DMSO) have been 
arbitrarily assigned the value of 1. (A - E) The two tailed Students’ T-test was used to determine 
statistical significance and is annotated as: * < 0.05, ** < 0.005, and *** < 0.0005. (B - E) The 
data shown are representative of three independent experiments. 
 




Acetate: - - + + - - + +
WT Gpr41-/-WT



































Non-detectable: CXCL13, C5/C5, CCL11, sICAM-1, IFN-, IL-2, 
IL-3, IL-4, IL-5, IL-7, IL-10, IL-13, IL-12, P70, IL-16, IL-17, IL-23, IL-
27, CXCL11, CCL12, CXCL9, CXCL12, CCL17, TREM-1
Relative OD:
0.00             0.22
0.19             1.90
Relative OD:
0.00             0.22


































































































































5 mM Acetate + 12 h LPS
10 mM Acetate + 12 h LPS
 
Figure 4. Acetate treatment alters the cytokine expression of LPS-activated mouse 
monocytes, independent of GPR43 and GPR41. (A - C) Mouse monocytes were treated with 
either acetate or the solvent control (NT) for 15 min followed by 100 ng/mL LPS challenge for 12 
h. Unless indicated otherwise, 5 mM acetate was used. (A) Cytokine proteome arrays revealed 
reductions in CXCL10, IL-1ra, TIMP-1 and CCL2 and increases in CXCL1, IL-1 and IL-1 in 
WT, Gpr43-/-, and Gpr41-/- monocytes upon acetate treatment. Two independent cultures for each 
treatment condition is shown; n = 2. (B - C) Real-time qPCR analysis showing changes in cytokine 
mRNA in mouse monocytes (WT, Gpr41-/- and Gpr43-/-) treated with acetate. The data shown are 
the means of three independent cultures for each treatment condition and is presented as the fold 
change of the acetate treated samples relative to the solvent controls ± SEM; n = 3. n.d: non-
detectable. Measurements were standardized to Rpl27 as the reference gene. The data shown are 
representative of three independent experiments. The two tailed Students’ T-test was used to 
determine the statistical significance of this fold change and is annotated as: * < 0.05, ** < 0.005, 
and *** < 0.0005.  
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Figure 5. GPR41 and GPR43 agonists repress cytokine expression in human monocytes. (A) 
Cytokine proteome arrays of human monocytes treated with either acetate or CFMB (GPR43 
agonist) or AR420626 (GPR41 agonist) or the respective solvent controls (NT, DMSO) for 15 min 
followed by 100 ng/mL LPS challenge for 6 h and 12 h. When compared to the respective solvent 
controls, a reduction in C5, CCL1, CCL2, GM-CSF, IL-1, IL-1 and ICAM-1 protein expression 
was observed for the acetate treated monocytes. Monocytes treated with either CFMB or 
AR420626 displayed reduced C5 and CCL2 expression. Two independent cultures for each 
treatment condition is shown; n = 2. (B) Acetate and CFMB- mediated inhibition of CCL2 was 
confirmed by ELISA. Monocytes were challenge with 100 ng/mL LPS challenge for 6 h. The data 
shown are the means concentration from three independent cultures for each treatment condition ± 
SEM; n=3. (C - F) Real-time qPCR analysis showing reduced CCL1, CCL2, CCL3, GM-CSF, 
IL1a, IL1b and ICAM1 mRNA in both acetate- and CFMB- treated monocytes at 4 h post-LPS 
induction, while IL8 and TNF levels remain unchanged. AR420626 treated monocytes show 
reduced CCL2 mRNA. The data shown are the means of three independent cultures for each 
treatment condition and is presented as the fold change of the treated samples (5 mM acetate or 10 
M CFMB or 10 M AR420626) relative to the respective solvent controls ± SEM; n = 3. 
Measurements were standardized to RPL27 as the reference gene. (B - F) The data shown are 
representative of three independent experiments. n.d: non-detectable. The two tailed Students’ T-
test was used to determine the statistical significance of this fold change and is annotated as: * < 
0.05, ** < 0.005, and *** < 0.0005.  
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Figure 6. Acetate inhibits cytokine expression via repression of Akt as determined through 
real-time PCR analysis. (A) Acetate-, CFMB (GPR43 agonist)-, and AR420626 (GPR41 agonist)-
mediated cytokine inhibition is dose-responsive. Human monocytes were treated with either 
acetate, CFMB, AR420626 or the respective solvent control for 15 min followed by a 4 h-
activation with LPS before the cytokine mRNA levels were measured. (B) The Akt and ERK 
pathways are required for transcription of CCL2, IL-1 and IL-1. Human monocytes were 
pretreated with either the solvent control, Wortmannin (PI3K-Akt pathway inhibitor), U0126 
(ERK inhibitor) or SB203580 (p38 inhibitor) followed by 100 ng/mL LPS activation for 4 h. (B) 
Inhibition of Gi/G0 and Gq/11 signaling with pertussis toxin (PT) and YM254890, respectively, 
did not rescue cytokine expression from acetate-mediated inhibition. Human monocytes were 
treated with PT for 2 h and/or YM254890 for 30 min.  This was followed by 15 min treatment with 
5 mM acetate and 12 h treatment with 100 ng/mL LPS. (C) Acetate mediated inhibition of CCL1, 
CCL2 and GM-CSF, is significantly diminished upon expression of the constitutively active 
myristoylated Akt construct (myr-Akt) in human monocytes. Human monocytes were 
electroporated with the myr-Akt expression vector (myrAkt-pcDNA) or the empty vector 
(pcDNA) as a control. 12 h after electroporation, the cells were treated with 5 mM acetate 
followed by 12 h with 100 ng/mL LPS. (A - D) The data shown are the means of three independent 
cultures for each treatment condition and is presented as the fold change of the treated samples 
relative to the solvent controls ± SEM; n = 3. n.d: non-detectable. Measurements were 
standardized to RPL27 as the reference gene. The data shown are representative of three 
independent experiments. The two tailed Students’ T-test was used to determine the statistical 
significance of this fold change and is annotated as: * < 0.05, ** < 0.005, and *** < 0.0005.  
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Figure S1. GPR43 weakly phosphorylates Akt and not ERK. Human monocytes were 
treated with either 5 mM acetate or 10 uM CFMB and the phosphorylation levels were 
determined with a western blot. Each lane represents an independent culture with n=3 for 
each treatment condition. 










Figure S2. Acetate treatment does not affect p38 activity. Western blot of human 
monocytes treated with 5 mM acetate for 15 min prior to 8 min LPS challenge. No change 
in p38 phosphorylation levels was detected compared to controls treated with the LPS 
alone. Each lane represents an independent culture (n=3) for each treatment condition. The 














Figure S3. Treatment with the GPR41 agonist (AR420626) does not alter Akt and 
ERK phosphorylation. Western blot of human monocytes treated with 10 M AR420626 
for 15 min prior to 8 min LPS challenge. No change in Akt and ERK phosphorylation 
levels was detected compared to controls treated with the LPS alone. Each lane represents 
an independent culture (n=3) for each treatment condition. The data shown are 
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Figure S4. Acetate-mediated Akt and ERK inhibition is not observed in mouse 
monocytes. Western blot of mouse monocytes treated with 5 mM acetate for 15 min 
followed by 100 ng/mL LPS challenge. No change in Akt and ERK phosphorylation levels 
was detected compared to controls treated with LPS alone. Each lane represents an 
independent culture with n=3 for each treatment condition. The data shown are 
representative of three independent experiments. 
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Figure S5












































































































































Figure S5. CFMB (GPR43 agonist) and AR420626 (GPR41 agonist) did not 
reproduce acetate-mediated cytokine modulation in mouse monocytes as determined 
through real-time qPCR analysis. Mouse monocytes show reduced Cxcl10, Timp1 and 
increased Ccl1, Cxcl1, Il1a and Il1b upon acetate treatment for 4 h post-LPS induction. 
Mouse monocytes treated with either CFMB or AR420626, show no obvious change in 
cytokine expression. Unless otherwise indicated, mouse monocytes were treated with 
either 5 mM acetate or 10 uM CFMB or 10 uM AR420262 or the solvent control for 15 
min followed by 100 ng/mL LPS challenge for the indicated times. The data shown is the 
mean of three independent cultures for each treatment condition and is presented as the 
fold change of the acetate/CFMB/AR420626 treated samples relative to the respective 
solvent controls ± SEM; n = 3. Measurements were standardized to Rpl27 as the reference 
gene. The data shown are representative of three independent experiments. The two tailed 
Students’ T-test was used to determine the statistical significance of this fold change and 
is annotated as: * < 0.05, ** < 0.005, and *** < 0.0005.  
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Figure S6



























































































































Figure S6. Cytokine mRNA at 12 h post-LPS challenge as determined by real time 
qPCR analysis. Human monocytes were treated with 5 mM acetate or 10 M CFMB or 10 
M AR420626 or the respective solvent controls for 15 mins, followed by 100 ng/mL LPS 
challenge for 12 h. The data shown are the mean of three independent cultures for each 
treatment condition and is presented as the fold change of the acetate/CFMB treated 
samples relative to the respective solvent controls ± SEM; n = 3. n.d: non-detectable. 
Measurements were standardized to RPL27 as the reference gene. The data shown are 
representative of three independent experiments. The two tailed Students’ T-test was used 
to determine the statistical significance of this fold change and is annotated as: * < 0.05, 
** < 0.005, and *** < 0.0005. 











































































Figure S7. Cytokine inhibition is observed in human monocytes pretreated for 12 h 
with 5 mM acetate followed by 4 h LPS induction but not for 12 h with 10 uM CFMB 
as determined by real time qPCR analysis. Human monocytes were treated with either 5 
mM acetate or 10 M CFMB or the respective solvent control for 12 h prior to 4 h LPS 
challenge. The data shown are the means of three independent cultures for each treatment 
condition and is presented as the fold change of the acetate/CFMB treated samples relative 
to the respective solvent controls ± SEM; n = 3. n.d: non-detectable. Measurements were 
standardized to RPL27 as the reference gene. The data shown are representative of three 
independent experiments. The two tailed Students’ T-test was used to determine the 
statistical significance of this fold change and is annotated as: * < 0.05, ** < 0.005, and 





































































Immune regulatory signaling through GPR43, a receptor for short-chain 
fatty acids produced by gut flora 
 
Ang Zhiwei.  
Supervisor: Prof Ding Jeak Ling 
Department of Biological Sciences, NUS. 
 
 Chronic inflammation has been linked to many diseases such as autoimmune 
disorders, asthma, rheumatoid arthritis, and cancer. The gut flora has been implicated in 
the regulation of the inflammatory response but little is known on how this is achieved. A 
breakthrough was made with the recent discovery that GPR43 is important in regulating 
inflammation. GPR43 is a receptor for short-chain fatty acids (SCFAs) produced by gut 
flora through the fermentation of fiber. Despite its importance, the mechanism by which 
GPR43 regulates inflammation remains to be elucidated. Here, we investigate the 
signaling pathway mediated by GPR43 and show that it inhibits NF-B transcription 
factor activity via the repression of TAK1 signaling. Ongoing studies are being 
undertaken to determine the mechanism of inhibition of TAK1 and to demonstrate the 
importance of this pathway in a GPR43 knockout mice model. Elucidating GPR43 
signaling will facilitate our understanding of the clinically important interactions between 
gut flora and our immune system, which may lead to the development of novel therapies 
to regulate inflammation via this pathway.  
 
Immune regulatory signaling of the gut flora through a 
short-chain fatty acid receptor, GPR43. 
 
Ang Zhiwei.  
Supervisor: Prof Ding Jeak Ling 
Department of Biological Sciences, NUS. 
 
 For every cell in the human body, there are about ten times as many 
microorganisms in the intestines that form the gut flora. These "residents" of our gut 
perform many useful functions, and have been implicated in immune development, and in 
preventing allergies and inflammatory bowel disease. However, not much is known of the 
molecular mechanisms involved. A potential molecular link is GPR43, a G protein 
coupled receptor that is activated by short chain fatty acids (SCFAs), produced by the gut 
flora during the fermentation of dietary fiber. In a recent study, treatment with acetate (a 
SCFA) reduced inflammation in mice models of colitis, arthritis and asthma; a response 
that is abolished in Gpr43-/- animals. This confirmed the importance of GPR43 in the 
resolution of inflammation though the exact mechanism by which GPR43 achieves this 
effect remains elusive. Here, we attempt to elucidate the mechanism by which GPR43 
attenuates inflammation. 
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